



US008846354B1

(12) **United States Patent**
Pfleger et al.

(10) **Patent No.:** **US 8,846,354 B1**
(45) **Date of Patent:** **Sep. 30, 2014**

(54) **MICROORGANISMS FOR PRODUCING ORGANIC ACIDS**

(71) Applicant: **Wisconsin Alumni Research Foundation, Madison, WI (US)**

(72) Inventors: **Brian Frederick Pfleger, Madison, WI (US); Matthew Brett Begemann, Madison, WI (US)**

(73) Assignee: **Wisconsin Alumni Research Foundation, Madison, WI (US)**

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/200,747**

(22) Filed: **Mar. 7, 2014**

Related U.S. Application Data

(63) Continuation-in-part of application No. 13/798,835, filed on Mar. 13, 2013, now Pat. No. 8,715,973.

(60) Provisional application No. 61/647,001, filed on May 15, 2012.

(51) **Int. Cl.**

C12P 7/52 (2006.01)
C12P 7/40 (2006.01)
C12P 7/56 (2006.01)
C12P 7/48 (2006.01)
C12P 21/02 (2006.01)
A61K 38/00 (2006.01)

(52) **U.S. Cl.**

CPC **C12P 7/56** (2013.01)
USPC **435/141; 435/139; 435/71.2**

(58) **Field of Classification Search**

None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

8,048,624 B1 11/2011 Lynch
2010/0210017 A1 8/2010 Gill
2011/0125118 A1 5/2011 Lynch
2011/0165637 A1 7/2011 Pfleger et al.

OTHER PUBLICATIONS

Niederholtmeyer et al. "Engineering Cyanobacteria to Synthesize and Export Hydrophilic Products" Applied and Environmental Microbiology, Jun. 2010, vol. 76, No. 11p. 3462-3466.*
Altschul et al., Basic Local Alignment Search Tool, *J. Mol. Biol.* 1990, 215:403410.
Angermayr et al., Energy biotechnology with cyanobacteria. *Current Opinion in Biotechnology*, 2009, 20(3): p. 257-263.
Ansedo et al., Metabolism of Acrylate to beta-Hydroxypropionate and Its Role in Dimethylsulfoniopropionate Lyase Induction by a Salt Marsh Sediment Bacterium, *Alcaligenes faecalis* M3A. *Appl. Environ. Microbiol.*, 1999, 65(11): p. 5075-5081.
Atsumi et al., Direct photosynthetic recycling of carbon dioxide to isobutyraldehyde. *Nat Biotech*, 2009, 27(12): p. 1177-1180.

Balasubramanian et al., Regulatory Roles for IscA and SufA in Iron Homeostasis and Redox Stress Responses in the Cyanobacterium *Synechococcus* sp. Strain PCC 7002. *J. Bacteriol.*, 2006, 188(9): p. 3182-3191.

Bauer, W., Acrylic Acid and Derivatives. *Kirk-Othmer Encyclopedia of Chemical Technology*, 2000: John Wiley & Sons, Inc.

Boynton et al., Intracellular Concentrations of Coenzyme A and Its Derivatives from *Clostridium acetobutylicum* ATCC 824 and Their Roles in Enzyme Regulation. *Appl. Environ. Microbiol.*, 1994, 60(1): p. 39-44.

Bozell et al., *Technology development for the production of biobased products from biorefinery carbohydrates—the US Department of Energy's "Top 10" revisited*. *Green Chemistry*, 2010, 12(4): p. 539-554.

Cherrington et al., Organic Acids: Chemistry, Antibacterial Activity and Practical Applications, in Advances in Microbial Physiology, A.H. Rose and D.W. Tempest, Editors. 1991, *Academic Press*. p. 87-108.

Chotani et al., The commercial production of chemicals using pathway engineering. *Biochimica et Biophysica Acta (BBA)—Protein Structure and Molecular Enzymology*, 2000, 1543(2): p. 434-455.

Current Protocols in Molecular Biology, F.M. Ausubel et al., eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (supplemented through 2008.

Dacey et al., Hydroxide decomposition of dimethylsulfoniopropionate to form dimethylsulfide. *Geophys. Res. Lett.* 1987, 14:1246-1249.

Ducat et al., Engineering cyanobacteria to generate high-value products. *Trends in Biotechnology*, 2011, 29(2): p. 95-103.

Feist et al., Reconstruction of biochemical networks in microorganisms. *Nat Rev Micro*, 2009, 7(2): p. 129-143.

Fridovich et al., Paraquat and the exacerbation of oxygen toxicity. *Trends in Biochemical Sciences*, 1979, 4(5): p. 113-115.

González et al., Genetics and Molecular Features of Bacterial Dimethylsulfoniopropionate (DMSP) and Dimethylsulfide (DMS) Transformations, in *Handbook of Hydrocarbon and Lipid Microbiology*, K.N. Timmis, Editor. 2010, Springer Berlin Heidelberg. p. 1201-1211.

Green et al., *Molecular Cloning: A Laboratory Manual*, 4th ed., Cold Spring Harbor Laboratory Press, 2001.

Hashimoto et al., Nitrile Pathway Involving Acyl-CoA Synthetase. *Journal of Biological Chemistry*, 2005, 280(10): p. 8660-8667.

Henikoff & Henikoff, Amino acid substitution matrices from protein blocks, *Proc. Natl. Acad. Sci. USA*, 1989, 89:10915.

(Continued)

Primary Examiner — Manjunath Rao

Assistant Examiner — Gerard Lacourciere

(74) *Attorney, Agent, or Firm* — Daniel A. Blasiolo; Joseph T. Leone, Esq.; DeWitt Ross & Stevens SC

(57) **ABSTRACT**

Organic acid-producing microorganisms and methods of using same. The organic acid-producing microorganisms comprise modifications that reduce or ablate AcsA activity or AcsA homolog activity. The modifications increase tolerance of the microorganisms to such organic acids as 3-hydroxypropionic acid, acrylic acid, propionic acid, lactic acid, and others. Further modifications to the microorganisms increase production of such organic acids as 3-hydroxypropionic acid, lactate, and others. Methods of producing such organic acids as 3-hydroxypropionic acid, lactate, and others with the modified microorganisms are provided. Methods of using acsA or homologs thereof as counter-selectable markers are also provided.

20 Claims, 12 Drawing Sheets

(56)

References Cited

OTHER PUBLICATIONS

- Holo, H., *Chloroflexus aurantiacus* secretes 3-hydroxypropionate, a possible intermediate in the assimilation of CO₂ and acetate. *Archives of Microbiology*, 1989, 151(3): p. 252-256.
- Horswill et al., Studies of Propionate Toxicity in *Salmonella enterica* Identify 2-Methylcitrate as a Potent Inhibitor of Cell Growth. *Journal of Biological Chemistry*, 2001, 276(22): p. 19094-19101.
- Howard, E.C., et al., *Bacterial Taxa That Limit Sulfur Flux from the Ocean*. *Science*, 2006, 314(5799): p. 649-652.
- Howard et al., Abundant and diverse bacteria involved in DMSP degradation in marine surface waters. *Environmental Microbiology*, 2008, 10(9): p. 2397-2410.
- Hugler et al., Malonyl-Coenzyme A Reductase from *Chloroflexus aurantiacus*, a Key Enzyme of the 3-Hydroxypropionate Cycle for Autotrophic CO₂ Fixation. *J. Bacteriol.*, 2002, 184(9): p. 2404-2410.
- Karlin et al., Application and statistics for multiple high-scoring segments in molecular sequences. *Proc. Natl. Acad. Sci. USA*, 1993, 90:5873-5787.
- Kasuya et al., Participation of a medium chain acyl-CoA synthetase in glycine conjugation of the benzoic acid derivatives with the electron-donating groups. *Biochemical Pharmacology*, 1996, 51(6): p. 805-809.
- Keasling, J.D., *Manufacturing Molecules Through Metabolic Engineering*. *Science*, 2010, 330(6009): p. 1355-1358.
- Kiene et al., Dimethylsulphoniopropionate and Methanethiol Are Important Precursors of Methionine and Protein-Sulfur in Marine Bacterioplankton. *Appl. Environ. Microbiol.*, 1999, 65(10): p. 4549-4558.
- Kumar et al., Development of suitable photobioreactors for CO₂ sequestration addressing global warming using green algae and cyanobacteria. *Bioresource Technology*, 2011, 102(8): p. 4945-4953.
- Latifi et al., Oxidative stress in cyanobacteria. *FEMS Microbiology Reviews*, 2009, 33(2): p. 258-278.
- Lindberg et al., Engineering a platform for photosynthetic isoprene production in cyanobacteria, using *Synechocystis* as the model organism. *Metabolic Engineering*, 2010, 12(1): p. 70-79.
- Liu et al., Fatty acid production in genetically modified cyanobacteria. *Proceedings of the National Academy of Sciences*, 2011.
- Malmstrom et al., Dimethylsulphoniopropionate (DMSP) Assimilation by *Synechococcus* in the Gulf of Mexico and Northwest Atlantic Ocean. *Limnology and Oceanography*, 2005, 50(6): p. 1924-1931.
- Man et al., The binding of propionyl-CoA and carboxymethyl-CoA to *Escherichia coli* citrate synthase. *Biochimica et Biophysica Acta (BBA)—Protein Structure and Molecular Enzymology*, 1995, 1250(1): p. 69-75.
- Maruyama et al., Mechanisms of Growth Inhibition by Propionate and Restoration of the Growth by Sodium Bicarbonate or Acetate in *Rhodospseudomonas sphaeroides* S. *Journal of Biochemistry*, 1985, 98(3): p. 819-824.
- Nakamura et al., Metabolic engineering for the microbial production of 1,3-propanediol. *Current Opinion in Biotechnology*, 2003, 14(5): p. 454-459.
- Needleman et al., A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins. *J. Mol. Biol.* 1970, 48:443.
- Niederholtmeyer et al., Engineering Cyanobacteria to Synthesize and Export Hydrophilic Products. *Appl. Environ. Microbiol.*, 2010, 76(11): p. 3462-3466.
- Olins et al., A Novel Sequence Element Derived from Bacteriophage T7 mRNA Acts as an Enhancer of Translation of the *lacZ* Gene in *Escherichia coli*. *Journal of Biological Chemistry*, 1989, 264(29):16973-16976.
- OPX nears commercial goal for bio-based acrylic acid Feb. 28, 2011; Available from: <http://www.opxbio.com/news/opxbio-rapidly-achieves-bioacrylic-commercial-goals/>.
- Pearson et al., Improved tools for biological sequence comparison. *Proc. Nat'l. Acad. Sci. USA*, 1988, 85:2444.
- Reisch et al., Novel pathway for assimilation of dimethylsulphoniopropionate widespread in marine bacteria. *Nature*, 2011, 473(7346): p. 208-211.
- Riddles et al., Ellman's reagent: 5,5'-dithiobis(2-nitrobenzoic acid)—a reexamination. *Analytical Biochemistry*, 1979, 94(1):75-81.
- Ross et al., Intraspecific Variation In Stress-Induced Hydrogen Peroxide Scavenging By The Ulvoid Macroalga *Ulva Lactuca*. *Journal of Phycology*, 2007, 43(3): p. 466-474.
- Russell, T.B., Another explanation for the toxicity of fermentation acids at low pH: anion accumulation versus uncoupling. *Journal of Applied Microbiology*, 1992, 73(5): p. 363-370.
- Sakamoto et al., Growth on Urea Can Trigger Death and Peroxidation of the Cyanobacterium *Synechococcus* sp. Strain PCC 7002. *Appl. Environ. Microbiol.*, 1998, 64(7): p. 2361-2366.
- Sambrook et al., *Molecular cloning: A Laboratory Manual*, 3rd ed., Cold Spring Harbor Laboratory Press, 2001.
- Simó, R., Production of atmospheric sulfur by oceanic plankton: biogeochemical, ecological and evolutionary links. *Trends in Ecology & Evolution*, 2001, 16(6): p. 287-294.
- Simó et al., Coupled Dynamics of Dimethylsulphoniopropionate and Dimethylsulfide Cycling and the Microbial Food Web in Surface Waters of the North Atlantic. *Limnology and Oceanography*, 2002, 47(1): p. 53-61.
- Smith et al., Comparison of Biosequences. *Adv. Appl. Math.* 1981, 2:482-489.
- Steinke et al., Determinations of dimethylsulphoniopropionate (DMSP) lyase activity using headspace analysis of dimethylsulphide (DMS). *Journal of Sea Research*, 2000, 43(3-4): p. 233-244.
- Straathof, A.J.J., et al., Feasibility of acrylic acid production by fermentation. *Applied Microbiology and Biotechnology*, 2005, 67(6): p. 727-734.
- Stefels, J., Physiological aspects of the production and conversion of DMSP in marine algae and higher plants. *Journal of Sea Research*, 2000, 43(3-4): p. 183-197.
- Sunda et al., An antioxidant function for DMSP and DMS in marine algae. *Nature*, 2002, 418(6895): p. 317-320.
- Thiel, T., Genetic Analysis of Cyanobacteria, in *The Molecular Biology of Cyanobacteria*, D.A. Bryant, Editor. 2004, Springer Netherlands. p. 581-611.
- Vila-Costa et al., Dimethylsulphoniopropionate Uptake by Marine Phytoplankton. *Science*, 2006, 314(5799): p. 652-654.
- Visscher et al., Production and Consumption of Dimethylsulphoniopropionate in Marine Microbial Mats. *Applied and Environmental Microbiology*, 1991, 57:3237-3242.
- Warnecke et al., Rapid dissection of a complex phenotype through genomic-scale mapping of fitness altering genes. *Metabolic Engineering*, 2010, 12:241-250.
- Xu et al., Expression of Genes in Cyanobacteria: Adaptation of Endogenous Plasmids as Platforms for High-Level Gene Expression in *Synechococcus* sp. PCC 7002, in *Photosynthesis Research Protocols*, R. Carpentier, Editor. 2011, Humana Press. p. 273-293.
- Yoch, D.C., Dimethylsulphoniopropionate: Its Sources, Role in the Marine Food Web, and Biological Degradation to Dimethylsulfide. *Appl. Environ. Microbiol.*, 2002, 68(12): p. 5804-5815.
- Zaldivar et al., Effect of organic acids on the growth and fermentation of ethanologenic *Escherichia coli* LY01. *Biotechnology and Bioengineering*; Journal vol. 66; Journal Issue: 4; Other Information: PBD: 1999; p. Medium: X; Size: pp. 203-210.

* cited by examiner




FIG. 1A




FIG. 1B




FIG. 2A

FIG. 2B

FIG. 2C




FIG. 3




FIG. 4B





FIG. 4A



1. WT PCC 7002
2. Spontaneous mutant
3. $\Delta acsA$
4. $\Delta acsA/pAQ1_acsAW49L$
5. $\Delta acsA/pAQ1_acsA$

FIG. 5




FIG. 6




FIG. 7




FIG. 8A




FIG. 8B

Pathway to 3-hydroxypropionate




FIG. 9B




FIG. 9A




FIG. 10




FIG. 11

Lactate dehydrogenase




FIG. 12A

Transhydrogenase




FIG. 12B

Lactate Production and Growth of PCC 7002 with IPTG-Inducible *ldh*




FIG. 13

Lactate Production and Growth of PCC 7002 with *ldh +/- udhA*




FIG. 14

1

MICROORGANISMS FOR PRODUCING ORGANIC ACIDS

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. patent application Ser. No. 13/798,835, filed Mar. 13, 2013, and claims priority under 35 USC §119(e) to U.S. Provisional Patent Application 61/647,001 filed May 15, 2012, the entireties of which are incorporated herein by reference. This application incorporates by reference co-filed U.S. patent application Ser. No. 14/200,686, which is also a continuation-in-part of U.S. patent application Ser. No. 13/798,835, filed Mar. 13, 2013, and claims priority under 35 USC §119(e) to U.S. Provisional Patent Application 61/647,001 filed May 15, 2012.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

This invention was made with government support under FA9550-11-1-0038 awarded by the USAF/AFOSR, DE-FC02-07ER64494 awarded by the US Department of Energy, and 1240268 awarded by the National Science Foundation. The government has certain rights in the invention.

FIELD OF THE INVENTION

The present invention relates to organic acid-tolerant microorganisms capable of producing organic acids and uses thereof for producing organic acids.

BACKGROUND

Production of industrially useful chemicals has conventionally focused on the use of petroleum-like compounds as starting materials. However, various factors have increased interest in the production of such chemicals through microorganism-mediated bioconversion of biomass and other renewable resources.

Accordingly, the U.S. Department of Energy (DOE) recently identified several "building block" chemicals to be produced via microorganism consumption of biomass. The identified chemicals include 1,4 succinic acid, fumaric and malic acids, 2,5 furan dicarboxylic acid, 3-hydroxypropionic acid (3HP), aspartic acid, glucaric acid, glutamic acid, itaconic acid, levulinic acid, 3-hydroxybutyrolactone, glycerol, sorbitol, and xylitol/arabinitol. These chemicals can be converted to high-value, bio-based chemicals or materials.

As an example, 3HP can be readily transformed into a variety of commodity chemicals such as acrylic acid, methyl acrylate, and 1,3-propanediol. These commodity chemicals represent a multi-billion dollar a year industry and are used in the production of plastics, coatings, and fibers. U.S. demand for acrylic acid in particular is growing, exceeding 1×10^9 kg/year. The current means of synthesizing acrylic acid include oxidation of propylene. A thermodynamically favorable pathway for microbial production of acrylic acid has not been identified.

One hurdle facing the microbial production of industrially useful chemicals is that many, including 3HP, are toxic to the microbes capable of producing them. Recently, efforts have been made not only to increase microbial output of the chemicals but also to increase microbial tolerance to the chemicals. Some of these efforts have focused on the production of 3HP in the heterotrophic microbe *Escherichia coli*. See, e.g., U.S.

2

Pat. No. 8,048,624 to Lynch, U.S. Pub. 2011/0125118 to Lynch, U.S. Pub. 2010/0210017 to Gill et al., and Warnecke et al. *Metabolic Engineering* (2010) 12:241-250.

While focusing on chemical production in heterotrophic microorganisms is a valuable strategy, a potential problem is the availability of carbon and energy sources such as food-based commodities and/or sugars derived from lignocellulosic biomass. An attractive alternative is to use phototrophic microorganisms, such as cyanobacteria. These microorganisms can produce chemical products from CO₂ and light energy without relying on consumption of higher-value carbon sources that can be used for other purposes, such as producing food, fuel, or other certain chemicals.

There is a need for microorganisms capable of producing high yields of industrially useful chemicals and having increased tolerance against those chemicals. There is also a need for microorganisms that use non-food-based feedstock in such production.

SUMMARY OF THE INVENTION

The present invention addresses the aforementioned needs by providing microorganisms with increased tolerance to organic acids. The present invention also provides microorganisms modified to produce organic acids. Methods of producing organic acids with the microorganisms described herein are also provided.

A preferred version of the invention comprises an organic acid-tolerant microorganism that includes a modification that reduces or ablates AcsA activity or AcsA homolog activity in the microorganism. The modification confers an increased tolerance to organic acids compared to a corresponding microorganism not comprising the modification.

The modification is preferably a genetic modification. The genetic modification is preferably a genetic modification other than or in addition to one resulting in a W49L substitution in AcsA or a corresponding substitution in an AcsA homolog.

The microorganism is preferably a bacterium, more preferably a cyanobacterium, and most preferably a cyanobacterium selected from the group consisting of *Synechococcus* sp., *Prochlorococcus* sp., *Synechocystis* sp., and *Nostoc* sp.

The tolerance to the organic acid is preferably increased at least about 25-fold in the microorganism of the invention compared to a corresponding microorganism.

In preferred versions of the invention, the microorganism is further modified to increase production of an organic acid. The microorganism may be modified to increase production of 3-hydroxypropionic acid, lactic acid, and/or others.

A microorganism of the invention modified to increase production of 3-hydroxypropionic acid preferably comprises one or more recombinant nucleic acids configured to express an enzyme selected from the group consisting of a malonyl-CoA reductase and a malonate semialdehyde reductase, wherein the microorganism produces an increased amount of 3-hydroxypropionic acid compared to a corresponding microorganism not comprising the one or more recombinant nucleic acids.

The malonyl-CoA reductase is preferably a malonyl-CoA reductase from *Sulfolobus tokodaii* or a homolog thereof. The malonyl-CoA reductase from *Sulfolobus tokodaii* or the homolog thereof preferably comprises an amino acid sequence at least about 80% identical, more preferably at least about 90% identical, and most preferably at least about 95% identical to SEQ ID NO:13.

The malonate semialdehyde reductase is preferably a malonate semialdehyde reductase from *Metallosphaera sedula*

or a homolog thereof. The malonate semialdehyde reductase from *Metallosphaera sedula* or the homolog thereof preferably comprises an amino acid sequence at least about 80% identical, more preferably at least about 90% identical, and most preferably at least about 95% identical to SEQ ID NO:16.

A microorganism of the invention modified to increase production of lactic acid preferably comprises one or more recombinant nucleic acids configured to express an enzyme selected from the group consisting of a lactate dehydrogenase and a pyridine nucleotide transhydrogenase, wherein the microorganism produces an increased amount of lactic acid compared to a corresponding microorganism not comprising the one or more recombinant nucleic acids.

The lactate dehydrogenase is may be a lactate dehydrogenase from *Bacillus subtilis* or a homolog thereof. The lactate dehydrogenase from *Bacillus subtilis* or the homolog thereof preferably comprises an amino acid sequence at least about 80% identical, more preferably at least about 90% identical, and most preferably at least about 95% identical to SEQ ID NO:18.

The lactate dehydrogenase is may also or alternatively be a lactate dehydrogenase from *Lactococcus lactis* or a homolog thereof. The lactate dehydrogenase from *Lactococcus lactis* or the homolog thereof preferably comprises an amino acid sequence at least about 80% identical, more preferably at least about 90% identical, and most preferably at least about 95% identical to SEQ ID NO:22.

The pyridine nucleotide transhydrogenase is preferably a soluble pyridine nucleotide transhydrogenase from *Escherichia coli* or a homolog thereof. The soluble pyridine nucleotide transhydrogenase from *Escherichia coli* or the homolog thereof preferably comprises an amino acid sequence at least about 80% identical, more preferably at least about 90% identical, and most preferably at least about 95% identical to SEQ ID NO:20.

The invention further provides methods of producing an organic acid. The methods comprise culturing one of the microorganisms as described herein.

The objects and advantages of the invention will appear more fully from the following detailed description of the preferred embodiment of the invention made in conjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A depicts a schema for using *acsA* or a homolog thereof as a selection marker for introducing a DNA fragment of interest into the *acsA* or homolog chromosomal locus.

FIG. 1B depicts a schema for using *acsA* or a homolog thereof as a selection marker for introducing a DNA fragment of interest into a locus other than the *acsA* or homolog chromosomal locus.

FIG. 2A depicts growth of *Synechococcus* sp. PCC 7002 at OD730 as a function of time in the presence of 5 mM dimethylsulfoniopropionate (DMSP).

FIG. 2B depicts growth of *Synechococcus* sp. PCC 7002 at OD730 as a function of time in the presence of 5 mM acrylic acid.

FIG. 2C depicts growth of a mutant pool of *Synechococcus* sp. PCC 7002 at OD730 as a function of time in the presence of 5 mM dimethylsulfoniopropionate (DMSP) and 5 mM acrylic acid.

FIG. 3 depicts acrylate production from DMSP as a function of time for *Synechococcus* sp. PCC 7002 and an abiotic control.

FIG. 4A depicts growth of BPSyn_006 (a Δ *acsA* strain of *Synechococcus* sp. PCC 7002 having a barcode sequence in place of the *acsA* gene (PCC 7002 *acsA*::BC)) and pH as a function of time in CO₂-limited conditions. Cultivation of BPSyn_006 with 5 mM DMSP under CO₂-limited conditions results in an increase in pH over time.

FIG. 4B depicts acrylic acid accumulation over time from cultivation of BPSyn_006 with 5 mM DMSP and abiotic controls with 5 mM DMSP at pH 8.0, 8.25, and 8.5. The rate of DMSP degradation to acrylic acid increases with an increase in pH.

FIG. 5 depicts plating of wild-type *Synechococcus* sp. PCC 7002, a mutant generated from growth in the presence of acrylic acid, a Δ *acsA* mutant, a Δ *acsA* mutant comprising the pAQ1 plasmid containing *acsAW49L*, and a Δ *acsA* mutant comprising the pAQ1 plasmid containing *acsA* on media containing no organic acid, 5 mM acrylic acid, or 30 mM 3-hydroxypropionic acid (3HP).

FIG. 6 depicts relative acyl-CoA ligase activity of *AcsA* for acetate, acrylate, propionate, and 3-hydroxypropionate (3HP).

FIG. 7 depicts two 3HP-production pathways, wherein 1 represents pyruvate kinase, 2 represents pyruvate dehydrogenase, 3 represents acetyl-CoA carboxylase, 4 represents malonyl-CoA reductase, 5 represents phosphoenolpyruvate carboxylase, 6 represents aspartate aminotransferase, 7 represents aspartate decarboxylase, and 8 represents β -alanine/ α -ketoglutarate aminotransferase.

FIG. 8A depicts the percent of colonies positive for yellow fluorescent protein (YFP) or a barcode sequence resulting from use of *acsA* as a counter selection marker upon introducing the YFP or the barcode sequence into the chromosomal *acsA* locus of *Synechococcus* sp. PCC 7002.

FIG. 8B depicts levels of YFP expression from cells in which YFP was introduced into the *glpK* chromosomal locus using *acsA* as a counter selection marker and cells in which YFP was introduced into the *acsA* chromosomal locus using *acsA* as a counter selection marker.

FIG. 9A depicts a schema of the production of 3HP from CO₂ and photons (sunlight) in cyanobacteria. FIG. 9B depicts a schema of the production of 3HP from acetyl-CoA, showing the malonyl-CoA reductase and the malonate semialdehyde reductase steps in detail. "AccABCD" represents acetyl-CoA carboxylase. "MCR" represents malonyl-CoA reductase. "MSR" represents malonate semialdehyde reductase. "AcsA" represents acetyl-CoA synthetase.

FIG. 10 depicts an artificial operon construct configured to express malonyl-CoA reductase and malonate semialdehyde reductase. "*p_{cpc}*BLacOO" represents a LacI-regulatable promoter based on the cyanobacterial *cpcB* gene promoter. "RBS" represents a ribosome binding site. "MCR" represents a malonyl-CoA reductase coding sequence. "MSR" represents a malonate semialdehyde reductase coding sequence. "LacI" represents a gene for the lac repressor (LacI).

FIG. 11 depicts growth in the presence and absence of 1 mM IPTG as a function of time for *Synechococcus* sp. PCC 7002 lacking *acsA* and comprising the construct depicted in FIG. 10.

FIG. 12A depicts a schema for the production of lactate from pyruvate as catalyzed by lactate dehydrogenase (Ldh).

FIG. 12B depicts an equation of the reaction catalyzed by pyridine nucleotide transhydrogenase.

FIG. 13 depicts growth and lactate production in the presence and absence of 1 mM IPTG as a function of time for *Synechococcus* sp. PCC 7002 lacking *acsA* and comprising an IPTG-inducible lactate dehydrogenase gene with a coding sequence (*ldh*) from *Bacillus subtilis*.

5

FIG. 14 depicts growth and lactate production in the presence of 1 mM IPTG as a function of time for *Synechococcus* sp. PCC 7002 lacking *acsA*, comprising an IPTG-inducible lactate dehydrogenase gene with a coding sequence (*ldh*) derived from *Bacillus subtilis*, and comprising a soluble pyridine nucleotide transhydrogenase gene with a coding sequence (*udhA*) derived from *Escherichia coli*.

DETAILED DESCRIPTION OF THE INVENTION

One version of the invention includes a microorganism wherein an *acsA* gene product or homolog thereof is functionally deleted. The *acsA* gene product (*AcsA*) and homologs thereof are acetyl-CoA synthetases classified under Enzyme Commission (EC) number 6.2.1.1. Other names for these acetyl-CoA synthetases include “acetate-CoA ligases,” “acetyl-CoA ligases,” and “acyl-activating enzymes.”

“Functional deletion” or its grammatical equivalents refers to any modification to a microorganism that ablates, reduces, inhibits, or otherwise disrupts production of a gene product, renders the gene product non-functional, or otherwise reduces or ablates the gene product’s activity. “Gene product” refers to a protein or polypeptide encoded and produced by a particular gene. “Gene” as used herein refers to a nucleic acid sequence capable of producing a gene product and may include such genetic elements as a coding sequence together with any other genetic elements required for transcription and/or translation of the coding sequence. Such genetic elements may include a promoter, an enhancer, and/or a ribosome binding site (RBS), among others. In some versions of the invention, “functionally deleted *acsA* gene product or homolog thereof” means that the *acsA* gene is mutated to an extent that an *acsA* gene product or homolog thereof is not produced at all.

One of ordinary skill in the art will appreciate that there are many well-known ways to functionally delete a gene product. For example, functional deletion can be accomplished by introducing one or more genetic modifications. As used herein, “genetic modifications” refer to any differences in the nucleic acid composition of a cell, whether in the cell’s native chromosome or in endogenous or exogenous non-chromosomal plasmids harbored within the cell. Examples of genetic modifications that may result in a functionally deleted gene product include but are not limited to mutations, partial or complete deletions, insertions, or other variations to a coding sequence or a sequence controlling the transcription or translation of a coding sequence; placing a coding sequence under the control of a less active promoter; blocking transcription of the gene with a trans-acting DNA binding protein such as a TAL effector or CRISPR guided Cas9; and expressing ribozymes or antisense sequences that target the mRNA of the gene of interest, etc. In some versions, a gene or coding sequence can be replaced with a selection marker or screenable marker. Various methods for introducing the genetic modifications described above are well known in the art and include homologous recombination, among other mechanisms. See, e.g., Green et al., *Molecular Cloning: A laboratory manual*, 4th ed., Cold Spring Harbor Laboratory Press (2012) and Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 3rd ed., Cold Spring Harbor Laboratory Press (2001). Various other genetic modifications that functionally delete a gene product are described in the examples below. Functional deletion can also be accomplished by inhibiting the activity of the gene product, for example, by chemically inhibiting a gene product with a small molecule inhibitor, by

6

expressing a protein that interferes with the activity of the gene product, or by other means.

In certain versions of the invention, the functionally deleted gene product may have less than about 95%, less than about 90%, less than about 85%, less than about 80%, less than about 75%, less than about 70%, less than about 65%, less than about 60%, less than about 55%, less than about 50%, less than about 45%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 1%, or about 0% of the activity of the non-functionally deleted gene product.

In certain versions of the invention, a cell with a functionally deleted gene product may have less than about 95%, less than about 90%, less than about 85%, less than about 80%, less than about 75%, less than about 70%, less than about 65%, less than about 60%, less than about 55%, less than about 50%, less than about 45%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 1%, or about 0% of the activity of the gene product compared to a cell with the non-functionally deleted gene product.

In certain versions of the invention, the functionally deleted gene product may be expressed at an amount less than about 95%, less than about 90%, less than about 85%, less than about 80%, less than about 75%, less than about 70%, less than about 65%, less than about 60%, less than about 55%, less than about 50%, less than about 45%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 1%, or about 0% of the amount of the non-functionally deleted gene product.

In certain versions of the invention, the functionally deleted gene product may result from a genetic modification in which at least 1, at least 2, at least 3, at least 4, at least 5, at least 10, at least 20, at least 30, at least 40, at least 50, or more nonsynonymous substitutions are present in the gene or coding sequence of the gene product.

In certain versions of the invention, the functionally deleted gene product may result from a genetic modification in which at least 1, at least 2, at least 3, at least 4, at least 5, at least 10, at least 20, at least 30, at least 40, at least 50, or more bases are inserted in the gene or coding sequence of the gene product.

In certain versions of the invention, the functionally deleted gene product may result from a genetic modification in which at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% of the gene product’s gene or coding sequence is deleted or mutated.

In certain versions of the invention, the functionally deleted gene product may result from a genetic modification in which at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% of a promoter driving expression of the gene product is deleted or mutated.

7

In certain versions of the invention, the functionally deleted gene product may result from a genetic modification in which at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% of an enhancer controlling transcription of the gene product's gene is deleted or mutated.

In certain versions of the invention, the functionally deleted gene product may result from a genetic modification in which at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% of a sequence controlling translation of gene product's mRNA is deleted or mutated.

In certain versions of the invention, the decreased activity or expression of the functionally deleted gene product is determined with respect to the activity or expression of the gene product in its unaltered state as found in nature. In certain versions of the invention, the decreased activity or expression of the functionally deleted gene product is determined with respect to the activity or expression of the gene product in its form in a corresponding microorganism. In certain versions, the genetic modifications giving rise to a functionally deleted gene product are determined with respect to the gene or coding sequence in its unaltered state as found in nature. In certain versions, the genetic modifications giving rise to a functionally deleted gene product are determined with respect to the gene or coding sequence in its form in a corresponding microorganism.

Some versions of the invention include a plurality of microorganisms, wherein greater than about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or more of the plurality of microorganisms comprise a functionally deleted *acsA* gene product or homolog thereof. In some versions, the plurality of microorganisms is a microbial culture.

Genetic modifications that can be introduced into the *acsA* gene or homologs thereof to functionally delete the *acsA* gene product or homologs thereof, such as generating *acsA* knock-outs, are described in the examples below.

The *acsA* gene is an acetyl-CoA synthetase gene in the exemplary cyanobacterium *Synechococcus* sp. PCC 7002, the coding sequence of which can be found in GenBank under accession number NC_010475.1 and is as follows:

(SEQ ID NO: 1)
 atgtccgaac aaaacattga atccatcctc caggagcagc
 gccttttttc gcctgcacca gactttgetg ccgaggccca
 gatcaagagc ttagaccagt accaagccct ctacgaccgg
 gcgaaaaatg accccgaagc cttttggggg gaactcgccg
 aacaggaatt ggaatggttt gagaaatggg acaaggtgct
 cgattggcaa ccgcctctcg ccaaatgggt tgtcaacggg

8

-continued

aaaattaaca tttcctacaa ttgcctcgac cgtcatctca
 5 aaacctggcg caaaaaataa gccgcctca tctgggaagg
 ggaaccgggt gactcccgta cctcaccta tgcccagcta
 caccacgagg tctgccagtt tgccaatgcg atgaaaaagt
 10 tgggctcaa aaaaggcgat cgcgtcgga tttatatgcc
 aatgatcccg gaagccgtcg ttgcctcct cgcctgtgcc
 cgcattggtg cgcccatac ggtgatattt ggtggcttta
 gtgccgaagc cctcccgagt cgcctcgaag acgctgaagc
 15 caaactggtg atcaccgccg acgggggctt ccgcaaagat
 aaagcggtag cctcaagga tcaagtagat gcggcgatcg
 ccgatcacca tgccccagc gttgagaatg ttttggctgt
 20 tcaacgcacc aaagagcctg tccacatgga agccggcgcg
 gatcactggt ggcatgattt gcaaaaagaa gtctccgctg
 actgtcccgc cgagccgatg gatgccgaag atatgctctt
 25 catcctctat accagcggca ccacgggtaa acccaagggc
 gttgtccaca ctacgggctg ttataatctc tacaccata
 taacgaccaa gtggatcttt gatctcaaag atgatgacgt
 30 gtattggtgt ggtgctgatg tgggttgat caccggccac
 agttacatta cctatggccc tctatctaac ggggcaacgg
 tcttaatgta tgaaggcgca ccccgctcgt ctaatcccgg
 35 ttgctattgg gaaattatc aaaaatattg tgtcaccatt
 ttctatacgg caccacagc gattcgggcc tttatcaaaa
 tgggtgaagg catcccgaat aaatatgaca tgagtccct
 40 gcgcctctta ggaaccgtgg gtgaaccgat taaccagaa
 gcttgatgt ggtaccaccg ggtcattggt gcggaacggt
 gtcccattgt tgatacatgg tggcaaacgg aaaccggtgg
 45 tgtgatgatt acgcctttac ccggtgcaac tcccacaaa
 cccggctcgg caactcgtcc ttttcggggg attgtggcgg
 atgtcgttga ccttgatgga aattccgttg gtgacaacga
 50 aggcggctac ctggtagtga aacaaccctg gcctgggatg
 atgcgtactg tttacggcaa tcccgaacgc ttcgggtcta
 cctattggga gcacatcgcc ccgaaagatg gacaatacct
 ttatttcgca ggtgacgggg cacgccgtga ccaagatggc
 55 tatttttggg ttaggggtcg cgtcgatgat gtcttaaatg
 tttcgggcca tcgcctcggc accatggaag tggaaatcggc
 cctcgtttcc caccctgccc tcgccaagc agccgtggtt
 60 ggaaagccag atccgggtta gggggaagag gtgtttgcct
 ttgtaccct tgagggcacc tacagtcgga gcgacgatct
 cgtaacggaa ctcaagggcc atgtggtgaa agaaattggg
 65 gcgatcgccc gtccgggaga aatccgtttt gccgatgtaa

-continued

```

tgccccaaac cegttctggg aagatcatgc ggcgtttgtt
gcgaaaccta gccgcaggtc aggaattgtt gggcgacacc
tccaccctcg aagaccgcag cgtcctcgat caactccggg
gctaa

```

The *acsA* coding sequence in the exemplary organism *Syn-echococcus* sp. PCC 7002 encodes a protein included in GenBank under accession number YP_001735082.1, having the following amino acid sequence:

```

(MSEQ ID NO: 2)
MSEQNIESIL QEQRLEFSPAP DFAAEAQIKS LDQYQALYDR
AKNDPEGFWG ELAEQELEWF EKWDKVLWDWQ PPFKWFVNG
KINISYNCLD RHLKTRWKNK AALIWEGEPG DSRTLTYAQL
HHEVCQFANA MKKLGVKKGD RVGIYMPMIP EAVVALLACA
RIGAPHTVIF GGFSAEALRS RLEDAAEALV ITADGGFRKD
KAVPLKDQVD AAADHHPAPS VENVLVVQRT KEPVHMEAGR
DHWHDLOKE VSADCPAEPM DAEDMLFILY TSGTTGKPKG
VVHTTGGYNL YTHITTKWIF DLKDDDVYWC GADVGWITGH
SYITYGPLSN GATVLMYEGA PRPSNPGCYW EIIQKYGVTI
FYTAPTAIRA FIKMGEIPN KYDMSLRLL GTVGEPIINPE
AWMWHYRIVG GERCPVDTW WQTETGGVMI TPLPGATPTK
PGSATRPFPG IVADVVDLDG NSVGDNEGGY LVVKQPWPGM
MRTVYGNPER FRSTYWEHIA PKDGQYLYFA GDGARRQDG
YFWIMGRVDD VLNVSghRLG TMEVESALVS HPAVAEAAV
GKPDVPKGEV VFAFVTLGEG YSPSDDLVE LKAHVVKKEIG
AIARPGEIRF ADVMPKTRSG KIMRLLRNL AAGQEIVGDT
STLEDRSVLD QLRG

```

Homologs of *acsA* include coding sequences, genes, or gene products that are homologous to the *acsA* coding sequence, *acsA* gene, or the *acsA* gene product, respectively. Proteins and/or protein sequences are “homologous” when they are derived, naturally or artificially, from a common ancestral protein or protein sequence. Similarly, nucleic acids and/or nucleic acid sequences are homologous when they are derived, naturally or artificially, from a common ancestral nucleic acid or nucleic acid sequence. Homology is generally inferred from sequence similarity between two or more nucleic acids or proteins (or sequences thereof). The precise percentage of similarity between sequences that is useful in establishing homology varies with the nucleic acid and protein at issue, but as little as 25% sequence similarity (e.g., identity) over 50, 100, 150 or more residues (nucleotides or amino acids) is routinely used to establish homology (e.g., over the full length of the two sequences to be compared). Higher levels of sequence similarity (e.g., identity), e.g., 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% or more, can also be used to establish homology. Accordingly, homologs of the coding sequences, genes, or gene products described herein include coding sequences, genes, or gene products, respectively, having at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identity to the

coding sequences, genes, or gene products described herein. Methods for determining sequence similarity percentages (e.g., BLASTP and BLASTN using default parameters) are described herein and are generally available. The homologous proteins should demonstrate comparable activities and, if an enzyme, participate in the same or analogous pathways. “Orthologs” are genes or coding sequences thereof in different species that evolved from a common ancestral gene by speciation. Normally, orthologs retain the same or similar function in the course of evolution. As used herein “orthologs” are included in the term “homologs”.

For sequence comparison and homology determination, one sequence typically acts as a reference sequence to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence based on the designated program parameters. A typical reference sequence of the invention is a nucleic acid or amino acid sequence corresponding to *acsA* or other coding sequences, genes, or gene products described herein.

Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, *Adv. Appl. Math.* 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, *J. Mol. Biol.* 48:443 (1970), by the search for similarity method of Pearson & Lipman, *Proc. Nat'l. Acad. Sci. USA* 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by visual inspection (see *Current Protocols in Molecular Biology*, F. M. Ausubel et al., eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (supplemented through 2008)).

One example of an algorithm that is suitable for determining percent sequence identity and sequence similarity for purposes of defining homologs is the BLAST algorithm, which is described in Altschul et al., *J. Mol. Biol.* 215:403-410 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length *W* in the query sequence, which either match or satisfy some positive-valued threshold score *T* when aligned with a word of the same length in a database sequence. *T* is referred to as the neighborhood word score threshold (Altschul et al., *supra*). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters *M* (reward score for a pair of matching residues; always >0) and *N* (penalty score for mismatching residues; always <0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity *X* from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters *W*, *T*, and *X* determine the sensitivity and speed of the alignment. The BLASTN program (for nucle-

otide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, a cutoff of 100, M=−5, N=−4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff (1989) Proc. Natl. Acad. Sci. USA 89:10915).

In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Natl. Acad. Sci. USA 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001. The above-described techniques are useful in identifying homologous sequences for use in the methods described herein.

The terms “identical” or “percent identity”, in the context of two or more nucleic acid or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence, as measured using one of the sequence comparison algorithms described above (or other algorithms available to persons of skill) or by visual inspection.

The phrase “substantially identical”, in the context of two nucleic acids or polypeptides refers to two or more sequences or subsequences that have at least about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 98%, or about 99% or more nucleotide or amino acid residue identity, when compared and aligned for maximum correspondence, as measured using a sequence comparison algorithm or by visual inspection. Such “substantially identical” sequences are typically considered to be “homologous” without reference to actual ancestry. Preferably, the “substantial identity” exists over a region of the sequences that is at least about 50 residues in length, more preferably over a region of at least about 100 residues, and most preferably, the sequences are substantially identical over at least about 150 residues, at least about 250 residues, or over the full length of the two sequences to be compared.

Homologs of the *acsA* gene product include enzymes falling under Enzyme Commission (EC) number 6.2.1.1. Non-limiting examples of homologs of the *acsA* gene product in various microorganisms include the acetyl-coenzyme A synthetase from *Fischerella* sp. JSC-11 represented by GenBank Accession No. ZP_08986431.1, the acetyl-coenzyme A from *Moorea producta* 3 L synthetase represented by GenBank Accession No. ZP_08425677.1, the acetate/CoA from *Cyanothece* sp. PCC 7822 ligase represented by GenBank Accession No. YP_003886065.1, the acetyl-CoA from *Cyanothece* sp. PCC 7424 synthetase represented by GenBank Accession No. YP_002378472.1, the unnamed protein product from *Thermosynechococcus elongatus* BP-1 represented by GenBank Accession No. NP_681677.1, the unnamed protein product from *Anabaena variabilis* ATCC 29413 represented by GenBank Accession No. YP_321725.1, the acetate-CoA ligase from *Cylindrospermopsis raciborskii* CS-505 represented by GenBank Accession No. ZP_06308209.1, the acetyl-CoA synthetase from *Nostoc punctiforme* PCC 73102 represented by GenBank

Accession No. YP_001869493.1, the acetate-CoA ligase from *Microcoleus chthonoplastes* PCC 7420 represented by GenBank Accession No. ZP_05030125.1, the acetyl-coenzyme A synthetase from *Nodularia spumigena* CCY9414 represented by GenBank Accession No. ZP_01629204.1, the acetyl-CoA synthetase from *Microcystis aeruginosa* NIES-843 represented by GenBank Accession No. YP_001660936.1, the acetate/CoA ligase from ‘*Nostoc azollae*’ 0708 represented by GenBank Accession No. YP_003723268.1, the *acsA* gene product from *Microcystis aeruginosa* PCC 7806 represented by GenBank Accession No. CAO86486.1, the acetyl-coenzyme A synthetase from *Microcoleus vaginatus* FGP-2 represented by GenBank Accession No. ZP_08490634.1, the Acetate-CoA ligase from *Raphidiopsis brookii* D9 represented by GenBank Accession No. ZP_06304063.1, the *acsA* gene product from *Acaryochloris marina* MBIC11017 represented by GenBank Accession No. YP_001517064.1, the acetyl-CoA synthetase from *Acaryochloris* sp. CCME5 5410 represented by GenBank Accession No. ZP_09248274.1, the acetyl-CoA synthetase from *Oscillatoria* sp. PCC 6506 represented by GenBank Accession No. ZP_07113076.1, the acetyl-CoA synthetase from *Cyanothece* sp. PCC 7425 represented by GenBank Accession No. YP_002484565.1, the Acetate-CoA ligase from *Lyngbya* sp. PCC 8106 represented by GenBank Accession No. ZP_01623739.1, the unnamed protein product from *Trichodesmium erythraeum* IMS101 represented by GenBank Accession No. YP_722064.1, the acetyl-CoA synthetase from *Arthrospira platensis* str. *Paraca* represented by GenBank Accession No. ZP_06383883.1, the acetate/CoA ligase from *Arthrospira maxima* CS-328 represented by GenBank Accession No. ZP_03274675.1, the acetyl-coenzyme A synthetase from *Arthrospira* sp. PCC 8005 represented by GenBank Accession No. ZP_09782650.1, the acetate/CoA ligase from *Arthrospira maxima* CS-328 represented by GenBank Accession No. EDZ93724.1, the acetyl-coenzyme A synthetase from *Arthrospira* sp. PCC 8005 represented by GenBank Accession No. CCE18403.1, the unnamed protein product from *Cyanothece* sp. PCC 8802 represented by GenBank Accession No. YP_003138301.1, the acetate/CoA ligase from *Cyanothece* sp. PCC 8802 represented by GenBank Accession No. ACV01466.1, the acetyl-CoA synthetase from *Cyanothece* sp. PCC 8801 represented by GenBank Accession No. YP_002373634.1, the acetyl-coenzyme A synthetase from *Cyanothece* sp. ATCC 51472 represented by GenBank Accession No. ZP_08974038.1, the unnamed protein product from *Synechococcus elongatus* PCC 6301 represented by GenBank Accession No. ZP_08974038.1, the acetyl-CoA synthetase from *Cyanothece* sp. ATCC 51142 represented by GenBank Accession No. YP_001803432.1, the acetyl-coenzyme A synthetase from *Cyanothece* sp. CCY0110 represented by GenBank Accession No. ZP_01730332.1, the AMP-dependent synthetase and ligase from *Crocospaera watsonii* WH 8501 represented by GenBank Accession No. ZP_00514814.1, the acetate-CoA ligase from *Synechococcus* sp. PCC 7335 represented by GenBank Accession No. ZP_05036109.1, the acetyl-coenzyme A synthetase from *Synechococcus* sp. WH 8102 represented by GenBank Accession No. NP_897106.1, the acetate-CoA ligase from *Synechococcus* sp. WH 7805 represented by GenBank Accession No. ZP_01123920.1, the acetate-CoA ligase from *Synechococcus* sp. WH 8109 represented by GenBank Accession No. ZP_05788236.1, the acetyl-coenzyme A synthetase from *Prochlorococcus marinus* str. MIT 9313 represented by GenBank Accession No. NP_894222.1, the acetyl-coenzyme A synthetase from *Prochlorococcus marinus* str. MIT 9303 represented by Gen-

13

Bank Accession No. YP_001017906.1, the acetyl-CoA synthetase from *Synechococcus* sp. WH 7803 represented by GenBank Accession No. YP_001224763.1, the acetyl-coenzyme A synthetase from *Synechococcus* sp. RS9917 represented by GenBank Accession No. ZP_01080065.1, the acetyl-coenzyme A synthetase from *Synechococcus* sp. WH 8016 represented by GenBank Accession No. ZP_08955323.1, the acetate-CoA ligase from *Synechococcus* sp. CC9311 represented by GenBank Accession No. YP_730758.1, the acetyl-coenzyme A synthetase from *Prochlorococcus marinus* str. MIT 9211 represented by GenBank Accession No. YP_001550915.1, the acetate-CoA ligase from *Synechococcus* sp. CC9902 represented by GenBank Accession No. YP_377326.1, the acetate-CoA ligase from *Synechococcus* sp. BL107 represented by GenBank Accession No. ZP_01467683.1, the acetyl-coenzyme A synthetase from *Synechococcus* sp. RS9916 represented by GenBank Accession No. ZP_01471857.1, the acetyl-coenzyme A synthetase from *Synechococcus* sp. CC9605 represented by GenBank Accession No. YP_381449.1, the acetyl-coenzyme A synthetase from *Synechococcus* sp. CB0205 represented by GenBank Accession No. ZP_07971118.1, the acetyl-CoA synthetase from *Synechococcus* sp. RCC307 represented by GenBank Accession No. YP_001227601.1, the acetyl-coenzyme A synthetase from *Synechococcus* sp. CB0101 represented by GenBank Accession No. ZP_07973216.1, the acetate-CoA ligase from *Cyanobium* sp. PCC 7001 represented by GenBank Accession No. ZP_05043915.1, the acetate-CoA ligase from *Synechococcus* sp. WH 5701 represented by GenBank Accession No. ZP_01085120.1, the acs gene product from *Prochlorococcus marinus* subsp. *marinus* str. CCMP1375 represented by GenBank Accession No. NP_875433.1, the acetyl-coenzyme A synthetase from *Prochlorococcus marinus* str. NATL2A represented by GenBank Accession No. YP_291252.1, the acetyl-coenzyme A synthetase from *Gloeobacter violaceus* PCC 7421 represented by GenBank Accession No. NP_923105.1, the acetyl-coenzyme A synthetase from *cyanobacterium* UCYN-A represented by GenBank Accession No. YP_003421821.1, the acetyl-coenzyme A synthetase from *Prochlorococcus marinus* str. NATL1A represented by GenBank Accession No. YP_001014503.1, the acetyl-coenzyme A synthetase from *Singulisphaera acidiphila* DSM 18658 represented by GenBank Accession No. ZP_09573232.1, the acetyl-coenzyme A synthetase from *Prochlorococcus marinus* subsp. *pastoris* str. CCMP1986 represented by GenBank Accession No. NP_892737.1, the acetyl-coenzyme A synthetase from *Prochlorococcus marinus* str. MIT 9312 represented by GenBank Accession No. YP_397116.1, the acetate/CoA ligase from *Meiothermus ruber* DSM 1279 represented by GenBank Accession No. YP_003507084.1, the acetyl-coenzyme A synthetase from *Prochlorococcus marinus* str. MIT 9215 represented by GenBank Accession No. YP_001483902.1, the acs gene product from *Prochlorococcus marinus* str. AS9601 represented by GenBank Accession No. YP_001009068.1, the acetyl-coenzyme A synthetase from *Prochlorococcus marinus* str. MIT 9515 represented by GenBank Accession No. YP_001011000.1, the acetate-CoA ligase from *Prochlorococcus marinus* str. MIT 9202 represented by GenBank Accession No. ZP_05137406.1, the acetyl-coenzyme A synthetase from *Marimithermus hydrothermalis* DSM 14884 represented by GenBank Accession No. YP_004368660.1, the acetyl-coenzyme A synthetase from *Prochlorococcus marinus* str. MIT 9301 represented by GenBank Accession No. YP_001090869.1, the unnamed protein product from *Nostoc* sp. PCC 7120 represented by GenBank Accession No.

14

NP_488297.1, the acetate/CoA ligase from *Truepera radiovictrix* DSM 17093 represented by GenBank Accession No. YP_003703935.1, the acetate/CoA ligase from *Haliangium ochraceum* DSM 14365 represented by GenBank Accession No. YP_003269915.1, the acetyl-coenzyme A synthetase from *Gemmata obscuriglobus* UQM 2246 represented by GenBank Accession No. ZP_02733777.1, the acetyl-coenzyme A synthetase from *Isosphaera pallida* ATCC 43644 represented by GenBank Accession No. YP_004179760.1, the acetyl-CoA synthetase from *Chloroherpeton thalassium* ATCC 35110 represented by GenBank Accession No. YP_001995147.1, the acetate-CoA ligase from *Planctomyces maris* DSM 8797 represented by GenBank Accession No. ZP_01856978.1, the acetyl-CoA synthetase from *Thermus thermophilus* HB8 represented by GenBank Accession No. YP_144514.1, the acetate/CoA ligase from *Planctomyces limmophilus* DSM 3776 represented by GenBank Accession No. YP_003632128.1, the acetyl-CoA synthetase from *Thermus thermophilus* HB27 represented by GenBank Accession No. YP_004855.1, the acetyl-coenzyme A synthetase from *Oceanitennus profundus* DSM 14977 represented by GenBank Accession No. YP_004057553.1, the acetyl-coenzyme A synthetase from *Candidatus Koribacter versatilis* Ellin345 represented by GenBank Accession No. YP_592595.1, the acetate/CoA ligase from *Meiothermus silvanus* DSM 9946 represented by GenBank Accession No. YP_003684983.1, the acetate-CoA ligase from *Verrucomicrobium spinosum* DSM 4136 represented by GenBank Accession No. ZP_02931268.1, the acetate/CoA ligase from *Thermus aquaticus* Y51MC23 represented by GenBank Accession No. ZP_03496427.1, the acetyl-coenzyme A synthetase from *Symbiobacterium thermophilum* IAM 14863 represented by GenBank Accession No. YP_074710.1, the acetate/CoA ligase from *bacterium* Ellin 514 represented by GenBank Accession No. ZP_03630513.1, the acetyl-CoA synthetase from uncultured candidate division OP1 bacterium represented by GenBank Accession No. BAL56248.1, the acetyl-coenzyme A synthetase from *Blastopirellula marina* DSM 3645 represented by GenBank Accession No. ZP_01092728.1, the acs2 gene product from *Thermus scotoductus* SA-01 represented by GenBank Accession No. YP_004201921.1, the acetyl-coenzyme A synthetase from *Archaeoglobus veneficus* SNP6 represented by GenBank Accession No. YP_004341076.1, the Acetyl-coenzyme A synthetase from *Desulfitobacterium dehalogenans* ATCC 51507 represented by GenBank Accession No. ZP_09634500.1, the unnamed protein product from *Candidatus Chloracidobacterium thermophilum* B represented by GenBank Accession No. YP_004864177.1, the acetate-CoA ligase from *Acidobacterium capsulatum* ATCC 51196 represented by GenBank Accession No. YP_002755829.1, the acetate/CoA ligase from *Pirellula staleyii* DSM 6068 represented by GenBank Accession No. YP_003369860.1, the acetyl-CoA synthetase from *Chlorobium chlorochromatii* CaD3 represented by GenBank Accession No. YP_379980.1, the acetate-CoA ligase from *Myxococcus xanthus* DK 1622 represented by GenBank Accession No. YP_630789.1, the acetate-CoA ligase from *Myxococcus fulvus* HW-1 represented by GenBank Accession No. YP_004667083.1, the unnamed protein product from *Candidatus Solibacter usitatus* Ellin 6076 represented by GenBank Accession No. YP_829106.1, the acetyl-coenzyme A synthetase from *Planctomyces brasiliensis* DSM 5305 represented by GenBank Accession No. YP_004268501.1, the acetyl-CoA synthetase from *Escherichia coli* UMN026 represented by GenBank Accession No. YP_002415210.1, the acetyl-CoA synthetase from *Escherichia coli* FVEC1412

represented by GenBank Accession No. ZP_06646805.1, the acetyl-coenzyme A synthetase from *Escherichia coli* FVEC1302 represented by GenBank Accession No. ZP_06988121.1, the acetate-CoA ligase from *Escherichia coli* MS198-1 represented by GenBank Accession No. ZP_07115900.1, the acetyl-CoA synthetase from *Escherichia coli* UMN026 represented by GenBank Accession No. CAR15720.1, the Acs2p from *Saccharomyces cerevisiae* S288c represented by GenBank Accession No. NP_013254.1, the acetyl CoA synthetase from *Saccharomyces cerevisiae* YJM789 represented by GenBank Accession No. EDN59693.1, the K7_Acs2p from *Saccharomyces cerevisiae* Kyokai no. 7 represented by GenBank Accession No. GAA25035.1, the acetyl CoA synthetase from *Saccharomyces cerevisiae* RM11-1a represented by GenBank Accession No. EDV09449.1, the bifunctional acetyl-CoA synthetase and propionyl-CoA synthetase from *Escherichia coli* str. K12 substr. W3110 represented by GenBank Accession No. BAE78071.1, and the acetyl-coenzyme A synthetase from *Pseudomonas fulva* 12-X represented by GenBank Accession No. YP_004473024.1, among others. The coding sequences encoding these gene products can be found in GenBank (<http://www.ncbi.nlm.nih.gov/GenBank/>).

Homologs of *acsA* and *AcsA* discussed in the examples include the acetyl-CoA synthetase from *Synechocystis* sp. PCC 6803 (slI0542; GenBank Accession No. NP_442428.1; SEQ ID NOS:3 and 4) and the unnamed protein product from *Synechococcus* sp. PCC 7942 (SYNPCC7942_1342; GenBank Accession No. YP_400369.1; SEQ ID NOS:5 and 6)

The microorganism of the present invention preferably includes any microorganism that harbors an *acsA* gene or homolog thereof or expresses an *acsA* gene product or homolog thereof that is capable of being functionally deleted to render the microorganism more tolerant of organic acids. The microorganism may be eukaryotic, such as yeast, or prokaryotic, such as bacteria or archaea. Among bacteria, gram-positive, gram-negative, and ungrouped bacteria are suitable. Phototrophs, lithotrophs, and organotrophs are also suitable. In preferred versions of the invention, the microorganism is a phototroph, such as a cyanobacterium. Suitable cyanobacteria include those from the genera *Agmenellum*, *Anabaena*, *Aphanocapsa*, *Arthrospira*, *Gloeocapsa*, *Haplo-siphon*, *Mastigocladus*, *Nostoc*, *Oscillatoria*, *Prochlorococcus*, *Scytonema*, *Synechococcus*, and *Synechocystis*. Preferred cyanobacteria include those selected from the group consisting of *Synechococcus* spp., spp., *Synechocystis* spp., and *Nostoc* spp. Particularly suitable examples of *Synechococcus* spp. include *Synechococcus* sp. PCC 7942 and *Synechococcus* sp. PCC 7002. A particularly suitable example of *Synechocystis* spp. includes *Synechocystis* sp. PCC 6803. A benefit of phototrophs is that they require only CO₂ as a carbon source and are not dependent on food-based commodities or other types of biomass for which there is a growing high demand.

Functional deletion of the *acsA* gene product or homolog thereof in the microorganism results in increased tolerance of the microorganism to organic acids compared to a corresponding microorganism. As used herein, "corresponding microorganism" refers to a microorganism of the same species having the same or substantially same genetic and proteomic composition as a microorganism of the invention, with the exception of genetic and proteomic differences resulting from the modifications described herein for the microorganisms of the invention. Such tolerance is with respect to any organic acid present within the organism or its growth medium, particularly those that may be present in high abundance. Non-limiting examples of organic acids to which the

microorganisms of the present invention have increased tolerance include acetic acid, acrylic acid, aspartic acid, benzoic acid, butyric acid, citric acid, formic acid, fumaric acid, furan dicarboxylic acid (2,5-furandicarboxylic acid), glucaric acid, glutamic acid, heptanoic acid, hexanoic acid, 3-hydroxypropionic acid (3HP), isophthalic acid, itaconic acid, lactic acid, levoascorbic acid, levulinic acid, malic acid, octanoic acid, oxalic acid, pentanoic acid, phosphoric acid, propionic acid, pyruvic acid, succinic acid (1,4 succinic acid), and terephthalic acid, among others. The examples show various aspects of increased tolerance to exemplary organic acids 3-hydroxypropionic acid (3HP), acrylic acid, and propionic acid.

One aspect of the increased tolerance to organic acids is an increase in the minimal inhibitory concentration (MIC) of a particular organic acid compared to a corresponding microorganism. MIC is the lowest concentration of an agent that will inhibit growth of a microorganism. An MIC can be determined by titrating the agent in the growth medium of the microorganism. The lowest concentration of the agent in which the microorganism is no longer able to grow is the MIC. Methods of culturing microorganisms and of detecting their growth are well known in the art and are not discussed in detail herein. A relative increase in MIC indicates a higher tolerance to an agent and indicates that the microorganism can grow in the presence of a higher concentration of the agent. Conversely, a relative decrease in MIC indicates a lower tolerance to an agent and indicates that the microorganism can grow only in the presence of a lower concentration of the agent.

Functional deletion of the *acsA* gene product or homolog thereof in the microorganism confers an MIC of at least about 10 μ M, 25 μ M, 50 μ M, 75 μ M, 100 μ M, 250 μ M, 500 μ M, 1 mM, 25 mM, 50 mM, 70 mM, 100 mM, 125 mM, or 150 mM to acrylic acid; an MIC of at least about 10 mM, 15 mM, 20 mM, 25 mM, 50 mM, 75 mM, 100 mM, 125 mM, 150 mM, 175 mM, 200 mM, 225 mM, 250 mM, 260 mM, 300 mM, 350 mM, or more to 3HP; and/or an MIC of at least about 250 μ M, 500 μ M, 1 mM, 50 mM, 100 mM, 200 mM, 300 mM, 350 mM, 400 mM, 450 mM, 500 mM, or more to propionic acid. Such MICs occur in at least *Synechococcus* sp. cyanobacteria, such as *Synechococcus* sp. PCC 7002 and *Synechococcus* sp. PCC 7942, when assayed at a pH of about 8. Such MICs also occur in *Synechocystis* sp., such as *Synechocystis* sp. PCC 6803, when assayed at a pH of about 8. Such MICs also occur in any other microorganism described herein, such as *Prochlorococcus* sp., *Nostoc* sp., or others.

Another aspect of increased tolerance is increased growth rate in the presence of a certain concentration of an organic acid or an equal growth rate in the presence of an increased concentration of an organic acid compared to a corresponding microorganism.

In various aspects of the invention, functional deletion of the *acsA* gene product or homolog thereof in the microorganism confers at least about a 1.5-fold, a 5-fold, a 10-fold, a 15-fold, a 25-fold, a 50-fold, a 75-fold, a 100-fold, a 500-fold, a 750-fold, a 1,000-fold, 1,250-fold, a 1,500-fold, a 1,750-fold, a 2,000-fold, a 2,250-fold, a 2,500-fold, a 2,750-fold, a 3,000-fold, a 3,250-fold, or a 3,500-fold increase in tolerance against an organic acid. The organic acid to which functional deletion of the *acsA* gene product confers such MICs may include acrylic acid, 3HP, propionic acid, or lactic acid, among others. In some versions of the invention, functional deletion of the *acsA* gene product in *Synechococcus* sp. PCC 7002 confers at least about a 2,800-fold increase in MIC for acrylic acid, at least about a 26-fold increase in MIC for 3HP, and at least about a 100-fold increase in MIC for propionic acid at pH of about 8 (see examples below).

The increased tolerance to organic acids conferred by functional deletion of the *acsA* gene product or homolog thereof renders the microorganism particularly suited for producing high amounts of organic acids, many of which have industrial utility. Accordingly, the microorganism in some versions of the invention is capable of producing an organic acid that can be isolated for industrial purposes. The microorganism may be able to naturally make the organic acid, may be genetically modified to make the organic acid, or may be genetically modified to make increased amounts of the organic acid that it already makes. Non-limiting examples of organic acids that the microorganisms of the present invention can produce include acetic acid, aspartic acid, benzoic acid, citric acid, formic acid, fumaric acid, furan dicarboxylic acid (2,5-furandicarboxylic acid), glucaric acid, glutamic acid, 3-hydroxypropionic acid (3HP), isophthalic acid, itaconic acid, lactic acid, levoascorbic acid, levulinic acid, malic acid, oxalic acid, phosphoric acid, propionic acid, pyruvic acid, succinic acid (1,4 succinic acid), and terephthalic acid, among others. In preferred versions of the invention, the microorganism is capable of making at least 3HP and or lactic acid.

The microorganism may be modified to express or increase expression of one or more genes involved in the production of the organic acid. Modifying the microorganism to express or increase expression of a gene can be performed using any methods currently known in the art or discovered in the future. Examples include genetically modifying the microorganism and culturing the microorganism in the presence of factors that increase expression of the gene. Suitable methods for genetic modification include but are not limited to placing the coding sequence under the control of a more active promoter, increasing the copy number of the gene, and/or introducing a translational enhancer on the gene (see, e.g., Olins et al. *Journal of Biological Chemistry*, 1989, 264(29):16973-16976). Increasing the copy number of the gene can be performed by introducing additional copies of the gene to the microorganism, i.e., by incorporating one or more exogenous copies of the native gene or a heterologous homolog thereof into the microbial genome, by introducing such copies to the microorganism on a plasmid or other vector, or by other means. "Exogenous" used in reference to a genetic element means the genetic element is introduced to a microorganism by genetic modification. "Heterologous" used in reference to a genetic element means that the genetic element is derived from a different species. A promoter that controls a particular coding sequence is herein described as being "operationally connected" to the coding sequence.

The microorganisms of the invention may include at least one recombinant nucleic acid configured to express or overexpress a particular enzyme. "Recombinant" as used herein with reference to a nucleic acid molecule or polypeptide is one that has a sequence that is not naturally occurring, has a sequence that is made by an artificial combination of two otherwise separated segments of sequence, or both. This artificial combination can be achieved, for example, by chemical synthesis or by the artificial manipulation of isolated segments of nucleic acid molecules or polypeptides, such as genetic engineering techniques. "Recombinant" is also used to describe nucleic acid molecules that have been artificially modified but contain the same regulatory sequences and coding regions that are found in the organism from which the nucleic acid was isolated. A recombinant cell or microorganism is one that contains a recombinant nucleic acid molecule or polypeptide. "Overexpress" as used herein means that a particular gene product is produced at a higher level in one cell, such as a recombinant cell, than in a corresponding cell.

For example, a microorganism that includes a recombinant nucleic acid configured to overexpress an enzyme produces the enzyme at a greater amount than a microorganism that does not include the recombinant nucleic acid.

In some versions of the invention, the microorganism is genetically modified to produce or enhance production of 3HP. Such a microorganism can be obtained by expressing or increasing expression of a gene for any one or more of the enzymes catalyzing the various steps in a 3HP-production pathway. Non-limiting examples of suitable enzymes include pyruvate kinase, pyruvate dehydrogenase, acetyl-CoA carboxylase, malonyl-CoA reductase, malonate semialdehyde reductase, phosphoenolpyruvate carboxylase, aspartate aminotransferase, aspartate decarboxylase, and β -alanine/ α -ketoglutarate aminotransferase. See FIGS. 7, 9A, and 9B. See also U.S. Pat. No. 8,048,624 to Lynch, U.S. Pub. 2011/0125118 to Lynch, U.S. Pub. 2010/0210017 to Gill et al., and Warnecke et al. *Metabolic Engineering* (2010) 12:241-250 for additional enzymes.

Accordingly, some microorganisms of the invention include at least one recombinant nucleic acid configured to express or overexpress a malonyl-CoA reductase. Malonyl-CoA reductases include the enzymes classified under EC 1.2.1.75. In some versions, the microorganism is modified to harbor a nucleic acid encoding the malonyl-CoA reductase from *Chloroflexus aurantiacus* or a homolog thereof. The coding sequence for the malonyl-CoA reductase from *Chloroflexus aurantiacus* is included in GenBank under accession number AY530019 and is represented by SEQ ID NO:7. The *Chloroflexus aurantiacus* malonyl-CoA reductase gene product is included in GenBank under accession number AAS20429 and has an amino acid sequence represented by SEQ ID NO:8. The malonyl-CoA reductase from *Chloroflexus aurantiacus* has been shown to be a bi-functional enzyme, having activity that converts malonyl-CoA to malonate semialdehyde in addition to activity that converts malonate semialdehyde to 3HP.

Exemplary homologs of the *Chloroflexus aurantiacus* malonyl-CoA reductase gene product include but are not limited to the short-chain dehydrogenase/reductase SDR from *Chloroflexus aggregans* DSM 9485 represented by GenBank Accession No. YP_002462600.1, the short-chain dehydrogenase/reductase SDR from *Oscillochloris trichoides* DG6 represented by GenBank Accession No. ZP_07684596.1, the short-chain dehydrogenase/reductase SDR from *Roseiflexus castenholzii* DSM 13941 represented by GenBank Accession No. YP_001433009.1, the short-chain dehydrogenase/reductase SDR from *Roseiflexus* sp. RS-1 represented by GenBank Accession No. YP_001277512.1, among others. The coding sequences encoding these gene products can be found in GenBank.

Homologs of the *Chloroflexus aurantiacus* malonyl-CoA reductase also include enzymes having an amino acid sequence at least about 80%, 85%, 90%, 95%, 97%, 98%, 99% or more identical to SEQ ID NO:8. Sequences having these percent identities can be obtained by aligning SEQ ID NO:8 to the sequences of the *Chloroflexus aurantiacus* malonyl-CoA reductase homologs listed above or otherwise known in the art to determine which residues are amenable to variation (i.e., substitution, deletion, addition, etc.) and the identities of the suitably substituted or added residues.

In some versions of the invention, the microorganism is modified to harbor a nucleic acid encoding the malonyl-CoA reductase from *Sulfolobus tokodaii* or a homolog thereof. The coding sequence for the malonyl-CoA reductase from *Sulfolobus tokodaii* is included in GenBank under accession number NC_003106.2 (positions 2170729-2171808; Gene

ID 1460244) and is represented by SEQ ID NO:11. A truncated, codon-optimized version of the coding sequence preferred for expression in cyanobacteria is represented by SEQ ID NO:12. The gene product of the malonyl-CoA reductase from *Sulfolobus tokodaii* is included in GenBank under accession number NP_378167. A truncated gene product encoded by SEQ ID NO:12 and suitable for use in the present invention has an amino acid sequence represented by SEQ ID NO:13. The malonyl-CoA reductase from *Sulfolobus tokodaii* has been shown to have activity that converts malonyl-CoA to malonate semialdehyde. It does not appear to have activity that converts malonate semialdehyde to 3HP.

Exemplary homologs of the malonyl-CoA reductase from *Sulfolobus tokodaii* include but are not limited to the aspartate-semialdehyde dehydrogenase from *Acidianus hospitalis* W1 represented by GenBank Accession No. YP_004459517.1, the aspartate-semialdehyde dehydrogenase from *Metallosphaera sedula* DSM 5348 represented by GenBank Accession No. YP_001190808.1, the malonyl/succinyl-CoA reductase from *Metallosphaera cuprina* Ar-4 represented by GenBank Accession No. YP_004410014.1, the aspartate-semialdehyde dehydrogenase from *Sulfolobales archaeon* AZ1 represented by GenBank Accession No. EWG07552.1, the aspartate-semialdehyde dehydrogenase from *Sulfolobus solfataricus* P2 represented by GenBank Accession No. NP_343563.1, the aspartate-semialdehyde dehydrogenase from *Metallosphaera yellowstonensis* represented by GenBank Accession No. WP_009071519.1, the aspartate-semialdehyde dehydrogenase from *Sulfolobus islandicus* M.16.27 represented by GenBank Accession No. YP_002844727.1, the aspartate-semialdehyde dehydrogenase from *Sulfolobus islandicus* L.S.2.15 represented by GenBank Accession No. YP_002833533.1, the aspartate-semialdehyde dehydrogenase from *Sulfolobus islandicus* HVE10/4 represented by GenBank Accession No. YP_005647305.1, the aspartate-semialdehyde dehydrogenase from *Sulfolobus islandicus* Y.N.15.51 represented by GenBank Accession No. YP_002841967.1, the aspartate-semialdehyde dehydrogenase from *Sulfolobus acidocaldarius* DSM 639 represented by GenBank Accession No. YP_256941.1, the aspartate-semialdehyde dehydrogenase from *Sulfolobus islandicus* M.14.25 represented by GenBank Accession No. YP_002830795.1, the aspartate-semialdehyde dehydrogenase from *Sulfolobus acidocaldarius* SUSAZ represented by GenBank Accession No. YP_008948306.1, the aspartate-semialdehyde dehydrogenase from *Sulfolobales archaeon* Acd1 represented by GenBank Accession No. WP_020198954.1, the aspartate-semialdehyde dehydrogenase from *Sulfolobus acidocaldarius* DSM 639 represented by GenBank Accession No. YP_256733.1, the aspartate-semialdehyde dehydrogenase from *Sulfolobus acidocaldarius* SUSAZ represented by GenBank Accession No. YP_008948046.1, the aspartate-semialdehyde dehydrogenase from *Archaeoglobus profundus* DSM 5631 represented by GenBank Accession No. YP_003401535.1, the aspartate-semialdehyde dehydrogenase from *Candidatus Caldiarchaeum subterraneum* represented by GenBank Accession No. YP_008797381.1, the aspartate-semialdehyde dehydrogenase from *Ferroglobus placidus* DSM 10642 represented by GenBank Accession No. YP_003435562.1, the aspartate-semialdehyde dehydrogenase from *Methanothermobacter marburgensis* str. Marburg represented by GenBank Accession No. YP_003850098.1, the aspartate-semialdehyde dehydrogenase from *Methanothermobacter thermotrophicus* CaT2 represented by GenBank Accession No. BAM69964.1, the aspartate-semialdehyde dehydrogenase from *Methanothermobacter thermotrophicus* str. Delta H

represented by GenBank Accession No. NP_275938.1, the aspartate semialdehyde dehydrogenase from *Archaeoglobus sulfatcallidus* PM70-1 represented by GenBank Accession No. YP_007906903.1, the aspartate-semialdehyde dehydrogenase from *Pyrobaculum arsenaticum* DSM 13514 represented by GenBank Accession No. YP_001153189.1, the aspartate semialdehyde dehydrogenase from *Methanothermobacter fervidus* DSM 2088 represented by GenBank Accession No. YP_004004235.1, and the aspartate-semialdehyde dehydrogenase from *Methanopyrus kandleri* AV19 represented by GenBank Accession No. NP_614672.1, among others. The coding sequences encoding these gene products can be found in GenBank.

Homologs of the *Sulfolobus tokodaii* malonyl-CoA reductase also include enzymes having an amino acid sequence at least about 80%, 85%, 90%, 95%, 97%, 98%, 99% or more identical to SEQ ID NO:13. Sequences having these percent identities can be obtained by aligning SEQ ID NO:13 to the sequences of the *Sulfolobus tokodaii* malonyl-CoA reductase homologs listed above or otherwise known in the art to determine which residues are amenable to variation (i.e., substitution, deletion, addition, etc.) and the identities of the suitably substituted or added residues.

In some versions of the invention, the microorganism is modified to express or increase expression of a malonate semialdehyde reductase. Malonate semialdehyde reductase converts malonate semialdehyde to 3HP. Such a modification is preferred in microorganisms modified to express or increase expression of a malonyl-CoA reductase that does not convert malonate semialdehyde to 3HP, such as the malonyl-CoA reductase from *Sulfolobus tokodaii*. Suitable malonate semialdehyde reductases can use either NADH (EC 1.1.1.59) or NADPH (EC 1.1.1.298) as cofactors. Malonate semialdehyde reductases that use NADPH are preferred. In some versions, the microorganism is modified to harbor a nucleic acid encoding the malonate semialdehyde reductase from *Metallosphaera sedula* or a homolog thereof. The coding sequence of the malonate semialdehyde reductase from *Metallosphaera sedula* is included in GenBank under accession number NC_009440.1 (Gene ID 5103380; positions 1929295-1930239) and is represented by SEQ ID NO:14. A codon-optimized version of the coding sequence preferred for expression in cyanobacteria is represented by SEQ ID NO:15. The gene product of the malonate semialdehyde reductase from *Metallosphaera sedula* is included in GenBank under accession number YP_001192057 and has an amino acid sequence represented by SEQ ID NO:16.

Exemplary homologs of the malonate semialdehyde reductase from *Metallosphaera sedula* include but are not limited to the 3-hydroxyacyl-CoA dehydrogenase from *Metallosphaera sedula* DSM 5348 represented by GenBank Accession No. YP_001192057.1, the malonate semialdehyde reductase from *Metallosphaera cuprina* Ar-4 represented by GenBank Accession No. YP_004408885.1, the 3-hydroxyacyl-CoA dehydrogenase NAD-binding protein from *Acidianus hospitalis* W1 represented by GenBank Accession No. YP_004458285.1, the 3-hydroxyacyl-CoA dehydrogenase from *Sulfolobales archaeon* AZ1 represented by GenBank Accession No. EWG08084.1, the 3-hydroxyacyl-CoA dehydrogenase from *Metallosphaera yellowstonensis* represented by GenBank Accession No. WP_009075415.1, the 3-hydroxyacyl-CoA dehydrogenase from *Sulfolobus solfataricus* P2 represented by GenBank Accession No. NP_342162.1, the 3-hydroxyacyl-CoA dehydrogenase NAD-binding protein from *Sulfolobus islandicus* HVE10/4 represented by GenBank Accession No. YP_005646018.1, the 3-hydroxyacyl-CoA dehydrogenase NAD-binding protein from *Sulfo-*

bus islandicus REY15A represented by GenBank Accession No. YP_005648646.1, the 3-hydroxyacyl-CoA dehydrogenase from *Sulfolobus islandicus* LAL14/1 represented by GenBank Accession No. YP_007865821.1, the 3-hydroxyacyl-CoA dehydrogenase from *Sulfolobus islandicus* M.14.25 represented by GenBank Accession No. YP_002829538.1, the 3-hydroxyacyl-CoA dehydrogenase from *Sulfolobus islandicus* represented by GenBank Accession No. WP_016732252.1, the 3-hydroxyacyl-CoA dehydrogenase from *Sulfolobales archaeon* Acd1 represented by GenBank Accession No. WP_020199213.1, the 3-hydroxybutyryl-CoA dehydrogenase from *Sulfolobus tokodaii* str. 7 represented by GenBank Accession No. NP_377470.1, the 3-hydroxyacyl-CoA dehydrogenase from *Sulfolobus acidocaldarius* SUSAZ represented by GenBank Accession No. YP_008947634.1, the 3-hydroxybutyryl-CoA dehydrogenase from *Sulfolobus acidocaldarius* DSM 639 represented by GenBank Accession No. YP_256228.1, the 3-hydroxyacyl-CoA dehydrogenase from *Archaeoglobus fulgidus* DSM 4304 represented by GenBank Accession No. NP_070034.1, the 3-hydroxyacyl-CoA dehydrogenase from *Burkholderia* sp. H160 represented by GenBank Accession No. WP_008917830.1, the 3-hydroxyacyl-CoA dehydrogenase represented by hbd-8 from *Planctomyces maris* represented by GenBank Accession No. WP_002645585.1, the 3-hydroxybutyryl-CoA dehydrogenase from *Megasphaera* sp. UPII 199-6 represented by GenBank Accession No. WP_007391670.1, the 3-hydroxyacyl-CoA dehydrogenase from *Burkholderia pseudomallei* 1026b represented by GenBank Accession No. YP_006275221.1, the 3-hydroxyacyl-CoA dehydrogenase from *Burkholderia oklahomensis* represented by GenBank Accession No. WP_010114811.1, and the 3-hydroxyacyl-CoA dehydrogenase from *Burkholderia pseudomallei* MSFHR305 represented by GenBank Accession No. YP_008340862.1, among others. The coding sequences encoding these gene products can be found in GenBank.

Homologs of the *Metallosphaera sedula* malonate semialdehyde reductase also include enzymes having an amino acid sequence at least about 80%, 85%, 90%, 95%, 97%, 98%, 99% or more identical to SEQ ID NO:16. Sequences having these percent identities can be obtained by aligning SEQ ID NO:16 to the sequences of the *Metallosphaera sedula* malonate semialdehyde reductase homologs listed above or otherwise known in the art to determine which residues are amenable to variation (i.e., substitution, deletion, addition, etc.) and the identities of the suitably substituted or added residues.

In some versions of the invention, the microorganism is modified to express or increase expression of acetyl-CoA carboxylase, either alone, with a malonyl-CoA reductase, with a malonate semialdehyde reductase, or with other enzymes. Such a microorganism can be obtained by introducing exogenous nucleic acids expressing the acetyl-CoA carboxylase subunits into the microorganism, by introducing highly expressed promoters in front of the endogenous acetyl-CoA carboxylase subunit coding sequences, by increasing translational efficiency, or by other means. In bacteria, acetyl-CoA carboxylase is a multisubunit enzyme that is encoded by four genes, accA, accB, accC, and accD. Exemplary acetyl-coA carboxylase subunit genes for use in the present invention can be those found in *Synechococcus* sp. PCC 7002 or homologs thereof. The complete genome of *Synechococcus* sp. PCC 7002 can be found in GenBank under Accession No. NC_010475. The coding sequence for accA can be found at positions 2536162-2537139 of NC_010475, the gene product of which has a sequence represented by GenBank Accession No. YP_001735676.1. The coding

sequence for accB can be found at positions 60707-61204 of NC_010475, the gene product of which has a sequence represented by GenBank Accession No. YP_001733325.1. The coding sequence for accC can be found at positions 2210473-2211819 of NC_010475, the gene product of which has a sequence represented by GenBank Accession No. YP_001735364.1". The coding sequence for accD can be found at positions 64484-65443 of NC_010475, the gene product of which has a sequence represented by GenBank Accession No. YP_001733331.1. Suitable promoters for increasing expression of these genes are known in the art. In some versions of the invention, an artificial operon comprising the accD, accA, accB, and accC coding sequences from *E. coli* can be introduced into the microorganism for expression or overexpression of acetyl-CoA carboxylase. See, e.g., US 2011/0165637 to Pflieger et al., which is incorporated herein by reference.

In some versions of the invention, the microorganism is genetically modified to produce or enhance production of lactate. Such a microorganism can be obtained by expressing or increasing expression of lactate dehydrogenase. Lactate dehydrogenase catalyzes the conversion of pyruvate to lactate. See FIG. 12A. Lactate dehydrogenases include the enzymes classified under EC 1.1.1.27 (L-lactate dehydrogenases) and 1.1.1.28 (D-lactate dehydrogenases). L-Lactate dehydrogenases are preferred.

In some versions of the invention, the microorganism is modified to harbor a nucleic acid encoding a lactate dehydrogenase from *Bacillus subtilis* or a homolog thereof. The coding sequence of the lactate dehydrogenase from *Bacillus subtilis* is included in GenBank under accession number AL009126.3 (positions 329774 to 330739) and is represented by SEQ ID NO:17. The gene product of the lactate dehydrogenase from *Bacillus subtilis* is included in GenBank under accession number NP_388187 and has an amino acid sequence represented by SEQ ID NO:18.

Exemplary homologs of the lactate dehydrogenase from *Bacillus subtilis* include but are not limited to the L-lactate dehydrogenase from *Bacillus subtilis* subsp. *subtilis* str. 168 represented by GenBank Accession No. NP_388187.2, the L-lactate dehydrogenase from *Bacillus subtilis* subsp. *natto* BEST195 represented by GenBank Accession No. YP_005559471.1, the L-lactate dehydrogenase from *Bacillus subtilis* BSn5 represented by GenBank Accession No. YP_004206262.1, the L-lactate dehydrogenase from *Bacillus subtilis* subsp. *spizizenii* TU-B-10 represented by GenBank Accession No. YP_004875853.1, the lactate dehydrogenase from *Bacillus subtilis* represented by GenBank Accession No. WP_017696103.1, the lactate dehydrogenase from *Bacillus subtilis* represented by GenBank Accession No. WP_003224788.1, the L-lactate dehydrogenase from *Bacillus subtilis* subsp. *subtilis* str. RO-NN-1 represented by GenBank Accession No. YP_005555343.1, the L-lactate dehydrogenase from *Bacillus subtilis* XF-1 represented by GenBank Accession No. YP_007425489.1, the L-lactate dehydrogenase from *Bacillus subtilis* represented by GenBank Accession No. WP_003241205.1, the lactate dehydrogenase from *Bacillus subtilis* represented by GenBank Accession No. WP_019257406.1, the lactate dehydrogenase from *Bacillus mojavensis* represented by GenBank Accession No. WP_010332943.1, the lactate dehydrogenase from *Bacillus vallismortis* represented by GenBank Accession No. WP_010331365.1, the L-lactate dehydrogenase from *Bacillus subtilis* subsp. *spizizenii* str. W23 represented by GenBank Accession No. YP_003864678.1, the L-lactate dehydrogenase from *Bacillus atrophaeus* represented by GenBank Accession No. WP_010787568.1, the lactate dehydrogenase

from *Bacillus amyloliquefaciens* LFB112 represented by GenBank Accession No. YP_008948730.1, the L-lactate dehydrogenase from *Bacillus licheniformis* 9945A represented by GenBank Accession No. YP_008076533.1, the L-lactate dehydrogenase from *Halobacillus halophilus* DSM 2266 represented by GenBank Accession No. YP_006181877.1, L-lactate dehydrogenase from *Halobacillus* sp. BAB-2008 represented by GenBank Accession No. WP_008633175.1, the L-lactate dehydrogenase from *Geobacillus* sp. WCH70 represented by GenBank Accession No. YP_002948666.1, the lactate dehydrogenase from *Geobacillus caldoxylosilyticus* represented by GenBank Accession No. WP_017436539.1, the L-lactate dehydrogenase from *Anoxybacillus flavithermus* represented by GenBank Accession No. WP_003394005.1, the lactate dehydrogenase from *Anoxybacillus kamchalkensis* represented by GenBank Accession No. WP_019416922.1, and the lactate dehydrogenase from *Lactococcus lactis* represented by GenBank Accession No. NP_267487, among others. The coding sequences encoding these gene products can be found in GenBank.

Homologs of the *Bacillus subtilis* lactate dehydrogenase also include enzymes having an amino acid sequence at least about 80%, 85%, 90%, 95%, 97%, 98%, 99% or more identical to SEQ ID NO:18. Sequences having these percent identities can be obtained by aligning SEQ ID NO:18 to the sequences of the *Bacillus subtilis* lactate dehydrogenase homologs listed above or otherwise known in the art to determine which residues are amenable to variation (i.e., substitution, deletion, addition, etc.) and the identities of the suitably substituted or added residues.

In some versions, the microorganism is modified to harbor a nucleic acid encoding the lactate dehydrogenase from *Lactococcus lactis* or a homolog thereof. The coding sequence of the lactate dehydrogenase from *Lactococcus lactis* is included in GenBank under accession number NC_002662.1 (Gene ID 1114981, complement of positions 1369224-1370201). A codon-optimized version of the coding sequence preferred for expression in cyanobacteria is represented by SEQ ID NO:21. The gene product of the lactate dehydrogenase from *Lactococcus lactis* is included in GenBank under accession number NP_267487 and has an amino acid sequence represented by SEQ ID NO:22.

Exemplary homologs of the lactate dehydrogenase from *Lactococcus lactis* include but are not limited to the L-lactate dehydrogenase from *Lactococcus lactis* subsp. *cremoris* UC509.9 represented by GenBank Accession No. YP_006999682.1, the lactate dehydrogenase from *Lactococcus lactis* represented by GenBank Accession No. WP_021165426.1, the L-lactate dehydrogenase from *Lactococcus lactis* represented by GenBank Accession No. AAB51677.1, the L-lactate dehydrogenase from *Lactococcus lactis* represented by GenBank Accession No. AAB51679.1, lactate dehydrogenase from *Lactococcus lactis* represented by GenBank Accession No. AAA25172.1, the lactate dehydrogenase from *Lactococcus lactis* subsp. *cremoris* TIFN6 represented by GenBank Accession No. EQC54698.1, the L-lactate dehydrogenase from *Streptococcus anginosus* C238 represented by GenBank Accession No. YP_008500777.1, the lactate dehydrogenase from *Streptococcus anginosus* represented by GenBank Accession No. WP_003029659.1, the lactate dehydrogenase from *Lactococcus garvieae* represented by GenBank Accession No. WP_003135756.1, the lactate dehydrogenase from *Streptococcus anginosus* represented by GenBank Accession No. WP_003042963.1, the malate/lactate dehydrogenases from *Streptococcus anginosus* represented by GenBank Accession

No. WP_022525868.1, the L-lactate dehydrogenase from *Streptococcus intermedius* C270 represented by GenBank Accession No. YP_008497003.1, the L-lactate dehydrogenase from *Lactococcus garvieae* ATCC 49156 represented by GenBank Accession No. YP_004779491.1, the lactate dehydrogenase from *Lactococcus garvieae* represented by GenBank Accession No. WP_019293709.1, the L-lactate dehydrogenase from *Streptococcus uberis* 0140J represented by GenBank Accession No. YP_002562208.1, the L-lactate dehydrogenase from *Streptococcus parauberis* KCTC 11537 represented by GenBank Accession No. YP_004478812.1, the L-lactate dehydrogenase from *Streptococcus intermedius* B196 represented by GenBank Accession No. YP_008512752.1, the lactate dehydrogenase from *Streptococcus pseudoporcinus* represented by GenBank Accession No. WP_007891460.1, the L-lactate dehydrogenase from *Streptococcus iniae* SF1 represented by GenBank Accession No. YP_008056778.1, the L-lactate dehydrogenase from *Streptococcus intermedius* JTH08 represented by GenBank Accession No. YP_006469731.1, the lactate dehydrogenase from *Streptococcus anginosus* represented by GenBank Accession No. WP_003069027.1, the lactate dehydrogenase from *Streptococcus porcinus* represented by GenBank Accession No. WP_003084658.1, the lactate dehydrogenase from *Streptococcus didelphis* represented by GenBank Accession No. WP_018365941.1, the L-lactate dehydrogenase from *Streptococcus pyogenes* M1 GAS represented by GenBank Accession No. NP_269302.1, the L-lactate dehydrogenase from *Streptococcus constellatus* subsp. *pharyngis* C1050 represented by GenBank Accession No. YP_008498899.1, the L-lactate dehydrogenase from *Streptococcus constellatus* subsp. *pharyngis* C232 represented by GenBank Accession No. YP_008495295.1, the L-lactate dehydrogenase from *Streptococcus equi* subsp. *zooepidemicus* MGCS10565 represented by GenBank Accession No. YP_002123389.1, the L-lactate dehydrogenase from *Streptococcus dysgalactiae* subsp. *equisimilis* GGS_124 represented by GenBank Accession No. YP_002996624.1, the L-lactate dehydrogenase from *Streptococcus equi* subsp. *equi* 4047 represented by GenBank Accession No. YP_002746472.1, the lactate dehydrogenase from *Streptococcus marimammalium* represented by GenBank Accession No. WP_018369606.1, the lactate dehydrogenase from *Streptococcus canis* represented by GenBank Accession No. WP_003048552.1, the lactate dehydrogenase from *Lactococcus raffinolactis* represented by GenBank Accession No. WP_003140351.1, the lactate dehydrogenase from *Streptococcus ictaluri* represented by GenBank Accession No. WP_008089442.1, the lactate dehydrogenase from *Streptococcus iniae* represented by GenBank Accession No. WP_017794816.1, the lactate dehydrogenase from *Streptococcus merionis* represented by GenBank Accession No. WP_018372720.1, the L-lactate dehydrogenase from *Streptococcus dysgalactiae* subsp. *equisimilis* 167 represented by GenBank Accession No. YP_008629609.1, and the lactate dehydrogenase from *Bacillus subtilis* represented by GenBank Accession No. NP_388187, among others. The coding sequences encoding these gene products can be found in GenBank.

Homologs of the *Lactococcus lactis* lactate dehydrogenase also include enzymes having an amino acid sequence at least about 80%, 85%, 90%, 95%, 97%, 98%, 99% or more identical to SEQ ID NO:22. Sequences having these percent identities can be obtained by aligning SEQ ID NO:22 to the sequences of the *Lactococcus lactis* lactate dehydrogenase homologs listed above or otherwise known in the art to deter-

mine which residues are amenable to variation (i.e., substitution, deletion, addition, etc.) and the identities of the suitably substituted or added residues.

In some versions of the invention, the microorganism is modified to express or increase expression of a transhydrogenase. Preferred transhydrogenases are pyridine nucleotide transhydrogenases, including the enzymes classified under EC 1.6.1.1, 1.6.1.2, and 1.6.1.3. Pyridine nucleotide transhydrogenases convert NAD and NADPH to and from NADH and NADP⁺. See FIG. 12B. Soluble (as opposed to membrane-bound) pyridine nucleotide transhydrogenases are preferred. Other transhydrogenases that produce either NADH or NADPH as a byproduct are also acceptable. Modifying a microorganism to express or increase expression of a transhydrogenase is preferred when the microorganism is modified to express or increase expression of a lactate dehydrogenase. In some versions, the microorganism is modified to harbor a nucleic acid encoding the soluble pyridine nucleotide transhydrogenase from *E. coli* (particularly *E. coli* K12 MG1655) or a homolog thereof. The coding sequence of the soluble pyridine nucleotide transhydrogenase from *E. coli* K12 MG1655 is included in GenBank under accession number U00096.3 (positions 4159390 to 4160790) and is represented by SEQ ID NO:19. The gene product of the soluble pyridine nucleotide transhydrogenase from *E. coli* K12 MG1655 is included in GenBank under accession number NP_418397 and is represented by SEQ ID NO:20.

Exemplary homologs of the soluble pyridine nucleotide transhydrogenase from *E. coli* K12 MG1655 include but are not limited to the soluble pyridine nucleotide transhydrogenase from *Escherichia coli* HS represented by GenBank Accession No. YP_001460757.1, the pyridine nucleotide-disulfide oxidoreductase family protein from *Escherichia coli* represented by GenBank Accession No. WP_001705589.1, the soluble pyridine nucleotide transhydrogenase from *Escherichia coli* represented by GenBank Accession No. WP_001120797.1, the pyridine nucleotide transhydrogenase from *Escherichia coli* represented by GenBank Accession No. WP_024228022.1, the soluble pyridine nucleotide transhydrogenase from *Escherichia coli* represented by GenBank Accession No. WP_001120803.1, the soluble pyridine nucleotide transhydrogenase from *Shigella flexneri* 2a str. 2457T represented by GenBank Accession No. NP_838918.2, the soluble pyridine nucleotide transhydrogenase from *Escherichia coli* CFT073 represented by GenBank Accession No. NP_756777.1, the soluble pyridine nucleotide transhydrogenase from *Escherichia coli* represented by GenBank Accession No. WP_023278586.1, the soluble pyridine nucleotide transhydrogenase from *Escherichia coli* represented by GenBank Accession No. WP_021576626.1, the soluble pyridine nucleotide transhydrogenase from *Escherichia coli* represented by GenBank Accession No. WP_021541750.1, the soluble pyridine nucleotide transhydrogenase from *Escherichia coli* represented by GenBank Accession No. WP_001403311.1, the soluble pyridine nucleotide transhydrogenase *Escherichia coli* represented by GenBank Accession No. WP_001120823.1, soluble pyridine nucleotide transhydrogenase from *Escherichia coli* represented by GenBank Accession No. WP_001120830.1, the soluble pyridine nucleotide transhydrogenase from *Escherichia coli* represented by GenBank Accession No. WP_021549795.1, the pyridine nucleotide-disulfide oxidoreductase family protein from *Escherichia coli* represented by GenBank Accession No. WP_001385008.1, soluble pyridine nucleotide transhydrogenase from *Escherichia coli* represented by GenBank Accession No. WP_001120811.1, the soluble pyridine nucleotide transhydrogenase *Escherichia*

coli 536 represented by GenBank Accession No. YP_672034.1, the soluble pyridine nucleotide transhydrogenase from *Escherichia coli* represented by GenBank Accession No. WP_001120808.1, the soluble pyridine nucleotide transhydrogenase from *Shigella boydii* Sb227 represented by GenBank Accession No. YP_410260.2, the soluble pyridine nucleotide transhydrogenase from *Escherichia coli* represented by GenBank Accession No. WP_021539635.1, the pyridine nucleotide-disulfide oxidoreductase family protein from *Escherichia coli* represented by GenBank Accession No. WP_001546140.1, the soluble pyridine nucleotide transhydrogenase from *Escherichia coli* represented by GenBank Accession No. WP_001545096.1, the soluble pyridine nucleotide transhydrogenase from *Shigella sonnei* Ss046 represented by GenBank Accession No. YP_312883.2, the pyridine nucleotide transhydrogenase from *Escherichia coli* represented by GenBank Accession No. WP_024197343.1, the pyridine nucleotide transhydrogenase from *Escherichia coli* represented by GenBank Accession No. WP_024172841.1, the pyridine nucleotide-disulfide oxidoreductase family protein from *Escherichia coli* represented by GenBank Accession No. WP_001646069.1, the pyridine nucleotide-disulfide oxidoreductase family protein from *Escherichia coli* represented by GenBank Accession No. WP_001561736.1, the pyridine nucleotide-disulfide oxidoreductase family protein from *Escherichia coli* represented by GenBank Accession No. WP_001406381.1, the soluble pyridine nucleotide transhydrogenase from *Shigella flexneri* represented by GenBank Accession No. WP_001120814.1, the soluble pyridine nucleotide transhydrogenase from *Shigella flexneri* represented by GenBank Accession No. WP_001120826.1, the soluble pyridine nucleotide transhydrogenase from *Shigella flexneri* 1235-66 represented by GenBank Accession No. EIQ63659.1, the soluble pyridine nucleotide transhydrogenase from *Escherichia albertii* represented by GenBank Accession No. WP_001120820.1, the soluble pyridine nucleotide transhydrogenase from *Shigella flexneri* represented by GenBank Accession No. WP_001120827.1, the soluble pyridine nucleotide transhydrogenase from *Shigella dysenteriae* Sd197 represented by GenBank Accession No. YP_405233.2, the soluble pyridine nucleotide transhydrogenase from *Salmonella enterica* represented by GenBank Accession No. WP_001120792.1, the soluble pyridine nucleotide transhydrogenase from *Citrobacter rodentium* ICC168 represented by GenBank Accession No. YP_003367222.1, the soluble pyridine nucleotide transhydrogenase from *Salmonella enterica* subsp. *enterica* serovar Choleraesuis str. SC-B67 represented by GenBank Accession No. YP_219002.1, the soluble pyridine nucleotide transhydrogenase from *Salmonella enterica* subsp. *enterica* serovar Heidelberg str. SL476 represented by GenBank Accession No. YP_002048124.1, the soluble pyridine nucleotide transhydrogenase from *Enterobacter cloacae* subsp. *dissolvens* SDM represented by GenBank Accession No. YP_006479868.1, the soluble pyridine nucleotide transhydrogenase from *Citrobacter* represented by GenBank Accession No. WP_016155291.1, the soluble pyridine nucleotide transhydrogenase from *Shigella flexneri* 1235-66 represented by GenBank Accession No. EIQ78768.1, and the pyridine nucleotide transhydrogenase from *Enterobacter asburiae* LF7a represented by GenBank Accession No. YP_004830801.1, among others. The coding sequences encoding these gene products can be found in GenBank.

Homologs of the *E. coli* K12 MG1655 soluble pyridine nucleotide transhydrogenase also include enzymes having an amino acid sequence at least about 80%, 85%, 90%, 95%, 97%, 98%, 99% or more identical to SEQ ID NO:20.

Sequences having these percent identities can be obtained by aligning SEQ ID NO:20 to the sequences of the *E. coli* K12 MG1655 soluble pyridine nucleotide transhydrogenase homologs listed above or otherwise known in the art to determine which residues are amenable to variation (i.e., substitution, deletion, addition, etc.) and the identities of the suitably substituted or added residues.

Other genetic modifications of the microorganism of the present invention include any of those described in U.S. Pat. No. 8,048,624 to Lynch, U.S. Pub. 2011/0125118 to Lynch, and U.S. Pub. 2010/0210017 to Gill et al., all of which are attached hereto. See also Warnecke et al. *Metabolic Engineering* (2010) 12:241-250. The genetic modifications in these references may be to enhance organic acid tolerance and/or increase organic acid production. The microorganism of the present invention may also be modified with homologs of any of the genes, constructs, or other nucleic acids discussed in the above references. Non-limiting examples of the genes that may be modified or introduced include *tyrA*, *aroA*, *aroB*, *aroC*, *aroD*, *aroE*, *aroF*, *aroG*, *aroH*, *aroK*, *aroL*, *aspC*, *entA*, *entB*, *entC*, *entD*, *entE*, *entF*, *folA*, *folB*, *folC*, *folD*, *folE*, *folK*, *folP*, *menA*, *menB*, *menC*, *menD*, *menE*, *menF*, *pabA*, *pabB*, *pabC*, *pheA*, *purN*, *trpA*, *trpB*, *trpC*, *trpD*, *trpE*, *tyrB*, *ubiA*, *ubiB*, *ubiC*, *ubiD*, *ubiE*, *ubiF*, *ubiG*, *ubiH*, *ubiX*, and *ydiB*, or homologs thereof. A non-limiting example of a pathway that may be modified includes the chorismate superpathway. These genes and pathways are primarily but not exclusively related to the production and tolerance of 3HP.

Exogenous, heterologous nucleic acids encoding enzymes to be expressed in the microorganism are preferably codon-optimized for the particular microorganism in which they are introduced. Codon optimization can be performed for any nucleic acid by a number of programs, including "GENEGPS"-brand expression optimization algorithm by DNA 2.0 (Menlo Park, Calif.), "GENEOPTIMIZER"-brand gene optimization software by Life Technologies (Grand Island, N.Y.), and "OPTIMUMGENE"-brand gene design system by GenScript (Piscataway, N.J.). Other codon optimization programs or services are well known and commercially available.

In addition to the microorganism itself, other aspects of the present invention include methods of producing organic acids with the microorganisms of the present invention. The methods involve culturing the microorganism in conditions suitable for growth of the microorganism. The microorganism either directly produces the organic acid or acids of interest or produces organic-acid precursors from which the organic acid or acids of interest are spontaneously converted. Such conditions include providing suitable carbon sources for the particular microorganism along with suitable micronutrients. For eukaryotic microorganisms and heterotrophic bacteria, suitable carbon sources include various carbohydrates. Such carbohydrates may include biomass or other suitable carbon sources known in the art. For phototrophic bacteria, suitable carbon sources include CO₂, which is provided together with light energy.

The microorganism of the present invention is capable of being cultured in high concentrations of the organic acid or acids that the organism is configured to produce. This enables increased production of the organic acid or acids of interest. The microorganism can be cultured in the presence of an organic acid in an amount up to the MIC for that organic acid. Various MICs for exemplary organic acids are described herein. Accordingly, the microorganisms of the invention (i.e., *Synechococcus* sp., *Prochlorococcus* sp., *Synechocystis* sp., etc.) can be cultured in the presence of at least about 10

μM, 1 mM, 25 mM, 50 mM, 70 mM, 75 mM, 100 mM, 125 mM, or 150 mM acrylic acid; at least about 10 mM, 25 mM, 50 mM, 75 mM, 100 mM, 150 mM, 200 mM, 250 mM, 260 mM, 300 mM, or 350 mM 3HP; at least about 250 μM, 500 μM, 750 μM, 1 mM, 25 mM, 50 mM, 75 mM, 100 mM, 150 mM, 200 mM, 250 mM, 300 mM, 350 mM, 400 mM, 450 mM, or 500 mM propionic acid; and/or at least about 10 μM, 25 μM, 50 μM, 75 μM, 100 μM, 250 μM, 500 μM, 750 μM, 1 mM, 25 mM, 50 mM, 70 mM, 75 mM, 100 mM, 125 mM, 150 mM, 200 mM, 250 mM, 300 mM, 350 mM, 400 mM, 450 mM, or 500 mM lactic acid. Such culturing preferably occurs at a pH of about 8.

The microorganisms of the invention may be modified as described herein to increase production of any of the organic acids described herein. The term "increase," whether used to refer to an increase in production of an organic acid, an increase in expression of an enzyme, etc., generally refers to an increase from a baseline amount, whether the baseline amount is a positive amount or none at all.

The microorganism of the invention may be configured to produce 3HP to a concentration of at least about 1 μM, 10 μM, 20 μM, 30 μM, 40 μM, 50 μM, 60 μM, 65 μM, 70 μM, 80 μM, 90 μM, 100 μM or more and/or up to about 10 μM, 20 μM, 30 μM, 40 μM, 50 μM, 60 μM, 65 μM, 70 μM, 80 μM, 90 μM, 100 μM, 200 μM or more. The microorganism of the invention may be configured to produce 3HP at a rate of at least about 0.01 mg/L/Day, 0.05 mg/L/Day, 0.1 mg/L/Day, 0.25 mg/L/Day, 0.5 mg/L/Day, 0.75 mg/L/Day, 1 mg/L/Day, 2.5 mg/L/Day, 5 mg/L/Day, 10 mg/L/Day or more and/or up to about 0.05 mg/L/Day, 0.1 mg/L/Day, 0.25 mg/L/Day, 0.5 mg/L/Day, 0.75 mg/L/Day, 1 mg/L/Day, 2.5 mg/L/Day, 5 mg/L/Day, 10 mg/L/Day, 15 mg/L/Day or more. The microorganism of the invention may be configured to convert at least about 0.1%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 4.5%, 5%, 10%, 15% or more of consumed carbon to 3HP and/or convert up to about 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 4.5%, 5%, 10%, 15%, 20%, 25%, 30% or more of consumed carbon to 3HP.

The microorganism of the invention may be configured to produce lactic acid to a concentration of at least about 0.1 mM, 0.5 mM, 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, 10 mM, 12 mM, 15 mM, 20 mM, or more and/or up to about 0.5 mM, 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, 10 mM, 12 mM, 15 mM, 20 mM, 30 mM or more. The microorganism of the invention may be configured to produce lactic acid at a rate of at least about 10 mg/L/Day, 50 mg/L/Day, 100 mg/L/Day, 150 mg/L/Day, 200 mg/L/Day, 250 mg/L/Day, 260 mg/L/Day, 300 mg/L/Day, or more and/or up to about 50 mg/L/Day, 100 mg/L/Day, 150 mg/L/Day, 200 mg/L/Day, 250 mg/L/Day, 260 mg/L/Day, 300 mg/L/Day, 350 mg/L/Day, or more. The microorganism of the invention may be configured to convert at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 45%, 50% or more of consumed carbon to lactic acid and/or convert up to about 5%, 10%, 15%, 20%, 25%, 30%, 45%, 50%, 60% or more of consumed carbon to lactic acid.

Some versions of the invention include using *acsA* or a homolog thereof as a counter selection marker. The *acsA* or homolog thereof provides sensitivity to the organic acids acrylic acid, 3HP, and propionic acid. By replacing the native copy of *acsA* or homolog thereof with a gene of interest through double homologous recombination, one can select for cells which have gone through the recombination event by plating on acrylic acid or another organic acid as described herein. Acrylic acid is preferred because it has the lowest MIC value and requires the lowest concentration for selection. Through this method, one can introduce a gene or operon of interest onto a chromosome without the need for antibiotics.

Additionally, one can plate on a higher organic acid concentration, i.e., one closer to the MIC value of the *acsA* mutant strain, to cure the strain of interest of any copies of the wild type chromosome. This is of particular interest because it can be difficult to create a homozygous strain using antibiotics as the selection agent.

One version comprises using *acsA* or homolog thereof as a counter selection marker for introducing DNA fragments of interest into the *acsA* or homolog locus. An exemplary version is shown in FIG. 1A. A host **10** is transformed with either linear DNA fragments or plasmid DNA comprising a sequence of interest **12** flanked by an upstream homologous sequence **14** and a downstream homologous sequence **16**. For introducing the sequence of interest **12** into the *acsA* locus, the upstream homologous sequence **14** is preferably homologous to a region **15** 5' of the *acsA* or homolog **19** on the host chromosome **18**, and the downstream homologous sequence **16** is preferably homologous to a region **17** 3' of the *acsA* or homolog **19** on the host chromosome **18**. The homologous sequences **14,16** are preferably at least about 25-base pairs (bp), about 50-bp, about 100-bp, about 200-bp, about 300-bp, about 400-bp, or about 500-bp long. The transformed culture is then plated in a concentration of an organic acid sufficient to select for transformed cells. In preferred versions, the transformed culture is plated in a sub-MIC concentration of an organic acid, such as a concentration greater than 0% the MIC but less than about 20% the MIC, about 40% the MIC, about 50% the MIC, about 60% the MIC, or about 70% the MIC. After colonies appear, the colonies are then plated on a higher concentration of the organic acid to ensure homozygosity.

Another version comprises using the *acsA* gene or homolog thereof as a counter selection marker to introduce DNA fragments of interest into loci other than an *acsA* or homolog locus without leaving an antibiotic resistance marker. An exemplary version is shown in FIG. 1B. The version shown in FIG. 1B is similar to that shown in FIG. 1A except that the *acsA* or homolog thereof **19** is not at the normal chromosomal locus. In the specific case of FIG. 1B, a homolog of *acsA*, *acsA**, is included on a non-chromosomal plasmid **20**. The *acsA* or homolog thereof **19** can also be at a locus on the chromosome **18** other than the native *acsA* or homolog locus. The upstream homologous sequence **14** in FIG. 1B is homologous to a region **15** 5' of the *acsA* or homolog **19** on the non-chromosomal plasmid **20**, and the downstream homologous sequence **16** is homologous to a region **17** 3' of the *acsA* or homolog **19** on the non-chromosomal plasmid **20**.

To increase the utility of *acsA* as a counter selection marker, two point mutations can be made, T144C and G150C. These point mutations maintain the same amino acid sequence but break up a run of base pairs that create a loss of function mutation hot spot. By creating these mutations, the background mutation frequency of this gene is reduced. This mutant version of *acsA*, *acsA**, can be incorporated onto a non-chromosomal plasmid, such as the endogenous plasmid pAQ1 of a Δ *acsA* strain of PCC 7002. This base strain allows for incorporating a gene or operon of interest onto the pAQ1 plasmid without the use of antibiotics and quickly creating a homozygous strain.

The elements and method steps described herein can be used in any combination whether explicitly described or not.

The singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise.

Numerical ranges as used herein are intended to include every number and subset of numbers contained within that range, whether specifically disclosed or not. Further, these

numerical ranges should be construed as providing support for a claim directed to any number or subset of numbers in that range. For example, a disclosure of from 1 to 10 should be construed as supporting a range of from 2 to 8, from 3 to 7, from 5 to 6, from 1 to 9, from 3.6 to 4.6, from 3.5 to 9.9, and so forth.

All patents, patent publications, and peer-reviewed publications (i.e., "references") cited herein are expressly incorporated by reference to the same extent as if each individual reference were specifically and individually indicated as being incorporated by reference. In case of conflict between the present disclosure and the incorporated references, the present disclosure controls.

It is understood that the invention is not confined to the particular construction and arrangement of parts herein illustrated and described, but embraces such modified forms thereof as come within the scope of the following claims.

EXAMPLES

Summary of the Examples

One of the potential applications of metabolic engineering is the use of cyanobacteria to photosynthetically produce commodity chemicals traditionally derived from petroleum. In particular, acrylic acid has been identified as a high-value product that could be biologically derived. Unfortunately, a viable metabolic pathway has not previously been identified for its direct production.

As described in further detail below, a mutation resulting in increased tolerance to 3HP was discovered through investigating the metabolism of a sulfur compound, dimethylsulfoxide (DMSO), by *Synechococcus* sp. PCC 7002 (PCC 7002). PCC 7002 was grown in the presence of DMSO to determine if it could be metabolized. This surprisingly resulted in the accumulation of acrylic acid, a by-product of DMSO metabolism, showing that *Synechococcus* sp. can produce acrylic acid. The accumulation of acrylic acid in the growth medium caused a stall in growth of the cyanobacteria, suggesting it had a toxic effect. After an additional incubation period, growth began to resume. It was originally hypothesized that the ability to grow in the presence of acrylic acid was the result of an adaptation to the stress through altered gene regulation. This hypothesis was later invalidated after an experiment was performed involving growing "unadapted" cells on solid medium containing acrylic acid. The number of colonies on the plate relative to a control suggested that a loss of function mutation was occurring that resulted in the ability to grow in the presence of acrylic acid. Additionally, all mutants obtained through growth in the presence of acrylic acid had increased tolerance levels to 3HP. The increase in tolerance caused by the mutation resulted in a strain of cyanobacteria constituting a platform for either 3HP or acrylic acid production.

Steps were taken to identify the site of the mutation. An RNA sequencing experiment was performed to characterize differential gene expression in the presence of DMSO or acrylic acid. This data set was used to identify genes that had single base pair mutations relative to the wild type strain. Through this analysis, mutations were identified in the gene *acsA*. In order to determine if *acsA* was involved in acrylic acid and 3HP toxicity, a strain of PCC 7002 was created that had a deletion of the *acsA* gene. This strain, PCC 7002 Δ *acsA*, had increased MIC values compared to wild type PCC 7002. These experiments determined that it is a loss of function of *acsA* that results in increased tolerance. The gene *acsA* was annotated as an acetyl-CoA ligase.

In order to demonstrate the utility of the Δ acsA strain, a pathway for producing 3HP was introduced into both the wild type PCC 7002 and Δ acsA strains. Several pathways exist for the production of 3HP from central metabolites. The chosen pathway involves an enzyme from the CO₂ fixation pathway of the thermophilic bacterium *Chloroflexus aurantiacus*. In this pathway, malonyl-CoA is converted to 3HP through a two-step reaction catalyzed by the enzyme malonyl-CoA reductase. Results have shown that expression of malonyl-CoA reductase confers the ability to produce 3HP on the order of 50 μ M.

The result of these experiments is an engineered strain of PCC 7002 that can produce 3HP and is more tolerant to 3HP than wild type PCC 7002 or other cyanobacterial species. Further work will increase the yield of 3HP. The approach to increasing yield will involve further metabolic engineering and optimizing of culturing conditions. To further engineer this strain, expression of the malonyl-CoA reductase will be optimized and genes related to making malonyl-CoA will be over-expressed. Additionally, the current and further engineered strains will be cultured in a photobioreactor in order to monitor 3HP production under optimal growth conditions, and culture parameters will be adjusted to increase yields. The outcome of this work will be a strain of cyanobacteria with optimized culturing conditions that will result in a competitive yield of 3HP.

Background and Significance of Examples

Engineering Bacteria to Produce Commodity Chemicals

A current focus of metabolic engineering and synthetic biology is the development of new methods for producing commodity chemicals that are traditionally produced from petroleum [1,2]. Demand for methods of bioconversion of renewable resources (biomass or CO₂) to these compounds has increased due to price volatility and reliance on foreign production of oil, concerns of increasing atmospheric CO₂, and increased consumer demand for "green" and sustainable products. An example of recent commercial success is the production of 1,3-propanediol (a precursor of nylon-like materials) by DuPont via *Escherichia coli* fermentation of corn sugar [3].

Another compound that could be produced from renewable sources is acrylic acid. Acrylic acid, traditionally produced through the oxidation of propene, is used in coatings, finishes, plastics, and superabsorbent polymers [4]. US demand for acrylic acid continues to grow, exceeding 1×10^9 kg/year, and is outpacing current production [4]. For this reason, non-petroleum based, sustainable methods for producing acrylic acid would be of value. Unfortunately, a thermodynamically favorable pathway for complete biological production of acrylic acid has not been identified [5]. An alternative route would be biological production of 3-hydroxypropionic acid (3HP), followed by a non-biological catalytic conversion to acrylic acid. Additionally, 3HP can be converted to other commodity chemicals including acrylamide and 1,3-propanediol [6]. One company, OPX Biotechnologies, has developed a bio-based technology for producing acrylic acid, via *Escherichia coli* fermentation of sugars to 3HP [7].

Cyanobacteria as an Alternative to Heterotrophic Bacteria

One of the concerns of using heterotrophic bacteria and yeast for fuel and chemical production is the use of food based commodities as feedstock. As the global population continues to grow and the cost of agricultural commodities continues to rise, an alternative route for biological production of commodity chemicals may be needed. An attractive alternative is to use cyanobacteria to convert CO₂ and light energy directly into chemical products. Using CO₂ rather than organic carbon as an input circumvents the problem of using

agricultural commodities and could potentially decrease costs. Species of cyanobacteria are susceptible to genetic modification and have well studied metabolisms [8,9]. Recently, cyanobacteria have been engineered to produce a variety of chemicals and fuels including ethanol, hydrogen, isobutyraldehyde, isoprene, sugars, and fatty acids [10-14].

In order for cyanobacteria to be effective host systems for chemical production, they will have to produce the compound of interest in high titers and have improved resistance to end product toxicity. As presented below, a mutant strain of cyanobacteria was isolated with dramatically increased tolerance to acrylic acid and 3HP. This mutation was identified through exploring the role cyanobacteria play in metabolism of the marine sulfur compound dimethylsulfoniopropionate (DMSP).

Metabolism of the Sulfur Compound DMSP

DMSP is an organic sulfur compound produced by eukaryotic algae and plants that accounts for 1-10% of primary productivity in the oceans [16]. DMSP has been shown to act as an osmoprotectant, antioxidant, predator deterrent, and a sink for reduced sulfur in marine eukaryotic algae [17,18]. Upon its release into the water, DMSP is metabolized by bacterioplankton for use as a carbon and reduced sulfur source [19]. The catabolism of DMSP has the potential to supply 1-15% of total carbon demand and nearly all of the sulfur demand for these bacterial communities [20]. Additionally, cyanobacteria have been shown to account for 10-34% of total DMSP assimilation in light-exposed waters [21,22].

DMSP is broken down through two major pathways. These pathways involve either direct cleavage of DMSP into dimethylsulfide (DMS) and acrylic acid or an initial demethylation followed by a cleavage reaction to form methanethiol and acrylic acid [16, 23-25]. Methanethiol is then used as a reduced sulfur source in methionine biosynthesis, while acrylic acid can be further metabolized into 3HP and used as a carbon source [26,27]. Additionally, release of DMS into the atmosphere from marine waters has been identified as a key intermediate in the cycling of terrestrial and marine sulfur pools [28]. While several genes have been identified in DMSP metabolism, none have been found in cyanobacteria.

Recent studies have shown that two different groups of cyanobacteria are involved in the metabolism of DMSP. These studies demonstrated that both *Synechococcus* and *Prochlorococcus* species are capable of assimilating radio labeled DMSP and methanethiol. In addition, four pure strains of *Synechococcus* were analyzed for DMSP assimilation. Two of the four strains were able to transport and assimilate DMSP, while another produced DMS [22]. Of the species of cyanobacteria currently being used in metabolic engineering, only one, *Synechococcus* sp. PCC 7002, is found in marine environments and potentially exposed to DMSP.

Example 1

Acrylic Acid is Produced from Incubation of DMSP with PCC 7002

Metabolism of DMSP can result in the accumulation of several metabolites, including acrylic acid and 3HP, and may alter growth patterns due to its use as a carbon and sulfur source. PCC 7002 was cultured in the presence of 5 mM DMSP and analyzed for the presence of acrylic acid and 3HP. Growth was determined by monitoring OD730 while metabolic byproducts were measured through high pressure liquid chromatography (HPLC) and gas chromatography (GC).

During incubation with DMSP, an increase in OD730 similar to a control culture was observed for several doubling events, followed by a delay in increased OD730 (FIG. 2A). HPLC analysis determined that during the initial growth period acrylic acid was being produced, although not at a rate significantly beyond an abiotic control (FIG. 3). However, extended incubation of PCC 7002 with DMSP resulted in an increase in acrylic acid concentrations beyond the abiotic control (FIG. 3). PCC 7002 does not contain genes with homology to those known to be involved in DMSP metabolism, but DMSP has been previously shown to slowly degrade to dimethylsulfide and acrylic acid at an alkaline pH [48,49]. The data presented in FIGS. 4A-B support a hypothesis that DMSP breakdown is abiotic and is enhanced by the increased pH resulting from cultivation of PCC 7002 under CO₂ limitation. The cultures in this study were not agitated or supplemented with bubbled air, creating a CO₂ limited environment. When grown in the presence of 5 mM acrylic acid, PCC 7002 exhibited a long lag followed by growth at a rate equal to the control (FIG. 2B). Both delays in increasing OD730 were linked by the presence of acrylic acid, suggesting that acrylic acid was causing growth inhibition. The eventual increase in OD730 in both cultures was due to spontaneous mutants within the population which were able to grow without inhibition. Sub-culturing of the mutant pool derived from wild type (WT) PCC 7002 grown with DMSP into medium containing acrylic acid resulted in no delay in growth (FIG. 2C). From these experiments it was concluded that DMSP incubated in the presence of PCC 7002 results in the production of acrylic acid, acrylic acid concentrations less than 5 mM are inhibitory, and spontaneous mutants can arise that are not inhibited by this concentration of acrylic acid.

Example 2

Acrylic Acid and 3HP Cause Toxicity at Low Concentrations

Accumulation of organic acid anions in the cytoplasm of bacteria has been shown to block metabolic pathways and arrest growth [32,33]. In addition to blocking metabolic pathways, high concentrations of organic acids have been shown to reduce the proton motive force through dissociation across the membrane [34]. Because of this, the toxicity of organic acids generally increases with the hydrophobicity of the compound [35]. The minimum inhibitory concentrations (MIC) for PCC 7002, *Synechococcus* sp. PCC 7942, and *Synechocystis* sp. PCC 6803 were determined for acrylic acid, 3HP, and propionic acid at a pH of about 8 (Table 1). In all three species, acrylic acid was significantly more toxic than propionic acid, which was more toxic than 3HP. Furthermore, the toxicity of acrylic acid (pKa 4.35) to PCC 7002 was shown to be pH dependent, with toxicity increasing with decreasing pH. The low MIC for acrylic acid explains why cultures grown with DMSP become growth inhibited. Cultures with DMSP only show growth inhibition when the accumulating acrylic acid concentration reaches inhibitory concentrations. This suggests that acrylic acid and not DMSP causes the inhibition of growth. The eventual increase in OD730 suggests that mutations can arise to overcome this inhibition.

TABLE 1

Minimum inhibitory concentration of organic acids in three cyanobacteria.			
Species	Acrylic Acid	3HP	Propionic Acid
<i>Synechococcus</i> sp. PCC 7942	3 μ M	2 mM	250 μ M
<i>Synechocystis</i> sp. PCC 6803	50 μ M	No Data	250 μ M
<i>Synechococcus</i> sp. PCC 7002	25 μ M	10 mM	4 mM
¹ PCC 7002 A*	7 mM	No Data	No Data

Minimum inhibitory concentration is defined as the concentration at which no increase in OD₇₃₀ was observed.

¹Strain A* was isolated from an agar plate containing 5 mM acrylic acid.

Example 3

A Mutation in an Acetyl-CoA Ligase Gene Increases Tolerance to Acrylic Acid and 3HP

When a dense culture of PCC 7002 was plated onto solid medium containing acrylic acid, colonies resulting from spontaneous mutants uninhibited by acrylic acid were observed. The mutation frequency when selecting for growth on 50 μ M acrylic acid was 7×10^{-6} . When selecting for growth on 5 mM acrylic acid, the mutation frequency was 4×10^{-6} . The mutation frequency is the frequency that a mutant with a given phenotype is found within the population of a culture. For example a mutation frequency of 1×10^{-6} suggests that in a population of 1×10^8 cells, there are 100 mutants. The observed mutation frequencies are suggestive of a loss of function mutation. All mutants obtained from medium containing 50 μ M acrylic acid were able to grow on 5 mM acrylic acid. In addition, these colonies were able to grow in media containing concentrations of propionic acid and 3HP that were above the WT PCC 7002 MIC values. One of the mutants, PCC 7002 A*, was analyzed to determine to what degree the tolerance to organic acids had increased. MIC values for this strain are presented in Table 1. Tolerance to acrylic acid increased about 280-fold over WT PCC 7002 MIC values. Increased tolerance to 3HP and propionic acid was also observed (data not shown). Due to the increased tolerance to all three organic acids, the mutation may affect a gene that links the metabolism of acrylic acid, 3HP, and propionic acid.

In addition to looking at gene expression levels, the results from the RNA-sequencing experiment were used to identify mutations that resulted in increased tolerance to acrylic acid. An analysis for single nucleotide permutations (SNP) on the data set for each condition was performed. In order to identify potential mutation candidates, two basic assumptions were made. First, growth in cultures containing DMSP and acrylic acid would require the same mutation. Second, the mutation is a base pair change, not a deletion or insertion. From the SNP analysis, mutations in five candidate genes were identified. One of these candidates was annotated as an acetyl-CoA ligase (acsA). The mutation resulted in the change of a highly conserved tryptophan residue to a leucine (W49L) in *Synechococcus* sp. PCC 7002. The mutation changes an FWGE amino acid sequence in *Synechococcus* sp. PCC 7002 to an FLGE amino acid sequence. This mutation was a result of a G146T substitution in the acsA coding sequence. The mutation was present in ~60% of reads that aligned to this segment of the open reading frame in both the DMSP and acrylic acid cultures. Manual inspection of control alignment data determined that this allele was only present in cultures containing DMSP and acrylic acid. The correlate of W49 is conserved in the acsA of *Escherichia coli* (GenBank NP_418493.1) and

Bacillus subtilis (GenBank NP_390846.1), among others, suggesting it is integral to a functional protein See, e.g., Table 2.

TABLE 2

Conservation of W49 and surrounding residues of <i>Synechococcus</i> sp. PCC 7002 <i>acsA</i> in acetyl-CoA ligases of <i>E. coli</i> K12 and <i>P. fulva</i>			
Organism	Gene	Protein Sequence	SEQ ID NO:
<i>Synechococcus</i> sp. PCC 7942	<i>acsA</i>	F-W-G-E	Residues 48-51 of SEQ ID NO: 2
<i>E. coli</i> K12	Acetyl-CoA ligase	F-W-G-E	Residues 39-41 of SEQ ID NO: 9
<i>P. fulva</i>	Acetyl-CoA ligase	F-W-G-E	Residues 38-41 of SEQ ID NO: 10

The W49L mutation residue resulted in an insoluble protein (data not shown) and, therefore, a non-functional protein. These data led to the hypothesis that loss of function of *acsA* would result in the observed increase in organic acid tolerance.

Without being limited by mechanism, it was hypothesized that the AcsA acetyl-CoA ligase may have a substrate specificity that would allow it to add a coenzyme A (CoA) to all three organic acids, and that the CoA bound acids or downstream metabolism of these CoA bound acids caused toxicity.

This hypothesis was tested by creating a knockout mutant of the *acsA* gene. This knockout was created by transforming wild type PCC 7002 with a DNA construct that would replace the *acsA* gene with an antibiotic resistance marker through homologous recombination. The resulting mutant, Δ *acsA*, was challenged with concentrations of acrylic acid, 3HP, and propionic acid above WT PCC 7002 MIC levels. In each case the Δ *acsA* mutant was able to grow without inhibition, including in the presence of >500 mM 3HP. Additionally, the Δ *acsA* mutant did not show any growth defects relative to wild type. These results show that loss of function of the acyl-CoA ligase increases the tolerance of PCC 7002 to acrylic acid and 3HP.

To confirm this phenotype is the result of the deletion mutation, a complementation mutant was created by integrating a copy of *acsA* into a plasmid native to PCC 7002 Δ *acsA*. A corresponding mutant harboring a copy of *acsA*-W49L was also constructed. In the presence of acrylic acid, no strains harboring wild-type *acsA* were capable of growing while those harboring the mutant *acsA* were able to grow (FIG. 5).

In addition, the *acsA* gene was heterologously expressed in *E. coli* for protein purification and the substrate specificity was determined for AcsA in vitro (see below).

From these results, several conclusions can be drawn. DMSP is converted to acrylic acid by PCC 7002. Spontaneous mutations occur within the population that results in a drastically increased tolerance to acrylic acid, 3HP, and propionic acid. One mutation that can result in this phenotype is a loss of function or deletion of the *acsA* gene, which codes for an acetyl-CoA ligase.

Example 4

Deletion and Complementation Studies

Deletion and complementation studies were performed in various *Synechococcus* spp. and *Synechocystis* spp. The results are shown in Table 3. Replacement of the gene *acsA* in *Synechococcus* sp. PCC 7002 with an antibiotic resistance marker (*aadA*) resulted in a dramatic increase in tolerance to acrylic acid, 3-hydroxypropionic acid (3HP), and propionic

acid. An identical level of increase was observed when *acsA* was replaced with a 20 base-pair barcode sequence. This phenotype was complemented in an *acsA* deletion strain by expression of *acsA* under the native promoter in another locus on the chromosome (*glpK*). Complementation resulted in the restored sensitivity to both acrylic acid and 3HP. The phenotype was only partially complemented upon expression of *acsA*W49L from the *glpK* locus, showing that the AW49L mutation does not result in a complete loss of AcsA activity.

Homologous genes were identified in the cyanobacteria *Synechocystis* sp. PCC 6803 (*sll0542*; SEQ ID NOS:3 and 4) and *Synechococcus* sp. PCC 7942 (*SYNPCC7942_1342*; SEQ ID NOS:5 and 6). Replacement of the gene *sll0542* in PCC 6803 with an antibiotic resistance marker resulted in an increase in tolerance to acrylic acid similar to the deletion of *acsA* in PCC 7002. When selecting for growth of *Synechocystis* sp. PCC 6803 on 50 μ M acrylic acid, the mutation frequency was 2×10^{-6} .

TABLE 3

Minimum inhibitory concentrations of organic acids			
Species	acrylic acid (mM)	3-HP (mM)	Propionic acid (mM)
<i>Synechococcus</i> sp. PCC 7942	0.003	2	0.25
<i>Synechocystis</i> sp. PCC 6803	0.050	>35	0.25
PCC 6803 <i>sll0542::KmR</i>	70	<50	No Data
<i>Synechococcus</i> sp. PCC 7002	0.025	10	4
PCC 7002 <i>acsA::aadA</i>	70	260	>400
PCC 7002 <i>acsA::BC*</i>	70	260	No Data
PCC 7002 <i>acsA::BC glpK::acsA aadA</i>	0.015	15	No Data
PCC 7002 <i>acsA::BC glpK::acsAW49L aadA</i>	7	No Data	No Data

*BC, 20 base-pair barcode

Example 5

Substrate Specificity of AcsA

The tolerance of PCC 7002 to acrylic acid and 3HP was dramatically increased by the deletion of the acetyl-CoA ligase gene (*acsA*). To obtain information regarding the *acsA*-dependent toxicity, the substrate specificity of AcsA was determined.

Acyl-CoA ligase purification: *Escherichia coli* BL21 containing plasmid pET28b with *acsA* were grown in 50 mL of LB to an OD_{600nm} of 0.6 and induced with 1 mM IPTG. The induced culture was shaken at 37° C. for 3 hrs. The culture was centrifuged and the resulting cell pellet was frozen at -20° C. The cell pellet was processed with Novagen Bug-Buster Protein Extraction Reagent (Part No. 70584-3). The resulting soluble protein fraction was used for His-tag purification using Ni-NTA agarose beads (Qiagen) and Pierce 0.8-mL centrifugation columns (Part No. 89868). Washes were done with 50 mM NaH_2PO_4 , 300 mM NaCl, and 30 mM imidazole pH 8.0. The his-tagged protein was eluted with 50 mM NaH_2PO_4 , 300 mM NaCl, and 250 mM imidazole pH 8.0. The insoluble fraction from the protein extraction was washed twice with BugBuster reagent followed by incubation with 400 μ L 8M urea, 100 mM Tris-HCl, and 100 mM β -mercaptoethanol pH 8.2 for 30 min. The resulting solution was centrifuged at 16,000 \times g and the supernatant was collected. Protein fractions were run on a SDS-PAGE gel. His-tag purified protein fractions used in the acyl-CoA ligase assay were concentrated and buffered exchanged using an Amicon

Ultra-4 centrifugation column. The buffer used for enzyme storage contained 0.1 M NaH₂PO₄, 1 mM EDTA, and 10% v/v glycerol.

Acyl-CoA ligase activity assay: Acyl-CoA ligase activity was determined by measuring the loss of free Coenzyme A (CoA) over time using Ellman's reagent. (Riddles P W, Blakeley R L, & Zerner B (1979) Ellman's reagent: 5,5'-dithiobis(2-nitrobenzoic acid—a reexamination. *Analytical Biochemistry* 94(1):75-81.) The enzyme reaction contained 10 mM ATP, 8 mM MgCl₂, 3 mM CoA, 0.1 M NaH₂PO₄, 1 mM EDTA, and 2 mM of the organic acid species. The concentration of AcsA in the reaction was 500 nM. Relative activity was determined by the amount of CoA consumed in 4 min relative to an acetate control. As shown in FIG. 6, AcsA has an activity towards acetate, acrylic acid, propionate, and 3HP.

Example 6

Use of *acsA* as a Counter-Selection Marker

The sensitivity of PCC 7002 to acrylic acid due to the activity of *AcsA* allows for one to directly integrate DNA fragments into the *acsA* locus and select for acrylic acid tolerance. This method results in integration into the PCC 7002 without the use of an antibiotic resistance marker. The use of antibiotic resistance markers is limited by the number of markers available and their tendency to result in heterozygous strains. PCC 7002 carries between 4-6 copies of the chromosome and the use of resistance markers can result in strains with a mixture of native and modified chromosomes. Use of *acsA* as a counter-selection marker can quickly produce homozygous strains.

The *acsA* gene was used as a counter-selection marker to introduce DNA fragments of interest into the *acsA* loci on the chromosome, thereby deleting *acsA* without leaving an antibiotic resistance marker. Wild type PCC 7002 was transformed with barcode DNA or DNA encoding yellow fluorescent protein (YFP), each flanked with 500 base-pair sequences homologous to regions directly 5' and 3' of *acsA*. The transformed culture was then plated on 50 μM acrylic acid. Colonies appeared after 3 days. The colonies were patched onto plates containing 50 μM acrylic acid and screened for the presence of the sequence of interest. Integration of the various sequences resulted in 30-50% of colonies being positive integrations. See FIG. 8A. Positive clones were streaked onto plates containing 10 mM acrylic acid. Colonies able to grow in the presence of 10 mM acrylic acid were homozygous for the integration. This method allows for fast and homozygous chromosomal integrations.

The *acsA* gene was also used as a counter selection marker to introduce DNA fragments of interest into other loci on the chromosome without leaving an antibiotic resistance marker. In an *acsA* deletion strain of PCC 7002, *acsA* along with an antibiotic resistance marker was introduced onto the chromosome into the gene *glpK*. See, e.g., PCC 7002 *acsA*:BC *glpK*::*acsA aadA* in Table 3. *glpK* was used as an insertion site because it is a pseudogene in PCC 7002 due to a frameshift mutation. The *acsA*-resistance marker was then replaced with yellow fluorescent protein (YFP) under the expression of a constitutive promoter. This resulted in a strain of PCC 7002 with YFP integrated onto the chromosome without a residual marker. YFP expressed from the *glpK* locus was shown to have an equal level of expression to YFP expressed from the *acsA* locus. See FIG. 8B. These experiments demonstrate the one can directly select for integration into the *acsA* locus and

use *acsA* as a counter selection tool to make clean integrations elsewhere on the chromosome.

Example 7

Production of 3HP with Engineered PCC 7002

While the ultimate goal is to produce acrylic acid through a single biological catalyst, no complete pathway has previously been demonstrated [5]. As an alternative, 3HP can be biologically derived and then catalytically converted to acrylic acid. A 3HP production pathway was introduced into PCC 7002 *ΔacsA* and its ability to produce 3HP from CO₂ and light energy was analyzed.

Effect of a Bifunctional Malonyl-CoA Reductase from *Chloroflexus aurantiacus* on Production of 3HP

FIG. 7 outlines two pathways for synthesizing 3HP from phosphoenolpyruvate (PEP). PEP is derived in cyanobacteria through the oxidation of glyceraldehyde 3-phosphate, a product of CO₂ assimilation. While both pathways would result in a cofactor imbalance, the route via malonyl-CoA balances out the NADPH derived from the light reactions of photosynthesis and results in the net production of 2ATP and 2 NADH per 3HP. In order to introduce this pathway into PCC 7002, a malonyl-CoA reductase gene was heterologously expressed. Malonyl-CoA reductase from *Chloroflexus aurantiacus* was cloned into PCC 7002 *ΔacsA* [44]. *C. aurantiacus* is a phototrophic bacterium that produces 3HP as an intermediate in CO₂ fixation [45]. The malonyl-CoA reductase from *Chloroflexus aurantiacus* has been shown to have activity that converts malonyl-CoA to malonate semialdehyde and, in addition, activity that converts malonate semialdehyde to 3HP. The *C. aurantiacus* malonyl-CoA reductase gene was introduced onto a native plasmid under a highly expressed promoter [46]. Integration onto a native plasmid rather than the chromosome ensured a higher copy number of the gene. The native plasmid is required for growth, ensuring that the plasmid was not lost [46]. After integration was confirmed, the ability of the strain to produce 3HP was determined through HPLC. Preliminary results have shown that expressing malonyl-CoA reductase in wild-type PCC 7002 and PCC 7002 *ΔacsA* confers the ability to produce 3HP on the order of 50 μM. Further experiments will be performed to determine if the *ΔacsA* strain has an advantage with respect to yield and growth rate. We predict that the *ΔacsA* strain has an advantage with respect to yield and growth rate.

Effect of a Mono Functional Malonyl-CoA Reductase from *Metallosphaera sedula* and a Malonate Semialdehyde Reductase from *Sulfolobus tokodaii* on Production of 3HP

As an alternative to producing 3HP by expressing the malonyl-CoA reductase from *Chloroflexus aurantiacus*, 3HP was produced by expressing a mono-functional malonyl-CoA reductase (MCR) from *Sulfolobus tokodaii* and a malonate semialdehyde reductase (MSR) from *Metallosphaera sedula*. Schemas outlining this strategy are shown in FIGS. 9A and 9B.

The *acsA* in *Synechococcus* sp. PCC 7002 was replaced with an artificial operon construct configured to express an N-terminally truncated version of the MCR from *Sulfolobus tokodaii* (SEQ ID NO:13) and the MSR from *Metallosphaera sedula* (SEQ ID NO:16) under IPTG-inducible conditions. The operon (*lacOOI_MCR_MSR*), shown in FIG. 10, included a *LacI*-regulatable promoter based on the cyanobacterial *cpcB* gene promoter (*p_{cpc}B_{LacOO}*), a truncated, codon-optimized MCR coding sequence (SEQ ID NO:12), a codon-optimized MSR coding sequence (SEQ ID NO:15), ribosome binding sites (RBSs) upstream of each of the MCR

and MSR coding sequences, and a *lad* gene. A strain of *Synechococcus* sp. PCC 7002 with *acsA* replaced with a barcode sequence (PCC 7002 *acsA::BC*) was generated as a control. The engineered PCC 7002 was grown in 10-ml volumes at a light intensity of 140 $\mu\text{E}/\text{m}^2/\text{s}$ at 35° C. and bubbled with air. Cell growth was monitored by measuring the optical density at 730 nm (OD_{730}) using a Spectrophotometer 20 (Milton Roy). The production of 3HP was determined with each generated strain through HPLC.

As shown in Table 4, the control strain (PCC 7002 *acsA::BC*) was incapable of producing 3HP. By contrast, the strain comprising the artificial operon (PCC 7002 *acsA::lacOOI_MCR_MSR*) produced 32 μM and 66 μM in the absence and presence, respectively, of 1 mM IPTG.

TABLE 4

Production of 3-HP		
Strain	IPTG (mM)	3HP (μM)
PCC 7002 <i>acsA::BC</i> (Control)	0	0
PCC 7002 <i>acsA::lacOOI_MCR_MSR</i>	0	32
PCC 7002 <i>acsA::lacOOI_MCR_MSR</i>	1	66

The growth of PCC 7002 *acsA::lacOOI_MCR_MSR* in both the absence and presence of 1 mM IPTG is shown in FIG. 11.

These data show that PCC 7002 and, more generally, cyanobacteria can be engineered to produce 3HP.

Further Engineering to Increase 3HP Titers

Several strategies can be employed to increase 3HP production. For example, flux through the 3HP production pathway can be increased by overexpressing the acetyl-CoA carboxylase genes, thus increasing the pool of malonyl-CoA. See FIG. 9A. Furthermore, a genome-scale metabolic model can be used to predict genetic modifications that would provide additional flux through the pathway and correct cofactor imbalances [47]. These strategies will potentially increase titers of 3HP to be comparable with production systems using heterotrophic bacteria.

Example 8

Production of Lactate with Engineered PCC 7002

A lactate production pathway was enhanced in PCC 7002 ΔacsA and its ability to produce 3HP from CO_2 and light energy was analyzed.

Effect of Lactase Dehydrogenase on Lactate Production

Lactate dehydrogenase catalyzes the conversion from pyruvate to lactate. See FIG. 12A. The *acsA* in *Synechococcus* sp. PCC 7002 was replaced with a construct configured to express the lactate dehydrogenase from *B. subtilis* (*ldh*, SEQ ID NOS: 17 and 18) under IPTG-inducible conditions. The resulting strain, PCC 7002 *acsA::ldh*, was grown in 10-ml volumes with or without 1 mM IPTG at a light intensity of 140 $\mu\text{E}/\text{m}^2/\text{s}$ at 35° C. and bubbled with air containing ambient CO_2 . Cell growth was monitored by measuring the optical density at 730 nm (OD_{730}) using a Spectrophotometer 20 (Milton Roy). Lactate production was determined using methods known in the art.

Lactate production from PCC 7002 *acsA::ldh* in the presence and absence of IPTG is shown in FIG. 13 and Table 5, and the growth of PCC 7002 *acsA::ldh* in the presence and absence of IPTG is shown in FIG. 13. Increasing expression of lactate dehydrogenase increased production of lactate without significantly compromising growth.

TABLE 5

Lactate production from PCC 7002 <i>acsA::ldh</i> in the presence and absence of IPTG			
IPTG	Final Lactate Concentration	Lactate Production Rate	Percent Consumed Carbon Converted to Lactate
-	0.4 mM (36 mg/L)	12 mg/L/Day	2.4%
+	0.7 mM (63 mg/L)	21 mg/L/Day	4.5%

Effect of Lactase Dehydrogenase and a Transhydrogenase on Lactate Production

Pyridine nucleotide transhydrogenases catalyze the conversion of the reducing equivalents NADH and NADPH. See FIG. 12B. NADH is a co-factor in the lactate dehydrogenase reaction. The *acsA* in *Synechococcus* sp. PCC 7002 was replaced with an artificial operon construct configured to express the lactate dehydrogenase from *B. subtilis* (*ldh*, SEQ ID NOS: 17 and 18) and a soluble pyridine nucleotide transhydrogenase from *E. coli* (*udhA*, SEQ ID NOS: 19 and 20) under IPTG-inducible conditions. The resulting strain, PCC 7002 *acsA::ldh-udhA*, and the PCC 7002 strain replacing *acsA* with the *ldh*-only construct, PCC 7002 *acsA::ldh*, were grown as described above except that 1 mM IPTG was used in all cultures and the cultures were bubbled with air containing 0.5% CO_2 . Cell growth and lactate production was determined as described above.

Lactate production from the PCC 7002 *acsA::ldh* and PCC 7002 *acsA::ldh-udhA* strains is shown in FIG. 14 and Table 6, and growth of the strains is shown in FIG. 14. Increasing expression of lactate dehydrogenase increased production of lactate without significantly compromising growth. Expressing the transhydrogenase along with the lactate dehydrogenase was capable of significantly increasing lactate production without significantly compromising growth. Notably, the cells expressing the soluble transhydrogenase in addition to the lactate dehydrogenase were able to produce about 1 g/L lactate after 5 days. In addition, about 22% of the fixed carbon was converted to lactate.

TABLE 6

Lactate production from PCC 7002 ΔacsA <i>ldh</i> with and without the <i>udhA</i> soluble transhydrogenase			
<i>udhA</i>	Final Lactate Concentration	Lactate Production Rate	Percent Consumed Carbon Converted to Lactate
-	4.4 mM (396 mg/L)	115 mg/L/Day	8.8%
+	8.9 mM (801 mg/L)	262 mg/L/Day	22%

Effect of the Lactase Dehydrogenase from *Lactococcus lactis* on Lactate Production

Expression constructs comprising a codon-optimized coding sequence of the lactate dehydrogenase from *Lactococcus lactis* (*ldhA*, SEQ ID NOS: 21 and 22) either alone or with the soluble pyridine nucleotide transhydrogenase from *E. coli* (*udhA*, SEQ ID NOS: 19 and 20) were generated. The constructs will be used to replace the *acsA* in *Synechococcus* sp. PCC 7002. The resulting strains will be grown as described above. Cell growth and lactate production will be determined as described above. It is predicted that expression of the lactate dehydrogenase from *Lactococcus lactis* will increase lactate production as well as or better than expression of the lactate dehydrogenase from *B. subtilis*.

Conclusions from Examples

Increasing the tolerance to organic acids and engineering the production of commodity chemicals makes biological synthesis of these chemicals from CO₂ with cyanobacteria and other microorganisms a viable option.

REFERENCES

1. Keasling, J. D., *Manufacturing Molecules Through Metabolic Engineering*. Science, 2010. 330(6009): p. 1355-1358.
2. Chotani, G., et al., *The commercial production of chemicals using pathway engineering*. Biochimica et Biophysica Acta (BBA)—Protein Structure and Molecular Enzymology, 2000. 1543(2): p. 434-455.
3. Nakamura, C. E. and G. M. Whited, *Metabolic engineering for the microbial production of 1,3-propanediol*. Current Opinion in Biotechnology, 2003. 14(5): p. 454-459.
4. Bauer, W., *Acrylic Acid and Derivatives*. Kirk-Othmer Encyclopedia of Chemical Technology. 2000: John Wiley & Sons, Inc.
5. Straathof, A. J. J., et al., *Feasibility of acrylic acid production by fermentation*. Applied Microbiology and Biotechnology, 2005. 67(6): p. 727-734.
6. Bozell, J. J. and G. R. Petersen, *Technology development for the production of biobased products from biorefinery carbohydrates—the US Department of Energy's "Top 10" revisited*. Green Chemistry, 2010. 12(4): p. 539-554.
7. *OPX nears commercial goal for bio-based acrylic acid* Feb. 28, 2011; Available from: <http://www.opxbiotechnologies.com/press/>.
8. Thiel, T., *Genetic Analysis of Cyanobacteria*, in *The Molecular Biology of Cyanobacteria*, D. A. Bryant, Editor. 2004, Springer Netherlands. p. 581-611.
9. Ducat, D. C., J. C. Way, and P. A. Silver, *Engineering cyanobacteria to generate high-value products*. Trends in Biotechnology, 2011. 29(2): p. 95-103.
10. Angermayr, S. A., et al., *Energy biotechnology with cyanobacteria*. Current Opinion in Biotechnology, 2009. 20(3): p. 257-263.
11. Atsumi, S., W. Higashide, and J. C. Liao, *Direct photosynthetic recycling of carbon dioxide to isobutyraldehyde*. Nat Biotech, 2009. 27(12): p. 1177-1180.
12. Lindberg, P., S. Park, and A. Melis, *Engineering a platform for photosynthetic isoprene production in cyanobacteria, using Synechocystis as the model organism*. Metabolic Engineering, 2010. 12(1): p. 70-79.
13. Liu, X., J. Sheng, and R. Curtiss III, *Fatty acid production in genetically modified cyanobacteria*. Proceedings of the National Academy of Sciences, 2011.
14. Niederholtmeyer, H., et al., *Engineering Cyanobacteria To Synthesize and Export Hydrophilic Products*. Appl. Environ. Microbiol., 2010. 76(11): p. 3462-3466.
15. Kumar, K., et al., *Development of suitable photobioreactors for CO₂ sequestration addressing global warming using green algae and cyanobacteria*. Bioresource Technology, 2011. 102(8): p. 4945-4953.
16. Howard, E. C., et al., *Bacterial Taxa That Limit Sulfur Flux from the Ocean*. Science, 2006. 314(5799): p. 649-652.
17. Stefels, J., *Physiological aspects of the production and conversion of DMSP in marine algae and higher plants*. Journal of Sea Research, 2000. 43(3-4): p. 183-197.
18. Sunda, W., et al., *An antioxidant function for DMSP and DMS in marine algae*. Nature, 2002. 418(6895): p. 317-320.
19. Yoch, D. C., *Dimethylsulfoniopropionate: Its Sources, Role in the Marine Food Web, and Biological Degradation to Dimethylsulfide*. Appl. Environ. Microbiol., 2002. 68(12): p. 5804-5815.
20. Simó R., et al., *Coupled Dynamics of Dimethylsulfoniopropionate and Dimethylsulfide Cycling and the Microbial Food Web in Surface Waters of the North Atlantic*. Limnology and Oceanography, 2002. 47(1): p. 53-61.
21. Vila-Costa, M., et al., *Dimethylsulfoniopropionate Uptake by Marine Phytoplankton*. Science, 2006. 314(5799): p. 652-654.
22. Malmstrom, R. R., et al., *Dimethylsulfoniopropionate (DMSP) Assimilation by Synechococcus in the Gulf of Mexico and Northwest Atlantic Ocean*. Limnology and Oceanography, 2005. 50(6): p. 1924-1931.
23. González, J. M., et al., *Genetics and Molecular Features of Bacterial Dimethylsulfoniopropionate (DMSP) and Dimethylsulfide (DMS) Transformations*, in *Handbook of Hydrocarbon and Lipid Microbiology*, K. N. Timmis, Editor. 2010, Springer Berlin Heidelberg. p. 1201-1211.
24. Howard, E. C., et al., *Abundant and diverse bacteria involved in DMSP degradation in marine surface waters*. Environmental Microbiology, 2008. 10(9): p. 2397-2410.
25. Reisch, C. R., et al., *Novel pathway for assimilation of dimethylsulphoniopropionate widespread in marine bacteria*. Nature, 2011. 473(7346): p. 208-211.
26. Kiene, R. P., et al., *Dimethylsulfoniopropionate and Methanethiol Are Important Precursors of Methionine and Protein-Sulfur in Marine Bacterioplankton*. Appl. Environ. Microbiol., 1999. 65(10): p. 4549-4558.
27. Ansedé, J. H., P. J. Pellechia, and D. C. Yoch, *Metabolism of Acrylate to beta-Hydroxypropionate and Its Role in Dimethylsulfoniopropionate Lyase Induction by a Salt Marsh Sediment Bacterium, Alcaligenes faecalis M3A*. Appl. Environ. Microbiol., 1999. 65(11): p. 5075-5081.
28. Simó, R., *Production of atmospheric sulfur by oceanic plankton: biogeochemical, ecological and evolutionary links*. Trends in Ecology & Evolution, 2001. 16(6): p. 287-294.
29. Ross, C. and K. L. V. Alstyne, *INTRASPECIFIC VARIATION IN STRESS-INDUCED HYDROGEN PEROXIDE SCAVENGING BY THE ULVOID MACROALGA ULVA LACTUCA1*. Journal of Phycology, 2007. 43(3): p. 466-474.
30. Latifi, A., M. Ruiz, and C.-C. Zhang, *Oxidative stress in cyanobacteria*. FEMS Microbiology Reviews, 2009. 33(2): p. 258-278.
31. Balasubramanian, R., et al., *Regulatory Roles for IscA and SufA in Iron Homeostasis and Redox Stress Responses in the Cyanobacterium Synechococcus sp. Strain PCC 7002*. J. Bacteriol., 2006. 188(9): p. 3182-3191.
32. Horswill, A. R., A. R. Dudding, and J. C. Escalante-Semerena, *Studies of Propionate Toxicity in Salmonella enterica Identify 2-Methylcitrate as a Potent Inhibitor of Cell Growth*. Journal of Biological Chemistry, 2001. 276(22): p. 19094-19101.
33. Russell, J. B., *Another explanation for the toxicity of fermentation acids at low pH: anion accumulation versus uncoupling*. Journal of Applied Microbiology, 1992. 73(5): p. 363-370.
34. Chemington, C. A., et al., *Organic Acids: Chemistry, Antibacterial Activity and Practical Applications*, in *Advances in Microbial Physiology*, A. H. Rose and D. W. Tempest, Editors. 1991, Academic Press. p. 87-108.
35. Zaldivar, J. and L. O. Ingram, *Effect of organic acids on the growth and fermentation of ethanologenic Escherichia coli LY01*. Journal Name: Biotechnology and Bioengineer-

- ing; Journal Volume: 66; Journal Issue: 4; Other Information: PBD: 1999, 1999: p. Medium: X; Size: page(s) 203-210.
36. Fridovich, I. and H. M. Hassan, *Paraquat and the exacerbation of oxygen toxicity*. Trends in Biochemical Sciences, 1979. 4(5): p. 113-115.
37. Sakamoto, T., V. B. Delgaizo, and D. A. Bryant, *Growth on Urea Can Trigger Death and Peroxidation of the Cyanobacterium Synechococcus sp. Strain PCC 7002*. Appl. Environ. Microbiol., 1998. 64(7): p. 2361-2366.
38. Steinke, M., et al., *Determinations of dimethylsulphonio-
propionate (DMSP) lyase activity using headspace analysis of dimethylsulphide (DMS)*. Journal of Sea Research, 2000. 43(3-4): p. 233-244.
39. Hashimoto, Y., et al., *Nitrile Pathway Involving Acyl-CoA Synthetase*. Journal of Biological Chemistry, 2005. 280 (10): p. 8660-8667.
40. Kasuya, F., K. Igarashi, and M. Fukui, *Participation of a medium chain acyl-CoA synthetase in glycine conjugation of the benzoic acid derivatives with the electron-donating groups*. Biochemical Pharmacology, 1996. 51(6): p. 805-809.
41. MARUYAMA, K. and H. KITAMURA, *Mechanisms of Growth Inhibition by Propionate and Restoration of the Growth by Sodium Bicarbonate or Acetate in Rhodospseudomonas sphaeroides S*. Journal of Biochemistry, 1985. 98(3): p. 819-824.
42. Man, W.-J., et al., *The binding of propionyl-CoA and carboxymethyl-CoA to Escherichia coli citrate synthase*. Biochimica et Biophysica Acta (BBA)—Protein Structure and Molecular Enzymology, 1995. 1250(1): p. 69-75.
43. Boynton, Z. L., G. N. Bennett, and F. B. Rudolph, *Intracellular Concentrations of Coenzyme A and Its Derivatives*

- from Clostridium acetobutylicum ATCC 824 and Their Roles in Enzyme Regulation*. Appl. Environ. Microbiol., 1994. 60(1): p. 39-44.
44. Hugler, M., et al., *Malonyl-Coenzyme A Reductase from Chloroflexus aurantiacus, a Key Enzyme of the 3-Hydroxypropionate Cycle for Autotrophic CO₂ Fixation*. J. Bacteriol., 2002. 184(9): p. 2404-2410.
45. Holo, H., & Chloroflexus aurantiacus & secretes 3-hydroxypropionate, a possible intermediate in the assimilation of CO₂ and acetate. Archives of Microbiology, 1989. 151(3): p. 252-256.
46. Xu, Y., et al., *Expression of Genes in Cyanobacteria: Adaptation of Endogenous Plasmids as Platforms for High-Level Gene Expression in & Synechococcus & sp. PCC 7002*, in *Photosynthesis Research Protocols*, R. Carpentier, Editor. 2011, Humana Press. p. 273-293.
47. Feist, A. M., et al., *Reconstruction of biochemical networks in microorganisms*. Nat Rev Micro, 2009. 7(2): p. 129-143.
48. Visscher, P. T., and H. van Gemerden. 1991. Production and Consumption of Dimethylsulfoniopropionate in Marine Microbial Mats. *Applied and Environmental Microbiology* 57:3237-3242.
49. Dacey, J. W. H., and N. V. Blough. 1987. Hydroxide decomposition of dimethylsulfoniopropionate to form dimethylsulfide. *Geophys. Res. Lett.* 14:1246-1249.
50. Begemann M B, Zess E K, Walters E M, Schmitt E F, Markley A L, Pflieger B F. An organic acid based counter selection system for cyanobacteria. *PLoS One*. 2013 Oct. 1; 8(10):e76594.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 22

<210> SEQ ID NO 1

<211> LENGTH: 1965

<212> TYPE: DNA

<213> ORGANISM: Synechococcus PCC7002

<400> SEQUENCE: 1

```

atgtccgaac aaaacattga atccatcctc caggagcagc gccttttttc gectgcacca      60
gactttgctg ccgaggccca gatcaagagc ttagaccagt accaagccct ctacgaccgg      120
gcgaaaaatg acccccgaag cttttggggg gaactcgccg aacaggaatt ggaatggttt      180
gagaaatggg acaagtgctc cgattggcaa ccgcccctcg ccaaattggtt tgtcaacggg      240
aaaattaaca tttcctacaa ttgcctcgac cgctcatctca aaacctggcg caaaaataaa      300
gccgccctca tctgggaagg ggaacccggt gactcccgta ccctcaacta tgcccagcta      360
caccacgagg tctgccagtt tgccaatgcg atgaaaaagt tgggctgcaa aaaaggcgat      420
cgcgctcgga tttatatgcc aatgatcccg gaagccgctg ttgccctcct cgctgtgccc      480
cgcattggtg cgccccatac ggtgatattt ggtggcttta gtgccgaagc cctccgcagt      540
cgcctcgaag acgctgaagc caaactggtg atcaccgccc acgggggctt cgcgaaagat      600
aaagcggtac cctcaagga tcaagtagat gcggcgatcg ccgatcacca tgccccccagc      660
gttgagaatg ttttggtcgt tcaacgcacc aaagagcctg tccacatgga agccggggcgg      720
gatcactggt ggcgatgatt gcaaaaagaa gtctccgctg actgtcccgc cgagccgatg      780
gatgccgaag atatgctctt catcctctat accagcggca ccacgggtaa acccaagggc      840

```

-continued

```

gttgccaca ctacgggegg ttataatctc tacaccata taacgaccaa gtggatcttt 900
gatctcaaag atgatgacgt gtattggtgt ggtgctgatg tgggttggat caccggccac 960
agttacatta cctatggccc tctatctaac ggggcaacgg tcttaatgta tgaaggcgca 1020
ccccgtccgt ctaatcccggt ttgctattgg gaaattatto aaaaatatgg tgtcaccatt 1080
ttctatacgg caccacacgc gattcggggc tttatcaaaa tgggtgaagg catccccaat 1140
aaatatgaca tgagttccct gcgcctctta ggaaccgtgg gtgaaccgat taaccagaa 1200
gcttgatgt ggtaccacgg ggtcattggt ggogaacggt gtcccattgt tgatacatgg 1260
tggaacacgg aaaccggtgg tgtgatgatt acgcctttac ccggtgcaac tcccacaaaa 1320
ccccgtccgg caactcgtcc tttccggggg attgtggcgg atgtcgttga ccttgatgga 1380
aattccgttg gtgacaacga aggcggctac ctggtagtga aacaaccctg gcctgggatg 1440
atgctactg tttacggcaa tcccgaacgc ttccggteta cctattggga gcacatcgcc 1500
ccgaaagatg gacaatacct ttatttcgca ggtgacgggg cacgccgtga ccaagatggc 1560
tatttttggg ttatgggtcg cgtcgatgat gtettaaatg tttcggggca tcgecteggc 1620
accatggaag tggaatcggc cctcgtttcc caccctgccg tcgccgaagc agccgtgggt 1680
ggaaagccag atccggttaa gggggaagag gtgtttgcct ttgtcacct tgagggcacc 1740
tacagtccga gcgacgatct cgtaacggaa ctcaaggccc atgtggtgaa agaaattggg 1800
gcgatcgccc gtccgggaga aatccgtttt gccgatgtaa tgcccaaac ccgttctggg 1860
aagatcatgc ggcgtttggt gcgaaaccta gccgcaggtc aggaaattgt gggcgacacc 1920
tccaccctcg aagaccgcag cgtcctcgat caactccggg gctaa 1965

```

<210> SEQ ID NO 2

<211> LENGTH: 654

<212> TYPE: PRT

<213> ORGANISM: Synechococcus PCC7002

<400> SEQUENCE: 2

```

Met Ser Glu Gln Asn Ile Glu Ser Ile Leu Gln Glu Gln Arg Leu Phe
1           5           10           15
Ser Pro Ala Pro Asp Phe Ala Ala Glu Ala Gln Ile Lys Ser Leu Asp
20          25          30
Gln Tyr Gln Ala Leu Tyr Asp Arg Ala Lys Asn Asp Pro Glu Gly Phe
35          40          45
Trp Gly Glu Leu Ala Glu Gln Glu Leu Glu Trp Phe Glu Lys Trp Asp
50          55          60
Lys Val Leu Asp Trp Gln Pro Pro Phe Ala Lys Trp Phe Val Asn Gly
65          70          75          80
Lys Ile Asn Ile Ser Tyr Asn Cys Leu Asp Arg His Leu Lys Thr Trp
85          90          95
Arg Lys Asn Lys Ala Ala Leu Ile Trp Glu Gly Glu Pro Gly Asp Ser
100         105         110
Arg Thr Leu Thr Tyr Ala Gln Leu His His Glu Val Cys Gln Phe Ala
115         120         125
Asn Ala Met Lys Lys Leu Gly Val Lys Lys Gly Asp Arg Val Gly Ile
130         135         140
Tyr Met Pro Met Ile Pro Glu Ala Val Val Ala Leu Leu Ala Cys Ala
145         150         155         160
Arg Ile Gly Ala Pro His Thr Val Ile Phe Gly Gly Phe Ser Ala Glu
165         170         175

```

-continued

Ala Leu Arg Ser Arg Leu Glu Asp Ala Glu Ala Lys Leu Val Ile Thr
180 185 190

Ala Asp Gly Gly Phe Arg Lys Asp Lys Ala Val Pro Leu Lys Asp Gln
195 200 205

Val Asp Ala Ala Ile Ala Asp His His Ala Pro Ser Val Glu Asn Val
210 215 220

Leu Val Val Gln Arg Thr Lys Glu Pro Val His Met Glu Ala Gly Arg
225 230 235 240

Asp His Trp Trp His Asp Leu Gln Lys Glu Val Ser Ala Asp Cys Pro
245 250 255

Ala Glu Pro Met Asp Ala Glu Asp Met Leu Phe Ile Leu Tyr Thr Ser
260 265 270

Gly Thr Thr Gly Lys Pro Lys Gly Val Val His Thr Thr Gly Gly Tyr
275 280 285

Asn Leu Tyr Thr His Ile Thr Thr Lys Trp Ile Phe Asp Leu Lys Asp
290 295 300

Asp Asp Val Tyr Trp Cys Gly Ala Asp Val Gly Trp Ile Thr Gly His
305 310 315 320

Ser Tyr Ile Thr Tyr Gly Pro Leu Ser Asn Gly Ala Thr Val Leu Met
325 330 335

Tyr Glu Gly Ala Pro Arg Pro Ser Asn Pro Gly Cys Tyr Trp Glu Ile
340 345 350

Ile Gln Lys Tyr Gly Val Thr Ile Phe Tyr Thr Ala Pro Thr Ala Ile
355 360 365

Arg Ala Phe Ile Lys Met Gly Glu Gly Ile Pro Asn Lys Tyr Asp Met
370 375 380

Ser Ser Leu Arg Leu Leu Gly Thr Val Gly Glu Pro Ile Asn Pro Glu
385 390 395 400

Ala Trp Met Trp Tyr His Arg Val Ile Gly Gly Glu Arg Cys Pro Ile
405 410 415

Val Asp Thr Trp Trp Gln Thr Glu Thr Gly Gly Val Met Ile Thr Pro
420 425 430

Leu Pro Gly Ala Thr Pro Thr Lys Pro Gly Ser Ala Thr Arg Pro Phe
435 440 445

Pro Gly Ile Val Ala Asp Val Val Asp Leu Asp Gly Asn Ser Val Gly
450 455 460

Asp Asn Glu Gly Gly Tyr Leu Val Val Lys Gln Pro Trp Pro Gly Met
465 470 475 480

Met Arg Thr Val Tyr Gly Asn Pro Glu Arg Phe Arg Ser Thr Tyr Trp
485 490 495

Glu His Ile Ala Pro Lys Asp Gly Gln Tyr Leu Tyr Phe Ala Gly Asp
500 505 510

Gly Ala Arg Arg Asp Gln Asp Gly Tyr Phe Trp Ile Met Gly Arg Val
515 520 525

Asp Asp Val Leu Asn Val Ser Gly His Arg Leu Gly Thr Met Glu Val
530 535 540

Glu Ser Ala Leu Val Ser His Pro Ala Val Ala Glu Ala Ala Val Val
545 550 555 560

Gly Lys Pro Asp Pro Val Lys Gly Glu Glu Val Phe Ala Phe Val Thr
565 570 575

Leu Glu Gly Thr Tyr Ser Pro Ser Asp Asp Leu Val Thr Glu Leu Lys
580 585 590

-continued

Ala His Val Val Lys Glu Ile Gly Ala Ile Ala Arg Pro Gly Glu Ile
 595 600 605
 Arg Phe Ala Asp Val Met Pro Lys Thr Arg Ser Gly Lys Ile Met Arg
 610 615 620
 Arg Leu Leu Arg Asn Leu Ala Ala Gly Gln Glu Ile Val Gly Asp Thr
 625 630 635 640
 Ser Thr Leu Glu Asp Arg Ser Val Leu Asp Gln Leu Arg Gly
 645 650

<210> SEQ ID NO 3
 <211> LENGTH: 1962
 <212> TYPE: DNA
 <213> ORGANISM: Synechocystis PCC6803

<400> SEQUENCE: 3

atgtcagata ccattgaatc catcctgcag gaagagcgac tgtttgatcc ccctacagaa 60
 tttagtgagc gggcttacgt gcgtagtggg cgggagtatg agcaactgta cagccgggcg 120
 gccagcaatc cggagaagt ttgggggtgag ctggcggagc aggaattaca ttggtttaa 180
 aatgggacc aggttttggg ttggcaacct ccttttgcga aatggtttgt ggggggtcag 240
 ttaaataattt cccataactg tttggatcgg cacttaacca cctggcggcg caataaggcg 300
 gccattattt gggaggggga accgggagat tcccggataa ttacctatgc ccaactccat 360
 cgggaagtgt gtcagtttgc caatgccttg aaaagtttag gcgtgcaaaa aggtgatcgg 420
 gtagcaattt atctgcccat gattcccga ggcggcatca ccatgttggc ctgttccgct 480
 atcggtgccg cccatagtgt tgtgtttggt gggtttagtg cggaaagcct gcgggatcga 540
 ttagtgatg ctgaagccaa attggtcata actgccgacg gtggttttcg taaagataag 600
 gcgatcgccc tgaagcagga agtgataag gcctggaac acggtgcccc cagcgtggaa 660
 aacgtcatcg tcgtgcaaag aactaaagcc gatgtgacca tgacggcggg acgggaccac 720
 tggtgccacg aactccaacc tcaacagtcg gccatttgc cagcggaaacc catagacagt 780
 gaagatatgc tgtttattct ctacacctct ggcagtactg gcaaaccaaa aggcgtggtc 840
 cacaccaccg ggggttacia cctttacacc cacatgacca ccaaatggat ctttgacctc 900
 aaagatacgg acgtttattg gtgtaccgct gatgtgggtt ggattacggg ccacagctac 960
 attgtttacg gccccctgtc caacgggtgca acaacggtaa tgtatgaagg ggtgccccgc 1020
 ccctccaacc ccggttgttt ttgggacgta attgaaaggt atggggtgaa tattttctac 1080
 accgccccca ccgccatcgc agcctttatt cgcattgggg aagccgtacc caacgccagg 1140
 gatttatcct ctctccgttt actgggcaact gtgggggaaac ccattaacct cgaagcttgg 1200
 atgtgttacc accgggtcat tggcggcggg aaatgcccc ttgtcgatac ctggtggcaa 1260
 acgaaaaccg gcgcatttat gctcaactcc ctacctggag ctatccctac caaacccggt 1320
 tcttgtagca aaccttttcc cggcattgtg gcgaaattg ttgatttaga tggcaatccc 1380
 gtcgagtcag accaaggggg ctttttagtg attaaacaac cttggcccag catgattcgg 1440
 gatgtgtacg gcgacaccga tcgcttccgc catacctatt gggaacatat tcaacccaag 1500
 gagggacaat atctctactt tgctggggac ggggcccccc gggataaaga cggttatttt 1560
 tgggtcatgg gccgggtgga tgatgtgatt aatgtctctg gtcaccgttt aggcactatg 1620
 gaaattgaat cggttttggg ttccccccc ctctgtagcgg aagcggcggg ggtgggtcgc 1680
 cccgatgaat tgactgggga agccatttcc gcctttgttt ctctggaggg taacgctgaa 1740
 cccagtgaag agttgaaaaa agatttggtc aagcacgtca ctgaagaaat tggggcgatc 1800

-continued

```

gccagggcag cggaaatcgc tttaccgat gtgttaccca aaaccggttc cggcaaaatt 1860
atgctgctgc tgttgccgag tttagcctcc gggcaggaaa tttccgggga cacttccacc 1920
ctggaggacc ggacagtgcg ggacaaatta cgggagggct aa 1962

```

```

<210> SEQ ID NO 4
<211> LENGTH: 653
<212> TYPE: PRT
<213> ORGANISM: Synechocystis PCC6803

```

```

<400> SEQUENCE: 4

```

```

Met Ser Asp Thr Ile Glu Ser Ile Leu Gln Glu Glu Arg Leu Phe Asp
1          5          10          15
Pro Pro Thr Glu Phe Ser Glu Arg Ala Tyr Val Arg Ser Gly Arg Glu
20        25        30
Tyr Glu Gln Leu Tyr Ser Arg Ala Ala Ser Asn Pro Glu Lys Phe Trp
35        40        45
Gly Glu Leu Ala Glu Gln Glu Leu His Trp Phe Lys Lys Trp Asp Gln
50        55        60
Val Leu Asp Trp Gln Pro Pro Phe Ala Lys Trp Phe Val Gly Gly Gln
65        70        75        80
Leu Asn Ile Ser His Asn Cys Leu Asp Arg His Leu Thr Thr Trp Arg
85        90        95
Arg Asn Lys Ala Ala Ile Ile Trp Glu Gly Glu Pro Gly Asp Ser Arg
100       105       110
Ile Ile Thr Tyr Ala Gln Leu His Arg Glu Val Cys Gln Phe Ala Asn
115      120      125
Ala Leu Lys Ser Leu Gly Val Gln Lys Gly Asp Arg Val Ala Ile Tyr
130      135      140
Leu Pro Met Ile Pro Glu Ala Ala Ile Thr Met Leu Ala Cys Ser Arg
145      150      155      160
Ile Gly Ala Pro His Ser Val Val Phe Gly Gly Phe Ser Ala Glu Ala
165      170      175
Leu Arg Asp Arg Leu Val Asp Ala Glu Ala Lys Leu Val Ile Thr Ala
180      185      190
Asp Gly Gly Phe Arg Lys Asp Lys Ala Ile Ala Leu Lys Gln Glu Val
195      200      205
Asp Lys Ala Leu Glu His Gly Ala Pro Ser Val Glu Asn Val Ile Val
210      215      220
Val Gln Arg Thr Lys Ala Asp Val Thr Met Thr Ala Gly Arg Asp His
225      230      235      240
Trp Trp His Glu Leu Gln Pro Gln Gln Ser Ala His Cys Pro Ala Glu
245      250      255
Pro Ile Asp Ser Glu Asp Met Leu Phe Ile Leu Tyr Thr Ser Gly Ser
260      265      270
Thr Gly Lys Pro Lys Gly Val Val His Thr Thr Gly Gly Tyr Asn Leu
275      280      285
Tyr Thr His Met Thr Thr Lys Trp Ile Phe Asp Leu Lys Asp Thr Asp
290      295      300
Val Tyr Trp Cys Thr Ala Asp Val Gly Trp Ile Thr Gly His Ser Tyr
305      310      315      320
Ile Val Tyr Gly Pro Leu Ser Asn Gly Ala Thr Thr Val Met Tyr Glu
325      330      335
Gly Val Pro Arg Pro Ser Asn Pro Gly Cys Phe Trp Asp Val Ile Glu

```


-continued

340				345				350							
Arg	Tyr	Gly	Val	Asn	Ile	Phe	Tyr	Thr	Ala	Pro	Thr	Ala	Ile	Arg	Ala
		355					360					365			
Phe	Ile	Arg	Met	Gly	Glu	Ala	Val	Pro	Asn	Ala	Arg	Asp	Leu	Ser	Ser
		370				375						380			
Leu	Arg	Leu	Leu	Gly	Thr	Val	Gly	Glu	Pro	Ile	Asn	Pro	Glu	Ala	Trp
385					390						395				400
Met	Trp	Tyr	His	Arg	Val	Ile	Gly	Gly	Gly	Lys	Cys	Pro	Ile	Val	Asp
				405						410				415	
Thr	Trp	Trp	Gln	Thr	Glu	Thr	Gly	Gly	Ile	Met	Leu	Thr	Pro	Leu	Pro
			420							425				430	
Gly	Ala	Ile	Pro	Thr	Lys	Pro	Gly	Ser	Cys	Thr	Lys	Pro	Phe	Pro	Gly
		435					440							445	
Ile	Val	Ala	Glu	Ile	Val	Asp	Leu	Asp	Gly	Asn	Pro	Val	Glu	Ser	Asp
		450				455					460				
Gln	Gly	Gly	Phe	Leu	Val	Ile	Lys	Gln	Pro	Trp	Pro	Ser	Met	Ile	Arg
465					470					475					480
Asp	Val	Tyr	Gly	Asp	Thr	Asp	Arg	Phe	Arg	His	Thr	Tyr	Trp	Glu	His
				485						490				495	
Ile	Gln	Pro	Lys	Glu	Gly	Gln	Tyr	Leu	Tyr	Phe	Ala	Gly	Asp	Gly	Ala
			500							505				510	
Arg	Arg	Asp	Lys	Asp	Gly	Tyr	Phe	Trp	Val	Met	Gly	Arg	Val	Asp	Asp
		515					520							525	
Val	Ile	Asn	Val	Ser	Gly	His	Arg	Leu	Gly	Thr	Met	Glu	Ile	Glu	Ser
		530				535					540				
Ala	Leu	Val	Ser	His	Pro	Leu	Val	Ala	Glu	Ala	Ala	Val	Val	Gly	Arg
545					550						555				560
Pro	Asp	Glu	Leu	Thr	Gly	Glu	Ala	Ile	Phe	Ala	Phe	Val	Ser	Leu	Glu
				565						570				575	
Gly	Asn	Ala	Glu	Pro	Ser	Glu	Glu	Leu	Lys	Lys	Asp	Leu	Val	Lys	His
			580							585				590	
Val	Thr	Glu	Glu	Ile	Gly	Ala	Ile	Ala	Arg	Pro	Ala	Glu	Ile	Arg	Phe
		595					600							605	
Thr	Asp	Val	Leu	Pro	Lys	Thr	Arg	Ser	Gly	Lys	Ile	Met	Arg	Arg	Leu
		610				615								620	
Leu	Arg	Ser	Leu	Ala	Ser	Gly	Gln	Glu	Ile	Ser	Gly	Asp	Thr	Ser	Thr
625					630						635				640
Leu	Glu	Asp	Arg	Thr	Val	Leu	Asp	Lys	Leu	Arg	Glu	Gly			
				645						650					

<210> SEQ ID NO 5
 <211> LENGTH: 1971
 <212> TYPE: DNA
 <213> ORGANISM: Synechococcus PCC7942

<400> SEQUENCE: 5

```

atgagccagc caacgatcga gtcgatctc caagagaagc gggtttttcc tcctcggca    60
gaatttgcca gtgcggcgcg aatcaatccc gaagcgtacg aagcgcctcg ccagaaagcg    120
gcggccgata cggttgcttt ttggggcgaa ttggcagctc aggagctgga ctggtttgag    180
ccttggaac agacgctgga ctggagcaat ccgccgtttg cgaagtgggt tgcggtggc    240
aaactcaata tttcccacaa ctgcctcgat cgccacttga cgacttggcg caaaaataaa    300
gcggcgatta tctgggaagg cgaacccggt gactcacgga cgctgaccta cgcgcaactg    360
    
```

-continued

```

catcgcgagg tctgtcagtt cgccaactg ctcaaatcct tgggcattca aaaaggtgat 420
tcgcttgccg tttacatgcc gatgattccc gaagcggcga tcgccatgct ggctgtgcg 480
cggattggcg cagtgcatag cgttgtcttt gggggcttta gtgcggaagc actgcgcgat 540
cgcttggtgg atggccaagc caagctgggt gtcacggcgg atggtggctg gcgcaaagat 600
gcgatcgtgc ccctcaagga tctgttgat caagccctgg aaggcaatgc ctgccccagc 660
gtccagcatg tcctcgtggt ggaacggacg aagcaagaca tccacatgga accggggcgc 720
gaccattggt ggcatgagct gcaacagacc gtcagcgtc cctgtccggc ggagccgatg 780
gacagcgaag atctgctctt cgtgctctac acctccggtg gcaccggcaa acccaaggg 840
gtcgtccaca ccaccggcgg ctacaacctc tacgcccaca tcaccacca gtggactttt 900
gaactgcagg ataccgatgt ctactggtgt acggcggacg tcggctggat taccggtcac 960
agtacatcgc tctacgggcc gctctccaac ggtgcgacca cactgatgta tgagggtgcc 1020
ccccgcgctt ctaatcccgg ttgcttctgg gatgtgattg aaaagtatgg cgttacgacc 1080
ttctacacag cccaacagc gatccgcgcc ttcataaaa tgggtgagca gcatcccgcc 1140
gtcgcgacc tctctcatt gcgactgttg ggcaccgtcg gagagcccat caatcccga 1200
gcttgatctt ggtatcacgg cgtcattggt ggcgatcgtc gcccgattgt cgatacctgg 1260
tggcagaccg aaacgggcgg ccatatgatt acgtcgtcgc cgggagccgt gccgaccaa 1320
ccgggctctg ccactaaacc tttcccgggc atcttggcag acggtgtcga tctggatggg 1380
cgatcgggtc cggataacga aggtggttac ttggtgattc gccatccttg gccaggcatg 1440
atgcccacgg tctacggcga tcccgatcgc ttcgctcga cctattggga gcatattcct 1500
ccgcaaaatg gccagtatct ctacttcgcc ggcgatggcg cgcgccgca tgccgatggc 1560
tatttctggg tgatggggcg cgtcgatgac gtgatcaatg tctcaggtea ccgtctcggc 1620
acgatgaaa ttgagtcggc cttggtctcc catccggcag ttgccgaagc tgcagttgtc 1680
ggtcggcctg acgatctcaa agtggaaggc attggtgctt tcatcacgct ggaatcgggc 1740
attgagactg gcgatgagtt agttaaagac ctgaagaaac acgtcgccca agaaattggc 1800
gcgatcgtc gtcccgatga aattcgcttc agtgaggcgc tgcccaaac gcgatcgggc 1860
aagattatgc gccgtctggt gcgcagctc gccgctggtc aagaagtctt gggcgacact 1920
tccaccttgg aagatcgtc ggtgctcgat aagctgcgtc aaggcaacta g 1971

```

<210> SEQ ID NO 6

<211> LENGTH: 656

<212> TYPE: PRT

<213> ORGANISM: *Synechococcus* PCC7942

<400> SEQUENCE: 6

```

Met Ser Gln Pro Thr Ile Glu Ser Ile Leu Gln Glu Lys Arg Val Phe
1           5           10           15

Pro Pro Ser Ala Glu Phe Ala Ser Ala Ala Arg Ile Asn Pro Glu Ala
20           25           30

Tyr Glu Ala Leu Cys Gln Lys Ala Ala Ala Asp Pro Val Ala Phe Trp
35           40           45

Gly Glu Leu Ala Ala Gln Glu Leu Asp Trp Phe Glu Pro Trp Gln Gln
50           55           60

Thr Leu Asp Trp Ser Asn Pro Pro Phe Ala Lys Trp Phe Val Gly Gly
65           70           75           80

Lys Leu Asn Ile Ser His Asn Cys Leu Asp Arg His Leu Thr Thr Trp
85           90           95

```

-continued

Arg Lys Asn Lys Ala Ala Ile Ile Trp Glu Gly Glu Pro Gly Asp Ser
 100 105 110
 Arg Thr Leu Thr Tyr Ala Gln Leu His Arg Glu Val Cys Gln Phe Ala
 115 120 125
 Asn Val Leu Lys Ser Leu Gly Ile Gln Lys Gly Asp Val Val Gly Val
 130 135 140
 Tyr Met Pro Met Ile Pro Glu Ala Ala Ile Ala Met Leu Ala Cys Ala
 145 150 155 160
 Arg Ile Gly Ala Val His Ser Val Val Phe Gly Gly Phe Ser Ala Glu
 165 170 175
 Ala Leu Arg Asp Arg Leu Val Asp Gly Gln Ala Lys Leu Val Val Thr
 180 185 190
 Ala Asp Gly Gly Trp Arg Lys Asp Ala Ile Val Pro Leu Lys Asp Ser
 195 200 205
 Val Asp Gln Ala Leu Glu Gly Asn Ala Cys Pro Ser Val Gln His Val
 210 215 220
 Leu Val Val Glu Arg Thr Lys Gln Asp Ile His Met Glu Pro Gly Arg
 225 230 235 240
 Asp His Trp Trp His Glu Leu Gln Gln Thr Val Ser Ala Thr Cys Pro
 245 250 255
 Ala Glu Pro Met Asp Ser Glu Asp Leu Leu Phe Val Leu Tyr Thr Ser
 260 265 270
 Gly Ser Thr Gly Lys Pro Lys Gly Val Val His Thr Thr Gly Gly Tyr
 275 280 285
 Asn Leu Tyr Ala His Ile Thr Thr Gln Trp Thr Phe Asp Leu Gln Asp
 290 295 300
 Thr Asp Val Tyr Trp Cys Thr Ala Asp Val Gly Trp Ile Thr Gly His
 305 310 315 320
 Ser Tyr Ile Val Tyr Gly Pro Leu Ser Asn Gly Ala Thr Thr Leu Met
 325 330 335
 Tyr Glu Gly Ala Pro Arg Ala Ser Asn Pro Gly Cys Phe Trp Asp Val
 340 345 350
 Ile Glu Lys Tyr Gly Val Thr Thr Phe Tyr Thr Ala Pro Thr Ala Ile
 355 360 365
 Arg Ala Phe Ile Lys Met Gly Glu Gln His Pro Ala Ala Arg Asp Leu
 370 375 380
 Ser Ser Leu Arg Leu Leu Gly Thr Val Gly Glu Pro Ile Asn Pro Glu
 385 390 395 400
 Ala Trp Ile Trp Tyr His Arg Val Ile Gly Gly Asp Arg Cys Pro Ile
 405 410 415
 Val Asp Thr Trp Trp Gln Thr Glu Thr Gly Gly His Met Ile Thr Ser
 420 425 430
 Leu Pro Gly Ala Val Pro Thr Lys Pro Gly Ser Ala Thr Lys Pro Phe
 435 440 445
 Pro Gly Ile Leu Ala Asp Val Val Asp Leu Asp Gly Arg Ser Val Pro
 450 455 460
 Asp Asn Glu Gly Gly Tyr Leu Val Ile Arg His Pro Trp Pro Gly Met
 465 470 475 480
 Met Arg Thr Val Tyr Gly Asp Pro Asp Arg Phe Arg Arg Thr Tyr Trp
 485 490 495
 Glu His Ile Pro Pro Gln Asn Gly Gln Tyr Leu Tyr Phe Ala Gly Asp
 500 505 510

-continued

Gly Ala Arg Arg Asp Ala Asp Gly Tyr Phe Trp Val Met Gly Arg Val
515 520 525

Asp Asp Val Ile Asn Val Ser Gly His Arg Leu Gly Thr Met Glu Ile
530 535 540

Glu Ser Ala Leu Val Ser His Pro Ala Val Ala Glu Ala Ala Val Val
545 550 555 560

Gly Arg Pro Asp Asp Leu Lys Gly Glu Gly Ile Val Ala Phe Ile Thr
565 570 575

Leu Glu Ser Gly Ile Glu Thr Gly Asp Glu Leu Val Lys Asp Leu Lys
580 585 590

Lys His Val Ala Gln Glu Ile Gly Ala Ile Ala Arg Pro Asp Glu Ile
595 600 605

Arg Phe Ser Glu Ala Leu Pro Lys Thr Arg Ser Gly Lys Ile Met Arg
610 615 620

Arg Leu Leu Arg Ser Leu Ala Ala Gly Gln Glu Val Ser Gly Asp Thr
625 630 635 640

Ser Thr Leu Glu Asp Arg Ser Val Leu Asp Lys Leu Arg Gln Gly Thr
645 650 655

<210> SEQ ID NO 7
<211> LENGTH: 3898
<212> TYPE: DNA
<213> ORGANISM: Chloroflexus aurantiacus
<400> SEQUENCE: 7

```

aacatcatgg tatactatac ctatcgataa ttcttcaact aattgcataa cagaacagcg      60
atggcgacgg gggagtccat gagcggaaca ggacgactgg caggaagatg tgcgttaatt      120
accggtggcg ccggcaatat cggcagtgaa ttgacacgtc gctttctcgc agagggagcg      180
acggtcatta ttagtggacg gaatcgggcg aagttgaccg cactggccga acggatgcag      240
gcagaggcag gagtgccggc aaagcgcacg gatctcgaag tcatggatgg gagtgatccg      300
gtcgcgggtac gtgccggtat cgaagcgatt gtggcccgtc acggccagat cgacattctg      360
gtcaacaatg caggaagtgc cggtgcccag cgtcgtctgg ccgagattcc actcaactgaa      420
gctgaattag gccctggcgc cgaagagacg cttcatgcca gcatcgcaa tttacttggt      480
atgggatggc atctgatgcg tattgcggca cctcatatgc cggtaggaag tgcggtcatc      540
aatgtctcga ccattctttc acgggctgag tactacgggc ggattccgta tgcaccacct      600
aaagctgctc ttaatgctct atctcaactt gctgcgctg agttaggtgc acgtggcacc      660
cgcgtaata cgatctttcc cggcccgatt gaaagtgate gcatccgtac agtgttccag      720
cgtatggatc agtccaaggg gcggcccga ggcgacacag cgcaccattt tttgaacacc      780
atgcgattgt gtcgtgcaa cgaccagggc gcgcttgaac gtcggttccc ctccgtcggt      840
gatgtggcag acgcccgtgt ctttctggcc agtgccgaat ccgccgctct ctccggtgag      900
acgattgagg ttacgcacgg aatggagtgg ccggcctgca gtgagaccag cctgctggcc      960
cgtactgacg tgcgcacgat tgatgccagt ggccgcacga cgctcatctg cgccggcgac     1020
cagattgaag aggtgatggc gctcaccggg atgttgcgta cctgtgggag tgaagtgate     1080
atcggcttcc gttcggctgc ggcgctggcc cagttcgagc aggcagtcaa tgagatcgg     1140
cggtggcccg gcgcagactt tacgcctccc attgccttgc cactcgatcc acgcgatccg     1200
gcaacaattg acgctgtctt cgattggggg gccggcgaga ataccggcgg gattcatgca     1260
gggtgatgac tgcctgctac cagtcacgaa ccggcacctg gcgtgattga gggtgatgat     1320

```

-continued

gagcgggtgc tgaattttct ggccgatgaa atcaccggga caattgtgat tgccagtcgc	1380
ctggccccgtt actggcagtc gcaacggcctt acccccggcg cacgtgcgcg tgggcccgcgt	1440
gtcatttttc tctcgaacgg tgccgatcaa aatgggaatg tttacggacg cattcaaagt	1500
gcccgtatcg gtcagctcat tcgtgtgtgg cgtcacgagg ctgaacttga ctatcagcgt	1560
gccagcgcgc cgggtgatca tgtgctgccg ccggtatggg ccaatcagat tgtgcgcttc	1620
gctaaccgca gccttgaagg gttagaattt gcctgtgcct ggacagctca attgctccat	1680
agtcaacgcc atatcaatga gattaccctc aacatccctg ccaacattag cgccaccacc	1740
ggcgcacgca gtgcatcggg cggatgggcg gaaagcctga tcgggttgca tttggggaaa	1800
gttgcccttga ttaccggtgg cagcgcgggt attggtgggc agatcgggcg cctcctggct	1860
ttgagtggcg cgcgcgtgat gctggcagcc cgtgatcggc ataagctcga acagatgcag	1920
gcatgatcc aatctgagct ggtgtaggtg ggtataaccg atgtcgaaga tcgcgtccac	1980
attgcaccgg gctgcgatgt gaggtagcga gcgcagcttg cggatcttgt tgaacgtacc	2040
ctgtcagctt ttggcaccgt cgattatctg atcaacaacg ccgggatcgc cgggtgcgaa	2100
gagatgggta tcgatatgcc agttgaggga tggcgccata ccctcttcgc caatctgatc	2160
agcaactact cgttgatcgc caaactggcg ccggtgatga aaaaacaggg tagcggttac	2220
atccttaacg tctcatcata ctttggcggg gaaaaagatg cggccattcc ctacccaac	2280
cgtgccgatt acgcccgtcc gaaggctggt cagcgggcaa tggccgaagt ctttgcgcgc	2340
ttccttggcc cggagataca gatcaatgcc attgcgccgg gtccggtcga aggtgatcgc	2400
ttgcgcggta ccggtgaacg tcccggcctc tttgccctc gggcgcggt gattttggag	2460
aacaagcggc tgaatgagct tcacgctgct cttatcgcgg ctgcgcgcac cgatgagcga	2520
tctatgcacg aactgggtga actgctctta cccaatgatg tggccgcact agagcagaat	2580
cccgcagcac ctaccgcgtt gcgtgaactg gcacgacggt ttccgcagcga aggcgatccg	2640
ggggcatcat caagcagtcg gctgctgaac cgttcaattg ccgctaaatt gctggctcgt	2700
ttgcataatg gtggtatgt gttgcctgcc gacatctttg caaacctgcc aaaccgcgcc	2760
gatcccttct tcacccgagc ccagattgat cgcgaggctc gcaaggttcg tgacggcacc	2820
atggggatgc tctacctgca acggatgccg actgagtttg atgtcgcaat ggccaccgtc	2880
tattaccttg ccgaccgcaa tgtcagtggt gagacattcc acccatcagg tggtttgcgt	2940
taacgaacgca cccctaccgg tggcgaactc ttggccttgc cctcaccgga acggctggcg	3000
gagctggctg gaagcagcgt ctatctgata ggtgaacatc tgactgaaca ccttaacctg	3060
cttgcccgtg cgtacctcga acgttacggg gcacgtcagg tagtgatgat tgttgagaca	3120
gaaaccgggg cagagacaat gcgtcgcttg ctccacgatc acgtcgaggc tggctcgctg	3180
atgactattg tggccggtga tcagatcgaa gccgctatcg accaggctat cactcgtac	3240
ggtgcgccag ggccggctgt ctgtaccccc ttccggccac tggccagcgt accactggtc	3300
gggctgtaaag acagtgactg gagcacagtg ttgagtgagg ctgaatttgc cgagtgtg	3360
gaacaccagc tcaccacca tttccgggta gcgcgcaaga ttgccctgag tgatggtgcc	3420
agtctcgcgc tggctcactcc cgaactacg gctacctcaa ctaccgagca atttgcctg	3480
getaacttca tcaaaaacgac ccttcaagct tttacggcta cgattgggtg cgagagcgaa	3540
agaactgctc agcgcattct gatcaatcaa gtgatctga cccggcgtgc gcgtgcccga	3600
gagccgcgtg atccgcacga gcgtcaacaa gaactggaac gttttatcga ggagctctg	3660
ctggctactg caccactccc gcctgaagcc gataccgctt acgcccggcg gattcatcgc	3720

-continued

```

ggacgggga ttaccgtgta aattctacgc cacaggaacc actaccaaac cagcatagta 3780
agagaacgat agagacgttg caatgcgacg tctctatcat atttccggcc ccccctagac 3840
aaacccccac gtcttcgtgt agactagaaa caggaggctg tatgcacgtc caacaaga 3898

```

```

<210> SEQ ID NO 8
<211> LENGTH: 1220
<212> TYPE: PRT
<213> ORGANISM: Chloroflexus aurantiacus

```

```

<400> SEQUENCE: 8

```

```

Met Ser Gly Thr Gly Arg Leu Ala Gly Lys Ile Ala Leu Ile Thr Gly
1          5          10          15
Gly Ala Gly Asn Ile Gly Ser Glu Leu Thr Arg Arg Phe Leu Ala Glu
20          25          30
Gly Ala Thr Val Ile Ile Ser Gly Arg Asn Arg Ala Lys Leu Thr Ala
35          40          45
Leu Ala Glu Arg Met Gln Ala Glu Ala Gly Val Pro Ala Lys Arg Ile
50          55          60
Asp Leu Glu Val Met Asp Gly Ser Asp Pro Val Ala Val Arg Ala Gly
65          70          75          80
Ile Glu Ala Ile Val Ala Arg His Gly Gln Ile Asp Ile Leu Val Asn
85          90          95
Asn Ala Gly Ser Ala Gly Ala Gln Arg Arg Leu Ala Glu Ile Pro Leu
100         105         110
Thr Glu Ala Glu Leu Gly Pro Gly Ala Glu Glu Thr Leu His Ala Ser
115         120         125
Ile Ala Asn Leu Leu Gly Met Gly Trp His Leu Met Arg Ile Ala Ala
130         135         140
Pro His Met Pro Val Gly Ser Ala Val Ile Asn Val Ser Thr Ile Phe
145         150         155         160
Ser Arg Ala Glu Tyr Tyr Gly Arg Ile Pro Tyr Val Thr Pro Lys Ala
165         170         175
Ala Leu Asn Ala Leu Ser Gln Leu Ala Ala Arg Glu Leu Gly Ala Arg
180         185         190
Gly Ile Arg Val Asn Thr Ile Phe Pro Gly Pro Ile Glu Ser Asp Arg
195         200         205
Ile Arg Thr Val Phe Gln Arg Met Asp Gln Leu Lys Gly Arg Pro Glu
210         215         220
Gly Asp Thr Ala His His Phe Leu Asn Thr Met Arg Leu Cys Arg Ala
225         230         235         240
Asn Asp Gln Gly Ala Leu Glu Arg Arg Phe Pro Ser Val Gly Asp Val
245         250         255
Ala Asp Ala Ala Val Phe Leu Ala Ser Ala Glu Ser Ala Ala Leu Ser
260         265         270
Gly Glu Thr Ile Glu Val Thr His Gly Met Glu Leu Pro Ala Cys Ser
275         280         285
Glu Thr Ser Leu Leu Ala Arg Thr Asp Leu Arg Thr Ile Asp Ala Ser
290         295         300
Gly Arg Thr Thr Leu Ile Cys Ala Gly Asp Gln Ile Glu Glu Val Met
305         310         315         320
Ala Leu Thr Gly Met Leu Arg Thr Cys Gly Ser Glu Val Ile Ile Gly
325         330         335
Phe Arg Ser Ala Ala Ala Leu Ala Gln Phe Glu Gln Ala Val Asn Glu

```

-continued

340				345				350							
Ser	Arg	Arg	Leu	Ala	Gly	Ala	Asp	Phe	Thr	Pro	Pro	Ile	Ala	Leu	Pro
		355					360							365	
Leu	Asp	Pro	Arg	Asp	Pro	Ala	Thr	Ile	Asp	Ala	Val	Phe	Asp	Trp	Gly
	370					375					380				
Ala	Gly	Glu	Asn	Thr	Gly	Gly	Ile	His	Ala	Ala	Val	Ile	Leu	Pro	Ala
385					390						395				400
Thr	Ser	His	Glu	Pro	Ala	Pro	Cys	Val	Ile	Glu	Val	Asp	Asp	Glu	Arg
			405						410					415	
Val	Leu	Asn	Phe	Leu	Ala	Asp	Glu	Ile	Thr	Gly	Thr	Ile	Val	Ile	Ala
			420						425					430	
Ser	Arg	Leu	Ala	Arg	Tyr	Trp	Gln	Ser	Gln	Arg	Leu	Thr	Pro	Gly	Ala
		435					440						445		
Arg	Ala	Arg	Gly	Pro	Arg	Val	Ile	Phe	Leu	Ser	Asn	Gly	Ala	Asp	Gln
	450					455					460				
Asn	Gly	Asn	Val	Tyr	Gly	Arg	Ile	Gln	Ser	Ala	Ala	Ile	Gly	Gln	Leu
465					470						475				480
Ile	Arg	Val	Trp	Arg	His	Glu	Ala	Glu	Leu	Asp	Tyr	Gln	Arg	Ala	Ser
			485						490					495	
Ala	Ala	Gly	Asp	His	Val	Leu	Pro	Pro	Val	Trp	Ala	Asn	Gln	Ile	Val
			500						505					510	
Arg	Phe	Ala	Asn	Arg	Ser	Leu	Glu	Gly	Leu	Glu	Phe	Ala	Cys	Ala	Trp
		515					520						525		
Thr	Ala	Gln	Leu	Leu	His	Ser	Gln	Arg	His	Ile	Asn	Glu	Ile	Thr	Leu
	530					535					540				
Asn	Ile	Pro	Ala	Asn	Ile	Ser	Ala	Thr	Thr	Gly	Ala	Arg	Ser	Ala	Ser
545					550					555					560
Val	Gly	Trp	Ala	Glu	Ser	Leu	Ile	Gly	Leu	His	Leu	Gly	Lys	Val	Ala
			565						570					575	
Leu	Ile	Thr	Gly	Gly	Ser	Ala	Gly	Ile	Gly	Gly	Gln	Ile	Gly	Arg	Leu
			580						585				590		
Leu	Ala	Leu	Ser	Gly	Ala	Arg	Val	Met	Leu	Ala	Ala	Arg	Asp	Arg	His
		595					600						605		
Lys	Leu	Glu	Gln	Met	Gln	Ala	Met	Ile	Gln	Ser	Glu	Leu	Ala	Glu	Val
	610					615					620				
Gly	Tyr	Thr	Asp	Val	Glu	Asp	Arg	Val	His	Ile	Ala	Pro	Gly	Cys	Asp
625					630					635					640
Val	Ser	Ser	Glu	Ala	Gln	Leu	Ala	Asp	Leu	Val	Glu	Arg	Thr	Leu	Ser
			645						650					655	
Ala	Phe	Gly	Thr	Val	Asp	Tyr	Leu	Ile	Asn	Asn	Ala	Gly	Ile	Ala	Gly
			660						665					670	
Val	Glu	Glu	Met	Val	Ile	Asp	Met	Pro	Val	Glu	Gly	Trp	Arg	His	Thr
			675				680						685		
Leu	Phe	Ala	Asn	Leu	Ile	Ser	Asn	Tyr	Ser	Leu	Met	Arg	Lys	Leu	Ala
	690					695					700				
Pro	Leu	Met	Lys	Lys	Gln	Gly	Ser	Gly	Tyr	Ile	Leu	Asn	Val	Ser	Ser
705					710					715					720
Tyr	Phe	Gly	Gly	Glu	Lys	Asp	Ala	Ala	Ile	Pro	Tyr	Pro	Asn	Arg	Ala
			725						730					735	
Asp	Tyr	Ala	Val	Ser	Lys	Ala	Gly	Gln	Arg	Ala	Met	Ala	Glu	Val	Phe
			740						745				750		
Ala	Arg	Phe	Leu	Gly	Pro	Glu	Ile	Gln	Ile	Asn	Ala	Ile	Ala	Pro	Gly
		755					760							765	

-continued

Pro Val Glu Gly Asp Arg Leu Arg Gly Thr Gly Glu Arg Pro Gly Leu
 770 775 780

Phe Ala Arg Arg Ala Arg Leu Ile Leu Glu Asn Lys Arg Leu Asn Glu
 785 790 795 800

Leu His Ala Ala Leu Ile Ala Ala Ala Arg Thr Asp Glu Arg Ser Met
 805 810 815

His Glu Leu Val Glu Leu Leu Leu Pro Asn Asp Val Ala Ala Leu Glu
 820 825 830

Gln Asn Pro Ala Ala Pro Thr Ala Leu Arg Glu Leu Ala Arg Arg Phe
 835 840 845

Arg Ser Glu Gly Asp Pro Ala Ala Ser Ser Ser Ser Ala Leu Leu Asn
 850 855 860

Arg Ser Ile Ala Ala Lys Leu Leu Ala Arg Leu His Asn Gly Gly Tyr
 865 870 875 880

Val Leu Pro Ala Asp Ile Phe Ala Asn Leu Pro Asn Pro Pro Asp Pro
 885 890 895

Phe Phe Thr Arg Ala Gln Ile Asp Arg Glu Ala Arg Lys Val Arg Asp
 900 905 910

Gly Ile Met Gly Met Leu Tyr Leu Gln Arg Met Pro Thr Glu Phe Asp
 915 920 925

Val Ala Met Ala Thr Val Tyr Tyr Leu Ala Asp Arg Asn Val Ser Gly
 930 935 940

Glu Thr Phe His Pro Ser Gly Gly Leu Arg Tyr Glu Arg Thr Pro Thr
 945 950 955 960

Gly Gly Glu Leu Phe Gly Leu Pro Ser Pro Glu Arg Leu Ala Glu Leu
 965 970 975

Val Gly Ser Thr Val Tyr Leu Ile Gly Glu His Leu Thr Glu His Leu
 980 985 990

Asn Leu Leu Ala Arg Ala Tyr Leu Glu Arg Tyr Gly Ala Arg Gln Val
 995 1000 1005

Val Met Ile Val Glu Thr Glu Thr Gly Ala Glu Thr Met Arg Arg
 1010 1015 1020

Leu Leu His Asp His Val Glu Ala Gly Arg Leu Met Thr Ile Val
 1025 1030 1035

Ala Gly Asp Gln Ile Glu Ala Ala Ile Asp Gln Ala Ile Thr Arg
 1040 1045 1050

Tyr Gly Arg Pro Gly Pro Val Val Cys Thr Pro Phe Arg Pro Leu
 1055 1060 1065

Pro Thr Val Pro Leu Val Gly Arg Lys Asp Ser Asp Trp Ser Thr
 1070 1075 1080

Val Leu Ser Glu Ala Glu Phe Ala Glu Leu Cys Glu His Gln Leu
 1085 1090 1095

Thr His His Phe Arg Val Ala Arg Lys Ile Ala Leu Ser Asp Gly
 1100 1105 1110

Ala Ser Leu Ala Leu Val Thr Pro Glu Thr Thr Ala Thr Ser Thr
 1115 1120 1125

Thr Glu Gln Phe Ala Leu Ala Asn Phe Ile Lys Thr Thr Leu His
 1130 1135 1140

Ala Phe Thr Ala Thr Ile Gly Val Glu Ser Glu Arg Thr Ala Gln
 1145 1150 1155

Arg Ile Leu Ile Asn Gln Val Asp Leu Thr Arg Arg Ala Arg Ala
 1160 1165 1170

-continued

Glu Glu Pro Arg Asp Pro His Glu Arg Gln Gln Glu Leu Glu Arg
 1175 1180 1185

Phe Ile Glu Ala Val Leu Leu Val Thr Ala Pro Leu Pro Pro Glu
 1190 1195 1200

Ala Asp Thr Arg Tyr Ala Gly Arg Ile His Arg Gly Arg Ala Ile
 1205 1210 1215

Thr Val
 1220

<210> SEQ ID NO 9
 <211> LENGTH: 652
 <212> TYPE: PRT
 <213> ORGANISM: Escherichia coli

<400> SEQUENCE: 9

Met Ser Gln Ile His Lys His Thr Ile Pro Ala Asn Ile Ala Asp Arg
 1 5 10 15

Cys Leu Ile Asn Pro Gln Gln Tyr Glu Ala Met Tyr Gln Gln Ser Ile
 20 25 30

Asn Val Pro Asp Thr Phe Trp Gly Glu Gln Gly Lys Ile Leu Asp Trp
 35 40 45

Ile Lys Pro Tyr Gln Lys Val Lys Asn Thr Ser Phe Ala Pro Gly Asn
 50 55 60

Val Ser Ile Lys Trp Tyr Glu Asp Gly Thr Leu Asn Leu Ala Ala Asn
 65 70 75 80

Cys Leu Asp Arg His Leu Gln Glu Asn Gly Asp Arg Thr Ala Ile Ile
 85 90 95

Trp Glu Gly Asp Asp Ala Ser Gln Ser Lys His Ile Ser Tyr Lys Glu
 100 105 110

Leu His Arg Asp Val Cys Arg Phe Ala Asn Thr Leu Leu Glu Leu Gly
 115 120 125

Ile Lys Lys Gly Asp Val Val Ala Ile Tyr Met Pro Met Val Pro Glu
 130 135 140

Ala Ala Val Ala Met Leu Ala Cys Ala Arg Ile Gly Ala Val His Ser
 145 150 155 160

Val Ile Phe Gly Gly Phe Ser Pro Glu Ala Val Ala Gly Arg Ile Ile
 165 170 175

Asp Ser Asn Ser Arg Leu Val Ile Thr Ser Asp Glu Gly Val Arg Ala
 180 185 190

Gly Arg Ser Ile Pro Leu Lys Lys Asn Val Asp Asp Ala Leu Lys Asn
 195 200 205

Pro Asn Val Thr Ser Val Glu His Val Val Val Leu Lys Arg Thr Gly
 210 215 220

Gly Lys Ile Asp Trp Gln Glu Gly Arg Asp Leu Trp Trp His Asp Leu
 225 230 235 240

Val Glu Gln Ala Ser Asp Gln His Gln Ala Glu Glu Met Asn Ala Glu
 245 250 255

Asp Pro Leu Phe Ile Leu Tyr Thr Ser Gly Ser Thr Gly Lys Pro Lys
 260 265 270

Gly Val Leu His Thr Thr Gly Gly Tyr Leu Val Tyr Ala Ala Leu Thr
 275 280 285

Phe Lys Tyr Val Phe Asp Tyr His Pro Gly Asp Ile Tyr Trp Cys Thr
 290 295 300

Ala Asp Val Gly Trp Val Thr Gly His Ser Tyr Leu Leu Tyr Gly Pro
 305 310 315 320

-continued

35				40				45							
Trp	Phe	Lys	Pro	Trp	Asp	Glu	Val	Cys	Ser	Gly	Ser	Leu	Ser	Lys	Gly
50					55						60				
Asp	Ile	Arg	Trp	Phe	Ser	Gly	Gly	Gln	Leu	Asn	Ile	Ser	His	Asn	Cys
65				70						75				80	
Ile	Asp	Arg	His	Leu	Ala	Lys	Arg	Gly	Asp	Gln	Val	Ala	Leu	Ile	Trp
			85						90					95	
Glu	Gly	Asp	Asp	Pro	Met	Asp	Ser	Ala	Arg	Ile	Thr	Tyr	Arg	Glu	Leu
			100					105					110		
His	Glu	Gln	Val	Cys	Arg	Leu	Ala	Asn	Val	Leu	Lys	Ser	Arg	Gly	Val
			115					120					125		
Lys	Lys	Gly	Asp	Arg	Val	Cys	Ile	Tyr	Met	Pro	Met	Val	Pro	Gln	Ala
			130			135					140				
Ala	Tyr	Ala	Met	Leu	Ala	Cys	Thr	Arg	Ile	Gly	Ala	Val	His	Ser	Val
145					150					155					160
Val	Phe	Gly	Gly	Phe	Ser	Pro	Asp	Ala	Leu	Arg	Asp	Arg	Ile	Leu	Asp
				165					170					175	
Ala	Asp	Cys	Arg	Thr	Val	Ile	Thr	Ala	Asp	Glu	Ala	Val	Arg	Gly	Gly
			180					185					190		
Lys	Leu	Ile	Pro	Leu	Lys	Ser	Asn	Val	Asp	Lys	Ala	Leu	Ala	Ser	Cys
			195				200						205		
Pro	Asn	Val	Ser	Thr	Val	Leu	Val	Val	Lys	Arg	Thr	Gly	Asn	Lys	Val
			210			215					220				
Asp	Trp	Asp	Asp	Lys	Arg	Asp	Leu	Trp	Tyr	Ala	Glu	Ala	Val	Gln	Gln
225					230					235				240	
Ala	Gly	Ala	Asp	Cys	Pro	Ala	Glu	Pro	Met	Asp	Ala	Glu	Asp	Pro	Leu
			245						250					255	
Phe	Ile	Leu	Tyr	Thr	Ser	Gly	Ser	Thr	Gly	Lys	Pro	Lys	Gly	Val	Leu
			260					265					270		
His	Ser	Thr	Ala	Gly	Tyr	Leu	Leu	Gln	Ala	Ala	Met	Thr	His	Lys	Tyr
			275				280						285		
Val	Phe	Asp	Tyr	His	Asp	Gly	Asp	Ile	Tyr	Trp	Cys	Thr	Ala	Asp	Val
			290			295					300				
Gly	Trp	Val	Thr	Gly	His	Ser	Tyr	Ile	Val	Tyr	Gly	Pro	Leu	Ala	Asn
305					310					315					320
Gly	Ala	Thr	Ser	Leu	Ile	Phe	Glu	Gly	Val	Pro	Asn	Tyr	Pro	Asp	Thr
			325						330					335	
Ser	Arg	Phe	Trp	Gln	Val	Ile	Asp	Lys	His	Gln	Val	Asn	Ile	Phe	Tyr
			340					345					350		
Thr	Ala	Pro	Thr	Ala	Leu	Arg	Ala	Leu	Met	Arg	Glu	Gly	Glu	Ala	Pro
			355			360							365		
Val	Lys	Lys	Ala	Ser	Arg	Ser	Ser	Leu	Arg	Leu	Leu	Gly	Ser	Val	Gly
			370			375					380				
Glu	Pro	Ile	Asn	Pro	Glu	Ala	Trp	Glu	Trp	Tyr	Phe	Lys	Val	Val	Gly
385					390					395					400
Glu	Gln	Arg	Cys	Pro	Ile	Val	Asp	Thr	Trp	Trp	Gln	Thr	Glu	Thr	Gly
			405						410					415	
Ala	Ile	Met	Ile	Thr	Pro	Leu	Pro	Gly	Ala	Thr	Asp	Leu	Lys	Pro	Gly
			420					425					430		
Ser	Ala	Thr	Arg	Pro	Phe	Phe	Gly	Val	Gln	Pro	Val	Leu	Leu	Asp	Glu
			435				440						445		
Gln	Gly	Lys	Glu	Ile	Asp	Gly	Pro	Gly	Ala	Gly	Val	Leu	Ala	Ile	Lys
			450			455					460				

-continued

Ala Ser Trp Pro Ser Gln Ile Arg Ser Val Tyr Gly Asp His Lys Arg
465 470 475 480

Met Leu Glu Thr Tyr Phe Thr Ala Tyr Pro Gly Tyr Tyr Phe Ser Gly
485 490 495

Asp Gly Ala Arg Arg Asp Glu Asp Gly Tyr Trp Trp Ile Thr Gly Arg
500 505 510

Ile Asp Asp Val Ile Asn Val Ser Gly His Arg Ile Gly Thr Ala Glu
515 520 525

Val Glu Ser Ala Leu Val Leu His Asp Ala Val Ala Glu Ala Ala Val
530 535 540

Val Gly Tyr Pro His Asp Val Lys Gly Gln Gly Ile Tyr Ala Phe Val
545 550 555 560

Thr Thr Met Asn Gly Val Glu Pro Ser Asp Glu Leu Lys Lys Glu Leu
565 570 575

Leu Ser Leu Val Gly Lys Glu Ile Gly Asn Phe Ala Lys Pro Glu Leu
580 585 590

Ile Gln Trp Ala Pro Gly Leu Pro Lys Thr Arg Ser Gly Lys Ile Met
595 600 605

Arg Arg Ile Leu Arg Lys Ile Ala Cys Asn Glu Leu Asp Ser Leu Gly
610 615 620

Asp Thr Ser Thr Leu Ala Asp Pro Ser Val Val Asp Ser Leu Ile Glu
625 630 635 640

Gln Arg Val Asn Asn
645

<210> SEQ ID NO 11

<211> LENGTH: 1080

<212> TYPE: DNA

<213> ORGANISM: Sulfolobus tokodaii

<400> SEQUENCE: 11

gtgatactca tgaggagaac attaaaagcc gcaatattag gtgctactgg tttagtagga 60

atcgaatcag taagaatgct atcaaatcat ccttatatta aaccagcata tttagctgga 120

aaaggttcag tgggtaaacc gtatggtgag gtagtaagat ggcaaacagt aggacaagtt 180

cctaaggaaa tagctgatat ggaataaaa ccaactgato ctaagttaat ggatgatgta 240

gacataatat tttctccatt acctcaaggt gctgctggcc cagtagaaga acaatttgca 300

aaagaaggat tcctgtgat tagtaattca ccagatcata gatttgatcc tgatgttccc 360

ttattggttc ctgaactaaa tcctcactact attagcttaa ttgatgagca aagaaaaga 420

agagaatgga aaggatttat agtaactaca ccaactatgca cagcccaggg tgcagcaata 480

ccattaggtg ctatatattaa agattataag atggatggag catttataac tactattcaa 540

tcgctatctg gtgccggtta tccaggaata coactcattag atgtagtaga taatatcttg 600

ccttaggtg atggatacga tgccaagacg ataaaagaga tcttcagaat ttaagcgaa 660

gttaagagaa atgtagatga acctaaatta gaagatgtaa gcttagcagc acaactcat 720

agaatagcta ctatacatgg tcattatgaa gtactatatg tatcgttcaa agaggaaact 780

gctgctgaaa aagttaagga gactttagaa aactttagag ggaaccaca agatctaaaa 840

ttaccaactg caccttcaaa gccaatatc gttatgaatg aggatacaag acctcaagtc 900

tattttgata gatgggctgg ggatattcca ggaatgagtg tagttgtagg tagattaaag 960

caagtgaata agagaatgat aaggttagta tcattaatto ataacacggt cagaggagcc 1020

-continued

gcaggaggag gtatattagc agctgaatta cttgtcgaaa aaggatatat tgaaaagtaa 1080

<210> SEQ ID NO 12

<211> LENGTH: 1071

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Codon-optimized coding sequence for Sulfolobus tokodaii malonate semialdehyde reductase

<400> SEQUENCE: 12

```

atgctgcgca cacttaaagc cgcgattctg ggcgcaaccg gtctcgtggg gatcgaatac    60
gtgcgtatgc tcagtaacca ccctacatt aaaccggcgt atttagcagg taaaggtagc    120
gtcggtaaac cctatggtga ggtgggtccg tggcaaactg ttggtcaggt accgaaagaa    180
attgctgata tggagattaa acccacggat cccaaactga tggatgatgt ggatatacatt    240
tttagcccc ttcccaagg tgcgcgggt ccagtggaag acaattcgc caaggaaggc    300
ttcccagtc tcagtaactc cccggaccac cgttttgatc ccgatgtccc gctcctcgtg    360
cccgaattga atccccacac catttccctc atcgatgaac agcgaagcg acgcgagtgg    420
aagggttca ttgttaccac acctctgtgt accgccaag gggcggcgat tcccttaggt    480
gcgattttca aagactataa aatggatggc gcctttatta ctaccatcca atccctcagt    540
ggggtggct atcccggtat tccgagtctg gatgtggtcg acaacatttt accgctgggg    600
gatggttatg acgctaaaac cattaaagaa atttttcgca tcttatcgga ggttaaaccg    660
aatgttgacg aacccaaact tgaagatgtc tcgtagccg cgaccactca tcggattgct    720
acgattcatg gtcattatga ggtcctctat gtgtccttca aagaagaaac cgcggcagaa    780
aaagtgaaag agacctaga aaattttcga ggggagcctc aagatctgaa actgccgacc    840
gcaccagta aaccatcat tgtaatgaac gaagacacgc ggccacaggt ttactttgat    900
cgttgggccc gcgatatccc cgggatgtct gtcgtggtgg ggcgtttgaa acaagtaaat    960
aagcgcata ttcggctggt gtccttaatc cacaacactg tacgcggtgc tgcgggcggt   1020
ggcatcctgg cggccgaact gttggtggag aaaggctaca ttgaaaaata a           1071

```

<210> SEQ ID NO 13

<211> LENGTH: 359

<212> TYPE: PRT

<213> ORGANISM: Sulfolobus tokodaii

<400> SEQUENCE: 13

```

Met Ile Leu Met Arg Arg Thr Leu Lys Ala Ala Ile Leu Gly Ala Thr
1           5           10          15
Gly Leu Val Gly Ile Glu Tyr Val Arg Met Leu Ser Asn His Pro Tyr
20          25          30
Ile Lys Pro Ala Tyr Leu Ala Gly Lys Gly Ser Val Gly Lys Pro Tyr
35          40          45
Gly Glu Val Val Arg Trp Gln Thr Val Gly Gln Val Pro Lys Glu Ile
50          55          60
Ala Asp Met Glu Ile Lys Pro Thr Asp Pro Lys Leu Met Asp Asp Val
65          70          75          80
Asp Ile Ile Phe Ser Pro Leu Pro Gln Gly Ala Ala Gly Pro Val Glu
85          90          95
Glu Gln Phe Ala Lys Glu Gly Phe Pro Val Ile Ser Asn Ser Pro Asp
100         105         110
His Arg Phe Asp Pro Asp Val Pro Leu Leu Val Pro Glu Leu Asn Pro

```

-continued

115	120	125
His Thr Ile Ser Leu Ile Asp Glu Gln Arg Lys Arg Arg Glu Trp Lys 130 135 140		
Gly Phe Ile Val Thr Thr Pro Leu Cys Thr Ala Gln Gly Ala Ala Ile 145 150 155 160		
Pro Leu Gly Ala Ile Phe Lys Asp Tyr Lys Met Asp Gly Ala Phe Ile 165 170 175		
Thr Thr Ile Gln Ser Leu Ser Gly Ala Gly Tyr Pro Gly Ile Pro Ser 180 185 190		
Leu Asp Val Val Asp Asn Ile Leu Pro Leu Gly Asp Gly Tyr Asp Ala 195 200 205		
Lys Thr Ile Lys Glu Ile Phe Arg Ile Leu Ser Glu Val Lys Arg Asn 210 215 220		
Val Asp Glu Pro Lys Leu Glu Asp Val Ser Leu Ala Ala Thr Thr His 225 230 235 240		
Arg Ile Ala Thr Ile His Gly His Tyr Glu Val Leu Tyr Val Ser Phe 245 250 255		
Lys Glu Glu Thr Ala Ala Glu Lys Val Lys Glu Thr Leu Glu Asn Phe 260 265 270		
Arg Gly Glu Pro Gln Asp Leu Lys Leu Pro Thr Ala Pro Ser Lys Pro 275 280 285		
Ile Ile Val Met Asn Glu Asp Thr Arg Pro Gln Val Tyr Phe Asp Arg 290 295 300		
Trp Ala Gly Asp Ile Pro Gly Met Ser Val Val Val Gly Arg Leu Lys 305 310 315 320		
Gln Val Asn Lys Arg Met Ile Arg Leu Val Ser Leu Ile His Asn Thr 325 330 335		
Val Arg Gly Ala Ala Gly Gly Gly Ile Leu Ala Ala Glu Leu Leu Val 340 345 350		
Glu Lys Gly Tyr Ile Glu Lys 355		

<210> SEQ ID NO 14

<211> LENGTH: 945

<212> TYPE: DNA

<213> ORGANISM: Metallosphaera sedula

<400> SEQUENCE: 14

```

atgactgaaa aggtatctgt agttggagca ggagttatag gcgtaggttg ggcgaccctt    60
tttgcgtcta agggatacag cgtctctctc tacaccgaaa agaaggaaac cctagacaag    120
ggaatagaga agctaaggaa ctacgttcag gtgatgaaga acaactccca gataaccgag    180
gacgtcaata ccgtgatctc gagggtttct cccaccacga atctggatga ggccggttagg    240
ggagccaact tcgtcattga ggcagttatt gaggattatg acgcaaaaaa gaaaatcttt    300
ggatacttgg acagcgtcct tgacaaggag gttatactag ctacagctac ttcaggtctc    360
ctcataacag aggttcagaa ggcaatgtcc aagcaccctg agagggcggt gatagcccat    420
ccctggaatc caccacact tctaccgctt gtcgagatag ttccaggaga gaagaccagt    480
atggaagtgg tggagaggac gaagtccttc atggagaagc tggacagaat agtagtggtg    540
ctcaagaagg agattccggg tttcataggg aacaggctcg cctttgctct tttccgagag    600
gccgtatacc ttgtagacga ggggtgggcc actgtggagg acatcgacaa ggtaatgaca    660
gggcaattg gactcagatg ggccttcatt ggtccgttcc tcacatacca tctagtggtg    720

```

-continued

```

ggagaaggag ggcttgagta cttctttaat aggggttttg ggtacggtgc taacgaatgg 780
atgcataccc tggcaaaata cgacaagttc cctacactg gggttacgaa agcgatacag 840
caaatgaagg aatactcctt cataaagggt aagactttcc aggaaatttc gaagtggagg 900
gacgaaaagc tcttgaaggt atacaaacta gtttgggaaa aataa 945

```

```

<210> SEQ ID NO 15
<211> LENGTH: 945
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Codon-optimized coding sequence for
Metallosphaera sedula malonyl-CoA reductase

```

```

<400> SEQUENCE: 15

```

```

atgaccgaaa aagtatctgt cgtgggtgct ggggtgatcg gcggtggatg ggccaccctt 60
tttgccagca aagggtattc cgtcagtttg tataccgaaa aaaaagaaac actcgataaa 120
ggaattgaaa aactgcggaa ctatgtgcag gtgatgaaaa ataatagcca aatcacggaa 180
gatgtcaata ccgtgattag tcgctgtgcc cctaccacca atttggatga agccgttcgc 240
ggcgcgaaact tcgttatcga agccgtcatt gaagactatg atgccaagaa aaaaattttt 300
ggatacctcg atagtgttct cgataaagaa gttattttgg ctctgtccac aagcgggctc 360
ttgattacag aagttcaaaa agcgtatgtc aaacatcccc aacgcgcggg gattgcacat 420
ccttgaatc caccaccct gctgcccttg gtcgaaatcg ttcccggaga aaaaaccagc 480
atggagggtcg tcgaacgcac gaaatccctc atggaaaaac tcgatcgcac cgtggtggtc 540
ctcaaaaaag aaattcctgg ttttatcggc aatcgtctcg cctttgcatt attccgtgaa 600
gccgtctacc tggttgatga gggggtggcg accgtggaag atatcgataa agtaatgacc 660
gccgcgattg gattacggtg ggcctttatg ggcccatttc tcacctacca cctcggtggc 720
ggggaaggcg gtttgaata ttttttaac cggggctttg gctatggcgc aaatgaatgg 780
atgcataccc ttgcaaaata tgataagttt ccctatactg gtgtaaccaa ggccattcaa 840
caaatgaagg aatactcgtt tattaagggt aaaacgttcc aggaaatctc caaatggcgg 900
gatgagaaac tcttaaaagt ctacaaactg gtctgggaaa aataa 945

```

```

<210> SEQ ID NO 16
<211> LENGTH: 314
<212> TYPE: PRT
<213> ORGANISM: Metallosphaera sedula

```

```

<400> SEQUENCE: 16

```

```

Met Thr Glu Lys Val Ser Val Val Gly Ala Gly Val Ile Gly Val Gly
1      5      10     15
Trp Ala Thr Leu Phe Ala Ser Lys Gly Tyr Ser Val Ser Leu Tyr Thr
20     25     30
Glu Lys Lys Glu Thr Leu Asp Lys Gly Ile Glu Lys Leu Arg Asn Tyr
35     40     45
Val Gln Val Met Lys Asn Asn Ser Gln Ile Thr Glu Asp Val Asn Thr
50     55     60
Val Ile Ser Arg Val Ser Pro Thr Thr Asn Leu Asp Glu Ala Val Arg
65     70     75     80
Gly Ala Asn Phe Val Ile Glu Ala Val Ile Glu Asp Tyr Asp Ala Lys
85     90     95
Lys Lys Ile Phe Gly Tyr Leu Asp Ser Val Leu Asp Lys Glu Val Ile
100    105   110

```

-continued

Leu Ala Ser Ser Thr Ser Gly Leu Leu Ile Thr Glu Val Gln Lys Ala
 115 120 125
 Met Ser Lys His Pro Glu Arg Ala Val Ile Ala His Pro Trp Asn Pro
 130 135 140
 Pro His Leu Leu Pro Leu Val Glu Ile Val Pro Gly Glu Lys Thr Ser
 145 150 155 160
 Met Glu Val Val Glu Arg Thr Lys Ser Leu Met Glu Lys Leu Asp Arg
 165 170 175
 Ile Val Val Val Leu Lys Lys Glu Ile Pro Gly Phe Ile Gly Asn Arg
 180 185 190
 Leu Ala Phe Ala Leu Phe Arg Glu Ala Val Tyr Leu Val Asp Glu Gly
 195 200 205
 Val Ala Thr Val Glu Asp Ile Asp Lys Val Met Thr Ala Ala Ile Gly
 210 215 220
 Leu Arg Trp Ala Phe Met Gly Pro Phe Leu Thr Tyr His Leu Gly Gly
 225 230 235 240
 Gly Glu Gly Gly Leu Glu Tyr Phe Phe Asn Arg Gly Phe Gly Tyr Gly
 245 250 255
 Ala Asn Glu Trp Met His Thr Leu Ala Lys Tyr Asp Lys Phe Pro Tyr
 260 265 270
 Thr Gly Val Thr Lys Ala Ile Gln Gln Met Lys Glu Tyr Ser Phe Ile
 275 280 285
 Lys Gly Lys Thr Phe Gln Glu Ile Ser Lys Trp Arg Asp Glu Lys Leu
 290 295 300
 Leu Lys Val Tyr Lys Leu Val Trp Glu Lys
 305 310

<210> SEQ ID NO 17

<211> LENGTH: 966

<212> TYPE: DNA

<213> ORGANISM: Bacillus subtilis

<400> SEQUENCE: 17

atgatgaaca aacatgtaaa taaagtagct ttaatcggag cgggttttgt tggaagcagt 60
 tatgcatttg cgtaattaa ccaaggaatc acagatgagc ttgtggatcat tgatgtaaat 120
 aaagaaaaag caatgggcca tgtgatggat ttaaaccacg gaaaggcgtt tgcgccacaa 180
 ccggtcaaaa catcttacgg aacatgatga gactgcaagg atgctgatat tgtctgcatt 240
 tgcgccggag caaaccacaa acctggtgag acacgccttg aattagtaga aaagaacttg 300
 aagatthtca aaggcatcgt tagtgaagtc atggcgagcg gatttgacgg cattttetta 360
 gtgcgcacaa atccggttga taccctgact tacgcaacat ggaaattcag cggcctgcca 420
 aaagagcggg tgattggaag cggcacaaca cttgattctg cgagattccg tttcatgctg 480
 agcgaatact ttggcgagc gcctcaaac gtacacgcgc atattatcgg agagcacggc 540
 gacacagagc ttcctgthtg gagccacgcg aatgtcggcg gtgtgccggt cagtgaactc 600
 gttgagaaaa acgatgcgta caaacaagag gagctggacc aaattgtaga tgatgtgaaa 660
 aacgcagcctt accatatcat tgagaaaaaa ggcgcgactt attatggggt tgcgatgagt 720
 cttgctcgca ttacaaaagc cattcttcat aatgaaaaa gcatattaac tgtcagcaca 780
 tatttggaag ggcaatacgg tgcagatgac gtgtacatcg gtgtgccggc tgcgtgaaat 840
 cgcggagggg tgcaggtat cactgagctg aacttaaatg agaaagaaaa agaacagttc 900
 cttcacagcg cggcgctcct taaaaacatt taaaaacctc attttcgaga acaaaaagtc 960

-continued

aactaa

966

<210> SEQ ID NO 18
 <211> LENGTH: 321
 <212> TYPE: PRT
 <213> ORGANISM: Bacillus subtilis

<400> SEQUENCE: 18

```

Met Met Asn Lys His Val Asn Lys Val Ala Leu Ile Gly Ala Gly Phe
 1           5             10             15
Val Gly Ser Ser Tyr Ala Phe Ala Leu Ile Asn Gln Gly Ile Thr Asp
 20           25           30
Glu Leu Val Val Ile Asp Val Asn Lys Glu Lys Ala Met Gly Asp Val
 35           40           45
Met Asp Leu Asn His Gly Lys Ala Phe Ala Pro Gln Pro Val Lys Thr
 50           55           60
Ser Tyr Gly Thr Tyr Glu Asp Cys Lys Asp Ala Asp Ile Val Cys Ile
 65           70           75           80
Cys Ala Gly Ala Asn Gln Lys Pro Gly Glu Thr Arg Leu Glu Leu Val
 85           90           95
Glu Lys Asn Leu Lys Ile Phe Lys Gly Ile Val Ser Glu Val Met Ala
 100          105          110
Ser Gly Phe Asp Gly Ile Phe Leu Val Ala Thr Asn Pro Val Asp Ile
 115          120          125
Leu Thr Tyr Ala Thr Trp Lys Phe Ser Gly Leu Pro Lys Glu Arg Val
 130          135          140
Ile Gly Ser Gly Thr Thr Leu Asp Ser Ala Arg Phe Arg Phe Met Leu
 145          150          155          160
Ser Glu Tyr Phe Gly Ala Ala Pro Gln Asn Val His Ala His Ile Ile
 165          170          175
Gly Glu His Gly Asp Thr Glu Leu Pro Val Trp Ser His Ala Asn Val
 180          185          190
Gly Gly Val Pro Val Ser Glu Leu Val Glu Lys Asn Asp Ala Tyr Lys
 195          200          205
Gln Glu Glu Leu Asp Gln Ile Val Asp Asp Val Lys Asn Ala Ala Tyr
 210          215          220
His Ile Ile Glu Lys Lys Gly Ala Thr Tyr Tyr Gly Val Ala Met Ser
 225          230          235          240
Leu Ala Arg Ile Thr Lys Ala Ile Leu His Asn Glu Asn Ser Ile Leu
 245          250          255
Thr Val Ser Thr Tyr Leu Asp Gly Gln Tyr Gly Ala Asp Asp Val Tyr
 260          265          270
Ile Gly Val Pro Ala Val Val Asn Arg Gly Gly Ile Ala Gly Ile Thr
 275          280          285
Glu Leu Asn Leu Asn Glu Lys Glu Lys Glu Gln Phe Leu His Ser Ala
 290          295          300
Gly Val Leu Lys Asn Ile Leu Lys Pro His Phe Ala Glu Gln Lys Val
 305          310          315          320

```

Asn

<210> SEQ ID NO 19
 <211> LENGTH: 1401
 <212> TYPE: DNA
 <213> ORGANISM: Escherichia coli

-continued

<400> SEQUENCE: 19

```

atgccacatt cctacgatta cgatgccata gtaatagggt cgggccccgg cggcgaaggg      60
gctgcaatgg gcttggttaa gcaagggtgcg cgcgtcgagc ttatcgagcg ttatcaaaat    120
gttgccggcg gttgcaccca ctggggcacc atcccgtcga aagctctcgg tcacgccgctc    180
agccgcatta tagaattcaa tcaaaacca ctttacagcg accattcccc actgctccgc      240
tcttcttttg cggatatect taacctgccc gataacgtga ttaatcaaca aacgcgcatg     300
cgtcagggat tttacgaacg taatcactgt gaaatattgc agggaaacgc tcgctttggt     360
gacgagcata cgttggcgct ggattgcccg gacggcagcg ttgaaacct aaccgctgaa     420
aaatttggtt ttgctcgagg ctctcgtcca tatcatccaa cagatggtga tttcacccat     480
ccacgcattt acgacagcga ctcaattctc agcatgcacc acgaaccggc ccatgtactt     540
atctatggtg ctggagtgat cggctgtgaa tatgcgtcga tcttccggcg tatggatgta     600
aaagtggatc tgatcaaac acgcgatcgc ctgctggcat ttctcgatca agagatgtca     660
gattctctct cctatcactt ctggaacagt ggcgtagtga ttcgtcacia cgaagagtac     720
gagaagatcg aaggctgtga cgatgggtgtg atcatgcac tgaagtccggg taaaaaactg     780
aaagctgact gctgctctta tgccaacggg cgcaccggta ataccgattc gctggcggtta     840
cagaacattg ggctagaaac tgacagccgc ggacagctga aggtcaacag catgtatcag     900
accgcacagc cacacgttta cgcggtgggc gacgtgattg gttatccgag cctggcgctcg     960
gcggcctatg accagggggc cattgcccgc caggcgtctgg taaaaggcga agccaccgca    1020
catctgattg aagatatccc taccgggtatt tacaccatcc cggaaatcag ctctgtgggc    1080
aaaaccgaac agcagctgac cgcaatgaaa gtgccatatt aagtggggcg cggccagttt    1140
aaacatctgg cacgcgcaca aatcgtcggc atgaacgtgg gcacgctgaa aattttgttc    1200
catcgggaaa caaaagagat tctgggtatt cactgctttg gcgagcgcgc tgccgaaatt    1260
attcatatcg gtcaggcgat tatggaacag aaaggtggcg gcaacactat tgagtacttc    1320
gtcaacacca cctttaacta cccgacgatg gcggaagcct atcgggtagc tgcgttaaac    1380
ggtttaaacg cctgttctta a

```

<210> SEQ ID NO 20

<211> LENGTH: 466

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 20

```

Met Pro His Ser Tyr Asp Tyr Asp Ala Ile Val Ile Gly Ser Gly Pro
 1           5           10           15
Gly Gly Glu Gly Ala Ala Met Gly Leu Val Lys Gln Gly Ala Arg Val
 20           25           30
Ala Val Ile Glu Arg Tyr Gln Asn Val Gly Gly Gly Cys Thr His Trp
 35           40           45
Gly Thr Ile Pro Ser Lys Ala Leu Arg His Ala Val Ser Arg Ile Ile
 50           55           60
Glu Phe Asn Gln Asn Pro Leu Tyr Ser Asp His Ser Arg Leu Leu Arg
 65           70           75           80
Ser Ser Phe Ala Asp Ile Leu Asn His Ala Asp Asn Val Ile Asn Gln
 85           90           95
Gln Thr Arg Met Arg Gln Gly Phe Tyr Glu Arg Asn His Cys Glu Ile
100          105          110

```

-continued

Leu Gln Gly Asn Ala Arg Phe Val Asp Glu His Thr Leu Ala Leu Asp
 115 120
 Cys Pro Asp Gly Ser Val Glu Thr Leu Thr Ala Glu Lys Phe Val Ile
 130 135 140
 Ala Cys Gly Ser Arg Pro Tyr His Pro Thr Asp Val Asp Phe Thr His
 145 150 155 160
 Pro Arg Ile Tyr Asp Ser Asp Ser Ile Leu Ser Met His His Glu Pro
 165 170 175
 Arg His Val Leu Ile Tyr Gly Ala Gly Val Ile Gly Cys Glu Tyr Ala
 180 185 190
 Ser Ile Phe Arg Gly Met Asp Val Lys Val Asp Leu Ile Asn Thr Arg
 195 200 205
 Asp Arg Leu Leu Ala Phe Leu Asp Gln Glu Met Ser Asp Ser Leu Ser
 210 215 220
 Tyr His Phe Trp Asn Ser Gly Val Val Ile Arg His Asn Glu Glu Tyr
 225 230 235 240
 Glu Lys Ile Glu Gly Cys Asp Asp Gly Val Ile Met His Leu Lys Ser
 245 250 255
 Gly Lys Lys Leu Lys Ala Asp Cys Leu Leu Tyr Ala Asn Gly Arg Thr
 260 265 270
 Gly Asn Thr Asp Ser Leu Ala Leu Gln Asn Ile Gly Leu Glu Thr Asp
 275 280 285
 Ser Arg Gly Gln Leu Lys Val Asn Ser Met Tyr Gln Thr Ala Gln Pro
 290 295 300
 His Val Tyr Ala Val Gly Asp Val Ile Gly Tyr Pro Ser Leu Ala Ser
 305 310 315 320
 Ala Ala Tyr Asp Gln Gly Arg Ile Ala Ala Gln Ala Leu Val Lys Gly
 325 330 335
 Glu Ala Thr Ala His Leu Ile Glu Asp Ile Pro Thr Gly Ile Tyr Thr
 340 345 350
 Ile Pro Glu Ile Ser Ser Val Gly Lys Thr Glu Gln Gln Leu Thr Ala
 355 360 365
 Met Lys Val Pro Tyr Glu Val Gly Arg Ala Gln Phe Lys His Leu Ala
 370 375 380
 Arg Ala Gln Ile Val Gly Met Asn Val Gly Thr Leu Lys Ile Leu Phe
 385 390 395 400
 His Arg Glu Thr Lys Glu Ile Leu Gly Ile His Cys Phe Gly Glu Arg
 405 410 415
 Ala Ala Glu Ile Ile His Ile Gly Gln Ala Ile Met Glu Gln Lys Gly
 420 425 430
 Gly Gly Asn Thr Ile Glu Tyr Phe Val Asn Thr Thr Phe Asn Tyr Pro
 435 440 445
 Thr Met Ala Glu Ala Tyr Arg Val Ala Ala Leu Asn Gly Leu Asn Arg
 450 455 460
 Leu Phe
 465

<210> SEQ ID NO 21

<211> LENGTH: 978

<212> TYPE: DNA

<213> ORGANISM: Lactococcus lactis

<400> SEQUENCE: 21

atggcggata agcaacgcaa aaaagtgatt ttggttggtg acggggcagt tggttcgteg

60

-continued

```

tatgcgtttg ccttggtaaa ccaaggtatc gcccaagaat taggcacgtg tgacttggtc 120
aaagaaaaaa cccaggggaga tgccgaagac ctctctcacg ccttagcctt caccagccct 180
aaaaaaaaat atagtgtgga ttatagtgat gcgtccgacg ccgatctcgt gggtcttacc 240
agcggtgccc cccagaagcc cggtgaaacc cggtagatc tcggtgaaaa gaatctgoga 300
attaccaaag atgttggtac taagatcgtg gcgtctggct ttaaggggat tttctcgtc 360
gcggctaacc cagtgacatc cctcacgtat gctacgtgga agtttagtgg ttttcccaag 420
aaccgagtgg tcggctctgg caccagcctc gataccgccc gtttccgga ggccttggt 480
gagaaggtcg atgtcgacgc ccggtcgatt cacgcgtaca ttatgggtga acatggtgac 540
agtgaatttg cagtctggag tcacgccaat gtggccggcg tgaaactgga acaatggttc 600
caagaaaatg attacctgaa tgaagccgaa attgtggagt tatttgaaag cgtgcgggat 660
gcgcctatt ctattatcgc caaaaaagg gccacgtttt atggagtcgc agtcgcactt 720
gcgcgcatta ccaaggccat tctggaagat gaacacgccc ttctcccggt gagtgtgttt 780
caagatggtc aatacggcgt gtctgattgt tatctcgggc aaccgcccg tgtgggtgca 840
gaaggagtgg taaatcctat ccatatcccc ttgaacgatg ccgagatgca gaagatggaa 900
gcctcgggcg cgcaattgaa agctattatt gatgaggcat ttgctaagga ggaatttgcg 960
agcgcggtga aaaattaa 978

```

<210> SEQ ID NO 22

<211> LENGTH: 325

<212> TYPE: PRT

<213> ORGANISM: *Lactococcus lactis*

<400> SEQUENCE: 22

```

Met Ala Asp Lys Gln Arg Lys Lys Val Ile Leu Val Gly Asp Gly Ala
 1           5           10          15
Val Gly Ser Ser Tyr Ala Phe Ala Leu Val Asn Gln Gly Ile Ala Gln
          20          25          30
Glu Leu Gly Ile Val Asp Leu Phe Lys Glu Lys Thr Gln Gly Asp Ala
          35          40          45
Glu Asp Leu Ser His Ala Leu Ala Phe Thr Ser Pro Lys Lys Ile Tyr
          50          55          60
Ser Ala Asp Tyr Ser Asp Ala Ser Asp Ala Asp Leu Val Val Leu Thr
          65          70          75          80
Ser Gly Ala Pro Gln Lys Pro Gly Glu Thr Arg Leu Asp Leu Val Glu
          85          90          95
Lys Asn Leu Arg Ile Thr Lys Asp Val Val Thr Lys Ile Val Ala Ser
          100         105         110
Gly Phe Lys Gly Ile Phe Leu Val Ala Ala Asn Pro Val Asp Ile Leu
          115         120         125
Thr Tyr Ala Thr Trp Lys Phe Ser Gly Phe Pro Lys Asn Arg Val Val
          130         135         140
Gly Ser Gly Thr Ser Leu Asp Thr Ala Arg Phe Arg Gln Ala Leu Ala
          145         150         155         160
Glu Lys Val Asp Val Asp Ala Arg Ser Ile His Ala Tyr Ile Met Gly
          165         170         175
Glu His Gly Asp Ser Glu Phe Ala Val Trp Ser His Ala Asn Val Ala
          180         185         190
Gly Val Lys Leu Glu Gln Trp Phe Gln Glu Asn Asp Tyr Leu Asn Glu
          195         200         205

```

-continued

Ala Glu Ile Val Glu Leu Phe Glu Ser Val Arg Asp Ala Ala Tyr Ser
 210 215 220

Ile Ile Ala Lys Lys Gly Ala Thr Phe Tyr Gly Val Ala Val Ala Leu
 225 230 235 240

Ala Arg Ile Thr Lys Ala Ile Leu Asp Asp Glu His Ala Val Leu Pro
 245 250 255

Val Ser Val Phe Gln Asp Gly Gln Tyr Gly Val Ser Asp Cys Tyr Leu
 260 265 270

Gly Gln Pro Ala Val Val Gly Ala Glu Gly Val Val Asn Pro Ile His
 275 280 285

Ile Pro Leu Asn Asp Ala Glu Met Gln Lys Met Glu Ala Ser Gly Ala
 290 295 300

Gln Leu Lys Ala Ile Ile Asp Glu Ala Phe Ala Lys Glu Glu Phe Ala
 305 310 315 320

Ser Ala Val Lys Asn
 325

We claim:

1. A microorganism comprising:
 a modification that reduces or ablates AcsA activity or AcsA homolog activity in the microorganism; and
 one or more recombinant nucleic acids configured to express an enzyme selected from the group consisting of a lactate dehydrogenase and a transhydrogenase, wherein the microorganism produces an increased amount of lactic acid compared to a corresponding microorganism not comprising the one or more recombinant nucleic acids.
2. The microorganism of claim 1 wherein the microorganism is a bacterium.
3. The microorganism of claim 1 wherein the microorganism is a cyanobacterium.
4. The microorganism of claim 1 wherein the one or more recombinant nucleic acids is configured to express a lactate dehydrogenase and a pyridine nucleotide transhydrogenase.
5. The microorganism of claim 1 wherein the one or more recombinant nucleic acids is configured to express a lactate dehydrogenase selected from the group consisting of a lactate dehydrogenase from *Bacillus subtilis* or a homolog thereof and a lactate dehydrogenase from *Lactococcus lactis* or a homolog thereof.
6. The microorganism of claim 1 wherein the lactate dehydrogenase is selected from the group consisting of a lactate dehydrogenase from *Bacillus subtilis* or a homolog thereof comprising a sequence at least about 80% identical to SEQ ID NO:18 and a lactate dehydrogenase from *Lactococcus lactis* or a homolog thereof comprising a sequence at least about 80% identical to SEQ ID NO:22.
7. The microorganism of claim 1 wherein the lactate dehydrogenase is selected from the group consisting of a lactate dehydrogenase from *Bacillus subtilis* or a homolog thereof comprising a sequence at least about 90% identical to SEQ ID NO:18 and a lactate dehydrogenase from *Lactococcus lactis* or a homolog thereof comprising a sequence at least about 90% identical to SEQ ID NO:22.
8. The microorganism of claim 1 wherein the lactate dehydrogenase is selected from the group consisting of a lactate dehydrogenase from *Bacillus subtilis* or a homolog thereof comprising a sequence at least about 90% identical to SEQ ID NO:18 and a lactate dehydrogenase from *Lactococcus lactis* or a homolog thereof comprising a sequence at least about 90% identical to SEQ ID NO:22.
9. The microorganism of claim 1 wherein the one or more recombinant nucleic acids is configured to express a soluble pyridine nucleotide transhydrogenase from *Escherichia coli* or a homolog thereof.
10. The microorganism of claim 9 wherein the soluble pyridine nucleotide transhydrogenase from *Escherichia coli* or the homolog thereof comprises a sequence at least about 80% identical to SEQ ID NO:20.
11. The microorganism of claim 9 wherein the soluble pyridine nucleotide transhydrogenase from *Escherichia coli* or the homolog thereof comprises a sequence at least about 90% identical to SEQ ID NO:20.
12. The microorganism of claim 9 wherein the soluble pyridine nucleotide transhydrogenase from *Escherichia coli* or the homolog thereof comprises a sequence at least about 95% identical to SEQ ID NO:20.
13. The microorganism of claim 1 wherein the microorganism is a bacterium, the one or more recombinant nucleic acids is configured to express a soluble pyridine nucleotide transhydrogenase from *Escherichia coli* or a homolog thereof comprising a sequence at least about 95% identical to SEQ ID NO:20 and a lactate dehydrogenase selected from the group consisting of a lactate dehydrogenase from *Bacillus subtilis* or a homolog thereof comprising a sequence at least about 95% identical to SEQ ID NO:18 and a lactate dehydrogenase from *Lactococcus lactis* or a homolog thereof comprising a sequence at least about 95% identical to SEQ ID NO:22.
14. The microorganism of claim 13 wherein the microorganism is a cyanobacterium.
15. The microorganism of claim 14 wherein the lactate dehydrogenase comprises the lactate dehydrogenase from *Bacillus subtilis* or the homolog thereof comprising the sequence at least about 95% identical to SEQ ID NO:18.
16. The microorganism of claim 14 wherein the lactate dehydrogenase comprises the lactate dehydrogenase from *Lactococcus lactis* or the homolog thereof comprising the sequence at least about 95% identical to SEQ ID NO:18.
17. A method of producing lactic acid comprising culturing a microorganism as recited in claim 1.
18. The method of claim 17 wherein the culturing produces lactic acid to a concentration of at least about 5 mM.

19. The method of claim 17 wherein the culturing produces lactic acid at a rate of at least about 200 mg/L/Day.

20. The method of claim 17 wherein the culturing converts at least about 15% of carbon consumed by the microorganism to lactic acid.

5

* * * * *